

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: 55562 AND 21617, NOVEL HUMAN PROTEINS AND
METHODS OF USE THEREOF

APPLICANT: RAJASEKHAR BANDARU AND RACHEL A. MEYERS

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL486014464US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D C. 20231

Date of Deposit

12/18/2001

Signature

Typed or Printed Name of Person Signing Certificate

55562 AND 21617, NOVEL HUMAN PROTEINS AND METHODS
OF USE THEREOF

Related Applications

This application claims priority to U.S. provisional application numbers 60/256,249 and 60/256,405, both filed on December 18, 2000, the contents of which are incorporated herein by reference.

Background of the Invention

Dehydrogenases

Short chain dehydrogenases (SDRs) are a large and diverse collection of enzymes grouped into a superfamily comprising over 700 different enzymes including isomerases, lyases, and oxidoreductases (Opperman et al. (1999) *Enzymology and Molecular Biology of Carbonyl Metabolism*, 7 ed., Weiner et al., Plenum Publishers, NY p. 365-371). They are important in metabolism of small molecules, production/removal of biologically important molecules that modulate development and growth, elimination of toxins, and associated physiological processes and pathological conditions. The enzymes of this family cover a wide range of substrate specificities including sugars, steroids, alcohols, prostaglandins, metabolites (e.g., lipids), and aromatic compounds (Opperman et al. (1999), *supra*, p. 373-377).

Members of the alcohol dehydrogenase and short-chain dehydrogenase/reductase families catalyze the reversible, rate limiting conversion of retinol to retinal, while the oxidation of retinal to retinoic acid is catalyzed by members of the aldehyde dehydrogenase or P450 enzyme families (Deuster et al. (1996), *Biochemistry* 35:12221-12227). Other SDR/retinol dehydrogenases function in the visual cycle by converting either 11-cis-retinol to 11-cis-retinal or all trans-retinol to all trans-retinal (Simon et al. (1995) *J Biol Chem* 270:1107-1112). Retinoic acid plays a key role in the regulation of embryonic development, spermatogenesis, and epithelial differentiation (Chambon et al. (1996), *FASEB J* 10:940-954, and Mangelsdorf et al. (1995), *Cell* 83:841-850).

Alcohol dehydrogenases play fundamental roles in degradative, synthetic, and detoxification pathways and have been implicated in a variety of developmental processes and pathophysiological disease states. For example, allelic variations of ADH2 and ADH3 appear to influence the susceptibility to alcoholism and alcoholic liver cirrhosis in Asians

(Thomasson et al. (1991), *Am J Hum Genet* 48:677-681, Chao et al. (1994), *Hepatology* 19:360-366, and Higuchi et al. (1995), *Am J Psychiatry* 152:1219-1221).

Tetratricopeptide repeats

5 Tetratricopeptide repeats (TPR) are found in a diverse collection of polypeptides (Boebel and Yanagida (1991) *Trends Biochem Sci.* 16:173; Lamb et al. (1995) *Trends Biochem. Sci.* 20:257). Typically, each repeat folds as an anti-parallel pair of α -helices; adjacent repeats pack against each other to form an extensive accordion-like structure. This polypeptide fold can serve a variety of functions, including scaffolding protein-protein
10 interactions for complex formation and regulation of protein function.

For example, the serine/threonine protein phosphatase PP5 has three tandem TPR motifs that have multiple functions (see, e.g., Das et al. (1998), *EMBO J.* 17:1192-99). In part, the TPR domain of PP5 is an allosteric regulator that inhibits phosphatase function until triggered by arachidonic acid. Arachidonic acid binds to the TPR domain, and relieves
15 the inhibition, thereby activating the enzyme. Additionally, the TPR domain interacts with hsp90 and the kinase domain of the ANP-guanylate cyclase receptor in a signalling network.

TPR motifs are also found in cell division cycle genes, such as *cdc16*, *cdc23*, and *cdc27*, all encoding polypeptide components of the anaphase-promoting complex, which regulates cell cycle progression in mitosis. Mutations in the TPR regions of these complex
20 members cause mitotic arrest prior to anaphase.

Another class of proteins, the SKD1 family of proteins contains a sole TPR motif. SKD1 family members, including VPS4, participate in intracellular protein trafficking, e.g., from the trans-Golgi network to the vacuole. This family of proteins can further include an AAA domain (an ATPase motif).
25

TPRs are also featured in proteins that regulate transcription, neurogenesis, protein kinase inhibition, NADPH oxidase, and protein folding. Thus, the TPR is a versatile and important polypeptide motif for regulating cell behaviors and physiology.

Dehydrogenases and tetratricopeptide repeat-containing protein have both been
30 implicated in human disease. Consequently, the isolation and characterization of additional dehydrogenases and tetratricopeptide repeat-containing proteins will provide novel reagents for the treatment or prevention of disease, as well as new targets for the development of drugs that can be used to treat or prevent disease.

Summary of the Invention

The present invention is based, in part, on the discovery of novel dehydrogenase or tetratricopeptide repeat family members, referred to herein as “21617” or “55562”, respectively. The nucleotide sequence of a cDNA encoding 21617 is shown in SEQ ID NO:1, and the amino acid sequence of a 21617 polypeptide is shown in SEQ ID NO:2. The nucleotide sequence of a cDNA encoding 55562 is shown in SEQ ID NO:4, and the amino acid sequence of a 55562 polypeptide is shown in SEQ ID NO:5. In addition, the nucleotide sequences of the 21617 and 55562 coding regions are depicted in SEQ ID NO:3 and SEQ ID NO:6, respectively.

Accordingly, in one aspect, the invention features a nucleic acid molecule that encodes a 21617 or 55562 protein or polypeptide, e.g., a biologically active portion of the 21617 or 55562 protein. In a preferred embodiment the isolated nucleic acid molecule encodes a polypeptide having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5. In other embodiments, the invention provides isolated 21617 or 55562 nucleic acid molecules having the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, or the sequence of a DNA insert of a plasmid deposited with ATCC Accession Number as described herein. In still other embodiments, the invention provides nucleic acid molecules that are substantially identical (e.g., naturally occurring allelic variants) to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, or the sequence of a DNA insert of a plasmid deposited with ATCC Accession Number as described herein. In other embodiments, the invention provides a nucleic acid molecule which hybridizes under a stringency condition described herein to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, or the sequence of a DNA insert of a plasmid deposited with ATCC Accession Number as described herein, wherein the nucleic acid encodes a full length 21617 or 55562 protein or an active fragment thereof.

In a related aspect, the invention further provides nucleic acid constructs that include a 21617 or 55562 nucleic acid molecule described herein. In certain embodiments, the nucleic acid molecules of the invention are operatively linked to native or heterologous regulatory sequences. Also included, are vectors and host cells containing the 21617 or 55562 nucleic acid molecules of the invention e.g., vectors and host cells suitable for producing 21617 or 55562 nucleic acid molecules and polypeptides.

In another related aspect, the invention provides nucleic acid fragments suitable as primers or hybridization probes for the detection of 21617 or 55562-encoding nucleic acids.

In still another related aspect, isolated nucleic acid molecules that are antisense to a 21617 or 55562 encoding nucleic acid molecule are provided.

5 In another aspect, the invention features, 21617 or 55562 polypeptides, and biologically active or antigenic fragments thereof that are useful, e.g., as reagents or targets in assays applicable to treatment and diagnosis of 21617 or 55562-mediated or -related disorders. In another embodiment, the invention provides 21617 or 55562 polypeptides having a 21617 or 55562 activity. Preferred polypeptides are 21617 or 55562 proteins
10 including at least one short chain dehydrogenase or tetratricopeptide repeat domain, and, preferably, having a 21617 or 55562 activity, e.g., a 21617 or 55562 activity as described herein.

In other embodiments, the invention provides 21617 or 55562 polypeptides, e.g., a 21617 or 55562 polypeptide having the amino acid sequence shown in SEQ ID NO:2 or
15 SEQ ID NO:5, or the amino acid sequence encoded by the cDNA insert of a plasmid deposited with ATCC Accession Number as described herein; an amino acid sequence that is substantially identical to the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5, or the amino acid sequence encoded by the cDNA insert of a plasmid deposited with ATCC Accession Number as described herein; or an amino acid sequence encoded by a
20 nucleic acid molecule having a nucleotide sequence which hybridizes under a stringency condition described herein to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, or the sequence of a DNA insert of a plasmid deposited with ATCC Accession Number as described herein, wherein the nucleic acid encodes a full length 21617 or 55562 protein or an active fragment thereof.

25 In a related aspect, the invention provides 21617 or 55562 polypeptides or fragments operatively linked to non-21617 or 55562 polypeptides to form fusion proteins.

In another aspect, the invention features antibodies and antigen-binding fragments thereof, that react with or, more preferably, specifically bind 21617 or 55562 polypeptides.

In another aspect, the invention provides methods of screening for agents, e.g.,
30 compounds, that modulate the expression or activity of a 21617 or 55562 polypeptide or nucleic acid.

In still another aspect, the invention provides a process for modulating 21617 or 55562 polypeptide or nucleic acid expression or activity, e.g. using the screened compounds.

In certain embodiments, the methods involve treatment of conditions related to aberrant activity or expression of the 21617 or 55562 polypeptides or nucleic acids, such as conditions involving aberrant or deficient cellular proliferation and/or differentiation, metabolic disorders, neural disorders, or viral disorders.

5 In yet another aspect, the invention provides methods for modulating the activity of a 21617- or a 55562-expressing cell. In one embodiment, the methods inhibit the proliferation or induce the killing of the cell. The methods include contacting the cell with an agent, e.g., a compound (e.g., a compound identified using the methods described herein) that modulates the activity, or expression, of the 14094 polypeptide or nucleic acid, thereby
10 modulating the activity of the 21617- or 55562-expressing cell.

In a preferred embodiment, the contacting step is effective *in vitro* or *ex vivo*. In other embodiments, the contacting step is effected *in vivo*, e.g., in a subject (e.g., a mammal, e.g., a human), as part of a therapeutic or prophylactic protocol.

In a preferred embodiment, the 21617- or 55562-expressing cell is a
15 hyperproliferative cell is found in a solid tumor, a soft tissue tumor, or a metastatic lesion. Preferably, the tumor is a sarcoma, a carcinoma, or an adenocarcinoma. Preferably, the hyperproliferative cell is found in a cancerous or pre-cancerous tissue, e.g., a cancerous or pre-cancerous tissue where a 21617- or 55562 polypeptide or nucleic acid is expressed, e.g., breast, ovarian, colon, liver, lung, kidney, or brain cancer. Most preferably, the
20 hyperproliferative cell is found in a tumor from the breast, ovary, colon, liver and lung.

In a preferred embodiment, the agent, e.g., the compound, is an inhibitor of a 21617- or 55562 polypeptide. Preferably, the inhibitor is chosen from a peptide, a phosphopeptide, a small organic molecule, a small inorganic molecule and an antibody (e.g., an antibody conjugated to a therapeutic moiety selected from a cytotoxin, a cytotoxic agent and a
25 radioactive metal ion).

In a preferred embodiment, the agent, e.g., the compound, is an inhibitor of a 21617- or 55562 nucleic acid, e.g., an antisense, a ribozyme, or a triple helix molecule.

In some embodiments, the agent, e.g., compound is administered (e.g., to cells or to a subject) in combination with a second agent, e.g., a compound, e.g., a known therapeutic
30 agent or compound. Such an agent, e.g., compound, could be used to treat or prevent cellular proliferation and differentiation disorders, metabolic disorders, neural disorders, or viral disorders. Examples of cytotoxic agents include anti-microtubule agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an anti-metabolite, a mitotic

inhibitor, an alkylating agent, an intercalating agent, an agent capable of interfering with a signal transduction pathway, an agent that promotes apoptosis or necrosis, and radiation.

In another aspect, the invention features methods for treating or preventing a disorder characterized by aberrant activity of a 21617 or 55562-expressing cell, in a subject.

- 5 Preferably, the method includes administering to the subject (e.g., a mammal, e.g., a human) an effective amount of a compound (e.g., a compound identified using the methods described herein) that modulates the activity, or expression, of the 21617 or 55562 polypeptide or nucleic acid.

In a preferred embodiment, the disorder is a cancerous or pre-cancerous condition.

- 10 In a further aspect, the invention provides methods for evaluating the efficacy of a treatment of a disorder, e.g., a cellular proliferative and differentiative disorder, metabolic disorder, neural disorder, or viral disorder. The method includes: treating a subject, e.g., a patient or an animal, with a protocol under evaluation (e.g., treating a subject with one or more of: chemotherapy, radiation, and/or a compound identified using the methods described herein); and evaluating the expression of a 21617 or 55562 nucleic acid or polypeptide before and after treatment. A change, e.g., a decrease or increase, in the level of a 21617 or 55562 nucleic acid (e.g., mRNA) or polypeptide after treatment, relative to the level of expression before treatment, is indicative of the efficacy of the treatment of the disorder. The level of 21617 or 55562 nucleic acid or polypeptide expression can be
20 detected by any method described herein.

In a preferred embodiment, the evaluating step includes obtaining a sample (e.g., a tissue sample, e.g., a biopsy, or a fluid sample) from the subject, before and after treatment and comparing the level of expressing of a 21617 or 55562 nucleic acid (e.g., mRNA) or polypeptide before and after treatment.

- 25 In another aspect, the invention provides methods for evaluating the efficacy of a therapeutic or prophylactic agent (e.g., an anti-neoplastic agent). The method includes: contacting a sample with an agent (e.g., a compound identified using the methods described herein or a cytotoxic agent) and, evaluating the expression of a 21617 or 55562 nucleic acid or polypeptide in the sample before and after the contacting step. A change, e.g., a decrease or increase, in the level of 21617 or 55562 nucleic acid (e.g., mRNA) or polypeptide in the sample obtained after the contacting step, relative to the level of expression in the sample before the contacting step, is indicative of the efficacy of the agent. The level of 21617 or 55562 nucleic acid or polypeptide expression can be detected by any method described
30

herein. In a preferred embodiment, the sample includes cells obtained from the lung, colon, prostate, liver, breast, ovary, or cervix, or a cancerous tissue, e.g., a cancerous lung, colon, prostate, liver, breast, ovary, or cervix tissue.

The invention also provides assays for determining the activity of, or the presence or
5 absence of, 21617 or 55562 polypeptides or nucleic acid molecules in a biological sample, including for disease diagnosis.

In further aspect, the invention provides assays for determining the presence or absence of a genetic alteration in a 21617 or 55562 polypeptide or nucleic acid molecule, including for disease diagnosis.

10 In another aspect, the invention features a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality, and each address of the plurality having a unique capture probe, e.g., a nucleic acid or peptide sequence. At least one address of the plurality has a capture probe that recognizes a 21617 or 55562 molecule. In one embodiment, the capture probe is
15 a nucleic acid, e.g., a probe complementary to a 21617 or 55562 nucleic acid sequence. In another embodiment, the capture probe is a polypeptide, e.g., an antibody specific for 21617 or 55562 polypeptides. Also featured is a method of analyzing a sample by contacting the sample to the aforementioned array and detecting binding of the sample to the array.

Other features and advantages of the invention will be apparent from the following
20 detailed description, and from the claims.

Brief Description of the Drawings

Figure 1 depicts a hydropathy plot of human 21617. Relative hydrophobic residues are shown above the dashed horizontal line, and relative hydrophilic residues are below the dashed horizontal line. Numbers corresponding to positions in the amino acid sequence of
25 human 21617 are indicated. Polypeptides of the invention include fragments which include: all or part of a hydrophobic sequence, i.e., a sequence above the dashed line, e.g., the sequence from about 1 to 20, from about 191 to 203, and from about 293 to 310 of SEQ ID NO:2; all or part of a hydrophilic sequence, i.e., a sequence below the dashed line, e.g., the sequence of from about 68 to 77, from about 222 to 236, and from about 325 to 340 of SEQ
30 ID NO:2.

Figure 2 depicts an alignment of the short chain dehydrogenase domain of human 21617 with a consensus amino acid sequence derived from a hidden Markov model (HMM) from PFAM. The upper sequence is the consensus amino acid sequence (SEQ ID NO:7),

while the lower amino acid sequence corresponds to amino acids 37 to 249 of SEQ ID NO:2.

Figure 3 depicts a hydropathy plot of human 55562. Relative hydrophobic residues are shown above the dashed horizontal line, and relative hydrophilic residues are below the dashed horizontal line. Numbers corresponding to positions in the amino acid sequence of human 55562 are indicated. Polypeptides of the invention include fragments which include: all or part of a hydrophobic sequence, i.e., a sequence above the dashed line, e.g., the sequence from about amino acid 39 to 44, from about 66 to 76, and from about 156 to 167 of SEQ ID NO:5; and all or part of a hydrophilic sequence, i.e., a sequence below the dashed line, e.g., the sequence of from about amino acid 2 to 9, from about 95 to 110, and from about 259 to 273 of SEQ ID NO:5.

Figure 4 depicts an alignment of the tetratricopeptide repeat domain of human 55562 with a consensus amino acid sequence derived from a hidden Markov model (HMM) from PFAM. The upper sequence is the consensus amino acid sequence (SEQ ID NO:8), while the lower amino acid sequence corresponds to amino acids 40 to 73 of SEQ ID NO:5.

Figure 5 depicts a BLAST alignment of a portion of human 55562 that includes the tetratricopeptide domain with a consensus amino acid sequence derived from a ProDomain, PD314595 (Release 2001.1). The upper sequence is the consensus amino acid sequence (SEQ ID NO:9), while the lower amino acid sequence corresponds to human 55562, about amino acids 40 to 266 of SEQ ID NO:5.

Figure 6 depicts a BLAST alignment of a portion of human 55562 that includes the tetratricopeptide domain with a consensus amino acid sequence derived from a ProDomain, PD014461 (Release 1999.2). The upper sequence is the consensus amino acid sequence (SEQ ID NO:10), while the lower amino acid sequence corresponds to human 55562, about amino acids 40 to 97 of SEQ ID NO:5.

Detailed Description

Human 21617

The human 21617 sequence (see SEQ ID NO:1, as recited in Example 1), which is approximately 3624 nucleotides long including untranslated regions, contains a predicted methionine-initiated coding sequence of about 1026 nucleotides, including the termination codon. The coding sequence encodes a 341 amino acid protein (see SEQ ID NO:2, as recited in Example 1). The human 21617 protein of SEQ ID NO:2 and Figure 2 includes an

amino-terminal hydrophobic amino acid sequence, consistent with a signal sequence, of about 21 amino acids (from amino acid 1 to about amino acid 21 of SEQ ID NO:2), which upon cleavage results in the production of a mature protein form). This mature protein form is approximately 319 amino acid residues in length (from about amino acid 22 to amino acid 341 of SEQ ID NO:2).

Human 21617 contains the following regions or other structural features:

a short chain dehydrogenase domain (PFAM Accession Number PF00106) located at about amino acid residues 37 to 249 of SEQ ID NO:2;

a predicted short-chain alcohol dehydrogenase family signature motif (PS00061) located at about amino acid residues 210 to 220 of SEQ ID NO:2;

a predicted signal peptide located at about amino acid residues 1 to 21 of SEQ ID NO:2, which when cleaved gives a predicted mature protein of 319 amino acids, from about amino acid residues 22 to 341 of SEQ ID NO:2;

two dileucine motifs located at about amino acid residues 62 to 63 and 154 to 155 of SEQ ID NO:2;

one predicted glycosaminoglycan attachment site (PS00002) located at about amino acid residues 46 to 49 of SEQ ID NO:2;

three predicted Protein Kinase C phosphorylation sites (PS00005) located at about amino acid residues 11 to 13, 176 to 178, and 289 to 291 of SEQ ID NO:2;

two predicted Casein Kinase II phosphorylation sites (PS00006) located at about amino acid residues 72 to 75, and 183 to 186 of SEQ ID NO:2;

six predicted N-myristoylation sites (PS00008) located at about amino acid residues 43 to 48, 147 to 152, 200 to 205, 235 to 240, 249 to 254, and 316 to 321 of SEQ ID NO:2; and

one predicted amidation site (PS00009) located at about amino acid residues 119 to 122 of SEQ ID NO:2.

For general information regarding PFAM identifiers, PS prefix and PF prefix domain identification numbers, refer to Sonnhammer et al. (1997) Protein 28:405-420 and <http://www.psc.edu/general/software/packages/pfam/pfam.html>.

A plasmid containing the nucleotide sequence encoding human 21617 (clone "Fbh21617FL") was deposited with American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on _____ and assigned Accession Number _____. This deposit will be maintained under the terms of the Budapest Treaty on

the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

5 Human 55562

The human 55562 sequence (see SEQ ID NO:4, as recited in Example 1), which is approximately 1327 nucleotides long including untranslated regions, contains a predicted methionine-initiated coding sequence of about 825 nucleotides, including the termination codon. The coding sequence encodes a 274 amino acid protein (see SEQ ID NO:5, as
10 recited in Example 1).

Human 55562 contains the following regions or other structural features:

a tetratricopeptide repeat domain (PFAM Accession Number PF00515) located at about amino acid residues 40 to 73 of SEQ ID NO:5;

a PD314595 homology domain (ProDom Accession Number PD314595) located at
15 about amino acid residues 40 to 266 of SEQ ID NO:5;

four predicted Protein Kinase C phosphorylation sites (PS00005) located at about amino acid residues 3 to 5, 22 to 24, 81 to 83, and 201 to 203 of SEQ ID NO:5;

four predicted Casein Kinase II phosphorylation sites (PS00006) located at about amino acid residues 139 to 142, 180 to 183, 216 to 219, 261 to 264 of SEQ ID NO:5;

20 three predicted cAMP/cGMP-dependent protein kinase phosphorylation sites (PS00004) located at about amino acid residues 5 to 8, 19 to 22, and 268 to 271 of SEQ ID NO:5;

two predicted N-glycosylation sites (PS00001) located at about amino acid residues 122 to 125, 137 to 140 of SEQ ID NO:5; and

25 one predicted N-myristylation sites (PS00008) located at about amino acid residues 76 to 81 of SEQ ID NO:5.

For general information regarding PFAM identifiers, PS prefix and PF prefix domain identification numbers, refer to Sonnhammer *et al.* (1997) *Protein* 28:405-420 and <http://www.psc.edu/general/software/packages/pfam/pfam.html>.

30 A plasmid containing the nucleotide sequence encoding human 55562 (clone "Fbh55562FL") was deposited with American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on _____ and assigned Accession Number _____. This deposit will be maintained under the terms of the Budapest Treaty on

the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

Gene Name	cDNA	Protein	Coding Region	ATCC accession number
21617	SEQ ID NO:1	SEQ ID NO:2	SEQ ID NO:3	
55562	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6	

5

21617 Polypeptide Characteristics

The 21617 protein contains a significant number of structural characteristics in common with members of the short chain dehydrogenase family. The term “family” when referring to the protein and nucleic acid molecules of the invention means two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin as well as other distinct proteins of human origin, or alternatively, can contain homologues of non-human origin, e.g., rat or mouse proteins. Members of a family can also have common functional characteristics.

A short chain dehydrogenase family of proteins is characterized by the presence of at least two domains; the first binds a coenzyme, such as NAD or NADP, and the second binds substrate. Sequence of the coenzyme domain does not appear to be conserved among dehydrogenases. The second domain determines substrate specificity and contains amino acids involved in catalysis.

Short-chain dehydrogenases/reductases (SDRs) typically function as dimers or tetramers. The subunits are composed of approximately 250 to 300 amino acid residues and include an N-terminal co-enzyme binding motif having the sequence G-X-X-X-G-X-G, and an active-site motif having the sequence Y-X-X-K (Opperman et al. (1999) *Enzymology and Molecular Biology of Carbonyl Metabolism* 7 ed. Weiner et al., Plenum Publishers, NY p. 373-377). Although identity between different SDR members is at the 15% to 30% level, three-dimensional structures thus far analyzed reveal a highly similar conformation consisting of a single subunit that includes seven to eight β -strands.

Members of short chain dehydrogenase family include alcohol dehydrogenase, 3- β -hydroxysteroid dehydrogenase, estradiol 17- β -dehydrogenase, retinal dehydrogenase, and NADPH-dependent carbonyl reductase. Thus, this family includes enzymes critical for the proper function of many physiological systems, including metabolism (e.g., alcohol
 5 metabolism, steroid metabolism, and the metabolism of toxins), and cellular proliferation and differentiation.

A 21617 polypeptide can include a "short chain dehydrogenase domain" or regions homologous with a "short chain dehydrogenase domain".

As used herein, the terms "short chain dehydrogenase domain" or "dehydrogenase"
 10 includes an amino acid sequence of about 100 to 300 amino acid residues in length, having a bit score for the alignment of the sequence to the short chain dehydrogenase domain profile (PFAM HMM) of at least 70. Preferably, a short chain dehydrogenase domain includes at least about 140 to 280 amino acids, more preferably about 200 to 220 amino acid residues, and has a bit score for the alignment of the sequence to the short chain dehydrogenase
 15 domain (HMM) of at least 100, 125, 135, or greater. The short chain dehydrogenase domain (HMM) has been assigned the PFAM Accession Number PF00106. An alignment of the short chain dehydrogenase domain (amino acids 37 to 249 of SEQ ID NO:2) of human 21617 with a consensus amino acid sequence (SEQ ID NO:7) derived from a hidden Markov model is depicted in Figure 2.

20 In a preferred embodiment 21617 polypeptide or protein has a "short chain dehydrogenase domain" or a region which includes at least about 100 to 300, more preferably about 140 to 280, or 200 to 220 amino acid residues and has at least about 50%, 60%, 70% 80% 90% 95%, 98%, 99%, or 100% homology with a "short chain dehydrogenase domain", e.g., the short chain dehydrogenase domain of human 21617 (e.g.,
 25 residues 37 to 249 of SEQ ID NO:2).

To identify the presence of a "short chain dehydrogenase" domain in a 21617 protein sequence, and make the determination that a polypeptide or protein of interest has a particular profile, the amino acid sequence of the protein can be searched against the PFAM database of HMMs (e.g., the PFAM database, release 2.1) using the default parameters. For
 30 example, the hmmsf program, which is available as part of the HMMER package of search programs, is a family specific default program for MILPAT0063 and a score of 15 is the default threshold score for determining a hit. Alternatively, the threshold score for determining a hit can be lowered (e.g., to 8 bits). A description of the PFAM database can

be found in Sonhammer *et al.* (1997), *Proteins* 28(3):405-420, and a detailed description of HMMs can be found, for example, in Gribskov *et al.*(1990), *Meth. Enzymol.* 183:146-159; Gribskov *et al.*(1987), *Proc. Natl. Acad. Sci. USA* 84:4355-4358; Krogh *et al.*(1994), *J. Mol. Biol.* 235:1501-1531; and Stultz *et al.*(1993), *Protein Sci.* 2:305-314, the contents of which are incorporated herein by reference. A search was performed against the PFAM HMM database resulting in the identification of a “short chain dehydrogenase” domain in the amino acid sequence of human 21617 located at about amino acid residues 37 to 249 of SEQ ID NO:2 (see Figure 2).

In some embodiments, a 21617 protein includes at least one dehydrogenase family signature motif. As used herein, a “dehydrogenase family signature motif” includes a sequence of at least eleven amino acid residues defined by the sequence: [LIVSPADNK]-X(12)-Y-[PSTAGNCSV]-[STAGNQCIVM]-[STAGC]-K-{PC}-[SAGFYR]-[LIVMSTAGD]-X(2)-[LIVMFYW]-X(3)-[LIVMFYWGAPTHQ]-[GSACQRHM]. A dehydrogenase family signature motif, as defined, can be involved in the oxidation of a chemical group, e.g., an alcohol group (C-OH), or the reduction of a chemical group, e.g., a carbonyl group (C=O). A dehydrogenase family signature motif can include 16, 24, and even 29 amino acid residues. The dehydrogenase family signature motif has been given the PROSITE Accession Number PS00061.

In preferred embodiments, a 21617 polypeptide or protein has at least one dehydrogenase family signature motif, or a region which includes at least 11 amino acid residues and has at least 70%, 80%, 90%, or 100% homology with a “dehydrogenase family signature motif”, e.g., dehydrogenase family signature motif of human 21617, e.g., about amino acid residues 210 to 220 of SEQ ID NO:2.

In some embodiments, a 21617 molecule can further include a signal sequence. As used herein, a “signal peptide” or “signal sequence” refers to a peptide of about 15 to 50, preferably about 20 to 40, more preferably, 21 amino acid residues in length which occurs at the N-terminus of secretory and integral membrane proteins and which contains a majority of hydrophobic amino acid residues. For example, a signal sequence contains at least about 15 to 50, preferably about 20 to 40, more preferably, 21 amino acid residues, and has at least about 40-70%, preferably about 50-65%, and more preferably about 55-60% hydrophobic amino acid residues (e.g., alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, or proline). Such a “signal sequence”, also referred to in the art as a “signal peptide”, serves to direct a protein containing such a sequence to a lipid bilayer. For

example, in one embodiment, a 21617 protein contains a signal sequence located at about amino acid residues 1 to 21 of SEQ ID NO:2. The "signal sequence" is cleaved during processing of the mature protein. The mature 21617 protein corresponds to about amino acid residues 23 to 341 of SEQ ID NO:2.

5 In preferred embodiments, a 21617 polypeptide or protein has at least one predicted signal sequence, or a region which includes at least 15, 18, 20, or even 21 amino acid residues and has at least 70%, 80%, 90%, or 100% homology with a "signal sequence", e.g., a signal sequence of human 21617, e.g., about amino acid residues 1 to 21 of SEQ ID NO:2.

A 21617 family member can include at least one short chain dehydrogenase domain.
10 Furthermore, a 21617 family member can include at least one dehydrogenase family signature motif; at least one signal sequence; at least one, two, preferably three protein kinase C phosphorylation sites; at least one, preferably two casein kinase II phosphorylation sites; at least one, two, three, four, five, preferably six N-myristylation sites; and at least one amidation site.

15 As the 21617 polypeptides of the invention may modulate 21617-mediated activities, they may be useful as of for developing novel diagnostic and therapeutic agents for 21617-mediated or related disorders, as described below.

As used herein, a "21617 activity", "biological activity of 21617" or "functional activity of 21617", refers to an activity exerted by a 21617 protein, polypeptide or nucleic acid molecule. For example, a 21617 activity can be an activity exerted by 21617 in a physiological milieu on, e.g., a 21617-responsive cell or on a 21617 substrate, e.g., a small molecule (e.g. a steroid molecule or a toxin) or a protein. A 21617 activity can be determined *in vivo* or *in vitro*. In one embodiment, a 21617 activity is a direct activity, such as an association with a 21617 target molecule. A "target molecule" or "binding partner" is
20 a molecule with which a 21617 protein binds or interacts in nature. In an exemplary embodiment, 21617 is an enzyme that oxidizes an alcohol group or reduces a carbonyl group found in a substrate.

A 21617 activity can also be an indirect activity, e.g., a cellular signaling activity mediated by interaction of a 21617 substrate with a receptor. The features of the 21617
30 molecules of the present invention can provide similar biological activities as short chain dehydrogenase family members. For example, the 21617 proteins of the present invention can have one or more of the following activities: (1) steroid biosynthesis or metabolism (breakdown); (2) developmental changes associated with steroid biosynthesis or metabolism

(e.g., sex trait development); (3) metabolism or removal of natural or xenobiotic substances (e.g., ethanol, toxins, etc.); or (4) cellular proliferation or differentiation.

Furthermore, the 21617 molecules of the invention can be expected to function in the tissues where they are expressed, e.g., colon, breast, lung, cervix, ovary, liver, kidney, endothelial cells, and tumor tissue derived thereof. Thus, the 21617 molecules can act as novel diagnostic targets and therapeutic agents for controlling metabolic disorders, e.g., involving the metabolism of small molecules (e.g., steroids or alcohols), proliferation and differentiation disorders, e.g., cancer (e.g., colon, colorectal, breast, lung, cervical, ovarian or liver cancer), kidney disorders, or endothelial cell disorders.

55562 Polypeptide Characteristics

The 55562 protein contains a significant number of structural characteristics in common with members of the tetratricopeptide repeat (TPR) family. The term “family” when referring to the protein and nucleic acid molecules of the invention means two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin as well as other distinct proteins of human origin, or alternatively, can contain homologues of non-human origin, e.g., rat or mouse proteins. Members of a family can also have common functional characteristics.

A common fold characterizes the TPR domains of the TPR family of proteins. TPR repeats can be highly degenerate. However, a pattern of small and large residues is required for the repeat to adopt the TPR fold. Each repeat of a TPR domain folds into an antiparallel pair of α -helices. Adjacent repeats can pack against one another in a parallel format to produce a right-handed super-helical structure with a continuous amphipathic groove, e.g., a possible binding site of an α -helix of an interaction partner (Das *et al.*, *supra*).

TPR domains can serve a variety of functions, including scaffolding protein-protein interactions for complex formation and regulation of protein function. Consequently, TPRs have been found in proteins that regulate a variety of different processes, including

transcription, neurogenesis, signal transduction, metabolism, and protein folding and trafficking.

A 55562 polypeptide can include a "TPR domain" or regions homologous with a "TPR domain".

5 As used herein, the terms "tetratricopeptide repeat domain" or "TPR domain" include an amino acid sequence of about 20 to 45 amino acid residues in length and having a bit score for the alignment of the sequence to the TPR domain (HMM) of at least 5. Preferably, a TPR domain includes at least about 15 to 60 amino acids, more preferably about 20 to 45 amino acid residues, or about 27 to 36 amino acids and has a bit score for the alignment of
10 the sequence to the TPR domain (HMM) of at least 1, 2, 3, 4, 5, 6, 7, or greater. Preferably, a TRP domain includes at least one small hydrophobic residue in both the first and second helix which are capable of interacting with one another such that interaction between the two helices is stabilized. In addition, a TRP domain can include a conserved aromatic residue. The TPR domain (HMM) has been assigned the PFAM Accession Number
15 PF00515. An alignment of the TPR domain (amino acids 40 to 73 of SEQ ID NO:5) of human 55562 with a consensus amino acid sequence (SEQ ID NO:8) derived from a hidden Markov model is depicted in Figure 4. As can be seen from the alignment, human 55562 includes alanine residues located at about amino acid residues 47 and 58 of SEQ ID NO:5, as well as a tyrosine residue located at about amino acid residue 55 of SEQ ID NO:5.

20 In a preferred embodiment, a 55562 polypeptide or protein has a "TPR domain" or a region which includes at least about 15 to 60 more preferably about 20 to 45 or 27 to 36, e.g., about 33 amino acid residues and has at least about 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% homology with a "TPR domain," e.g., the TPR domain of human 55562 (e.g., residues 40 to 73 of SEQ ID NO:5).

25 To identify the presence of a "TPR" domain in a 55562 protein sequence, and make the determination that a polypeptide or protein of interest has a particular profile, the amino acid sequence of the protein can be searched against the PFAM database of HMMs (e.g., the Pfam database, release 2.1) using the default parameters. For example, the hmmsf program, which is available as part of the HMMER package of search programs, is a family specific
30 default program for MILPAT0063 and a score of 15 is the default threshold score for determining a hit. Alternatively, the threshold score for determining a hit can be lowered (e.g., to 8 bits). A description of the PFAM database can be found in Sonhammer *et al.* (1997) *Proteins* 28(3):405-420 and a detailed description of HMMs can be found, for

example, in Gribskov *et al.*(1990) *Meth. Enzymol.* 183:146-159; Gribskov *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:4355-4358; Krogh *et al.* (1994) *J. Mol. Biol.* 235:1501-1531; and Stultz *et al.*(1993) *Protein Sci.* 2:305-314, the contents of which are incorporated herein by reference. A search was performed against the HMM database resulting in the
 5 identification of a “TPR domain” domain in the amino acid sequence of human 55562 located at about amino acid residues 40 to 73 of SEQ ID NO:5 (see Figure 4).

A 55562 family member can further include a “PD314595 homology domain” or regions homologous with a “PD314595 homology domain”.

As used herein, the term “PD314595 homology domain” includes an amino acid
 10 sequence of about 150 to 300 amino acid residues in length and having a bit score for the alignment of the sequence to the TPR domain (HMM) of at least 70. Preferably, a PD314595 homology domain includes at least about 175 to 275 amino acids, more preferably about 200 to 250 amino acid residues, or about 220 to 235 amino acids and has a bit score for the alignment of the sequence to the TPR domain (HMM) of at least 100, 125,
 15 130, 135, 140, or greater. Preferably, a PD314595 homology domain includes at least one tetratricopeptide repeat located near the N-terminus of the domain. The PD314595 homology domain has been given the ProDom accession number PD134595. An alignment of the PD314595 homology domain (about amino acids 40 to 266 of SEQ ID NO:5) of human 55562 with a consensus amino acid sequence (SEQ ID NO:9) is depicted in Figure 5.

20 In a preferred embodiment, a 55562 polypeptide or protein has a “PD314595 homology domain” or a region which includes at least about 175 to 275, more preferably about 200 to 250, or about 220 to 235 amino acid residues and has at least about 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% homology with a “PD314595 homology domain,” e.g., the PD314595 homology domain of human 55562 (e.g., residues 40 to 266 of SEQ ID
 25 NO:5).

To identify the presence of a “PD314595 homology domain” in a 55562 protein sequence, and make the determination that a polypeptide or protein of interest has a particular profile, the human 55562 amino acid sequence can be searched against the ProDom database of domains (Corpet *et al.* (1999), *Nucl. Acids Res.* 27:263-267). The
 30 ProDom protein domain database consists of an automatic compilation of homologous domains. Current versions of ProDom are built using recursive PSI-BLAST searches (Altschul SF *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402; Gouzy *et al.* (1999) *Computers and Chemistry* 23:333-340.) of the SWISS-PROT 38 and TREMBL protein databases. The

database automatically generates a consensus sequence for each domain. A BLAST search was performed against the ProDom database resulting in the identification of a consensus amino acid sequence for the PD314595 homology domain in the amino acid sequence of human 55562 at about residues 40 to 266 of SEQ ID NO:5 (see Figure 5).

5 A 55562 family member can include at least one TPR domain and at least one PD314595 homology domain. Furthermore, a 55562 family member can include at least one, preferably two predicted N-glycosylation sites; at least one, two, three, preferably four protein kinase C phosphorylation sites (PS00005); at least one, two, three, preferably four predicted casein kinase II phosphorylation sites (PS00006); at least one, two, preferably
10 three cAMP and cGMP-dependent protein kinase phosphorylation sites; and at least one predicted N-myristylation sites (PS00008).

As the 55562 polypeptides of the invention may modulate 55562-mediated activities, they may be useful as of for developing novel diagnostic and therapeutic agents for 55562-mediated or related disorders, as described below.

15 As used herein, a "55562 activity", "biological activity of 55562" or "functional activity of 55562", refers to an activity exerted by a 55562 protein, polypeptide or nucleic acid molecule on e.g., a 55562-responsive cell or on a 55562 substrate, e.g., a protein substrate, as determined *in vivo* or *in vitro*. In one embodiment, a 55562 activity is a direct activity, such as an association with a 55562 target molecule. A "target molecule" or
20 "binding partner" is a molecule with which a 55562 protein binds or interacts in nature. In an exemplary embodiment, 55562 is a receptor, e.g., for a polyunsaturated fatty acid; a interface for binding a chaperone; or an interface for scaffolding with a protein complex. A 55562 activity can also be an indirect activity, e.g., a cellular signaling activity mediated by interaction of the 55562 protein with a 55562 receptor.

25 Based on the above-described sequence similarities, the 55562 molecules of the present invention are predicted to have similar biological activities as TPR family members. For example, the 55562 proteins of the present invention can have one or more of the following activities: (1) sensing a second messenger, e.g., a polyunsaturated fatty acid (e.g., arachidonic acid); (2) associating with other proteins so as to form a multimeric protein
30 assembly; (3) allosterically inhibiting an enzyme activity, e.g., an anaphase promoting activity, a kinase activity, or a phosphatase activity; (4) regulating an intracellular trafficking pathway; (5) interfacing with intracellular trafficking landmark and regulator proteins; (6) regulation of metabolic processes including, e.g., regulation of metabolic enzymes, e.g.,

NADPH oxidase; or (7) inhibiting any of (1)-(6), e.g., via the formation of a dominant negative fragment of 55562.

Thus, the 55562 molecules can act as novel diagnostic targets and therapeutic agents for controlling cell proliferation and/or differentiation disorders, neural disorders (e.g., disorders of the brain), metabolic disorders, or viral disorders (e.g., as related to the viral inhibition of protein trafficking).

The 21617 or 55562 molecules can act as novel diagnostic targets and therapeutic agents for controlling one or more of cellular proliferative and/or differentiative disorders, metabolic disorders, kidney disorders, endothelial cell disorders, neural disorders (e.g., brain disorders), and viral disorders.

Examples of cellular proliferative and/or differentiative disorders include cancer, e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.

As used herein, the terms "cancer", "hyperproliferative" and "neoplastic" refer to cells having the capacity for autonomous growth. Examples of such cells include cells having an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. "Pathologic hyperproliferative" cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair.

The terms "cancer" or "neoplasms" include malignancies of the various organ systems, such as affecting lung, breast, thyroid, lymphoid, gastrointestinal, and genitourinary tract, as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.

The term "carcinoma" is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system

carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary. The term also includes carcinosarcomas, e.g., which include malignant tumors
 5 composed of carcinomatous and sarcomatous tissues. An "adenocarcinoma" refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.

The term "sarcoma" is art recognized and refers to malignant tumors of mesenchymal derivation.

10 Examples of cellular proliferative and/or differentiative disorders of the colon include, but are not limited to, non-neoplastic polyps, adenomas, familial syndromes, colorectal carcinogenesis, colorectal carcinoma, and carcinoid tumors.

Examples of cellular proliferative and/or differentiative disorders of the liver include, but are not limited to, nodular hyperplasias, adenomas, and malignant tumors, including
 15 primary carcinoma of the liver and metastatic tumors.

Examples of cellular proliferative and/or differentiative disorders of the breast include, but are not limited to, proliferative breast disease including, e.g., epithelial hyperplasia, sclerosing adenosis, and small duct papillomas; tumors, e.g., stromal tumors such as fibroadenoma, phyllodes tumor, and sarcomas, and epithelial tumors such as large
 20 duct papilloma; carcinoma of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma, and miscellaneous
 25 malignant neoplasms. Disorders in the male breast include, but are not limited to, gynecomastia and carcinoma.

Examples of cellular proliferative and/or differentiative disorders of the lung include, but are not limited to, bronchogenic carcinoma, including paraneoplastic syndromes, bronchioloalveolar carcinoma, neuroendocrine tumors, such as bronchial carcinoid,
 30 miscellaneous tumors, and metastatic tumors; pathologies of the pleura, including inflammatory pleural effusions, noninflammatory pleural effusions, pneumothorax, and pleural tumors, including solitary fibrous tumors (pleural fibroma) and malignant mesothelioma.

Additional examples of proliferative disorders include hematopoietic neoplastic disorders. As used herein, the term "hematopoietic neoplastic disorders" includes diseases involving hyperplastic/neoplastic cells of hematopoietic origin. A hematopoietic neoplastic disorder can arise from myeloid, lymphoid or erythroid lineages, or precursor cells thereof.

5 Preferably, the diseases arise from poorly differentiated acute leukemias, e.g., erythroblastic leukemia and acute megakaryoblastic leukemia. Additional exemplary myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) *Crit Rev. in Oncol./Hematol.* 11:267-97); lymphoid malignancies include, but are not
10 limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGL), Hodgkin's disease and
15 Reed-Sternberg disease.

Examples of metabolic disorders include, but are not limited to, diseases of metabolic imbalance, e.g., obesity, anorexia nervosa, cachexia, lipid disorders (e.g., involving lipid
20 production or storage, or the conversion of steroids, e.g., to active or inactive forms), and diabetes. In addition, metabolic disorders can be associated with an inability to eliminate toxins by enzymatically converting a toxin to an inactive form or, conversely, by converting a xenobiotic compound into a toxin.

Disorders involving the kidney include, but are not limited to, congenital anomalies including, but not limited to, cystic diseases of the kidney, that include but are not limited to,
25 cystic renal dysplasia, autosomal dominant (adult) polycystic kidney disease, autosomal recessive (childhood) polycystic kidney disease, and cystic diseases of renal medulla, which include, but are not limited to, medullary sponge kidney, and nephronophthisis-uremic medullary cystic disease complex, acquired (dialysis-associated) cystic disease, such as simple cysts; glomerular diseases including pathologies of glomerular injury that include, but are not
30 limited to, in situ immune complex deposition, that includes, but is not limited to, anti-GBM nephritis, Heymann nephritis, and antibodies against planted antigens, circulating immune complex nephritis, antibodies to glomerular cells, cell-mediated immunity in glomerulonephritis, activation of alternative complement pathway, epithelial cell injury, and

pathologies involving mediators of glomerular injury including cellular and soluble mediators, acute glomerulonephritis, such as acute proliferative (poststreptococcal, postinfectious) glomerulonephritis, including but not limited to, poststreptococcal glomerulonephritis and nonstreptococcal acute glomerulonephritis, rapidly progressive (crescentic) glomerulonephritis, 5 nephrotic syndrome, membranous glomerulonephritis (membranous nephropathy), minimal change disease (lipoid nephrosis), focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, IgA nephropathy (Berger disease), focal proliferative and necrotizing glomerulonephritis (focal glomerulonephritis), hereditary nephritis, including but not limited to, Alport syndrome and thin membrane disease (benign familial hematuria), chronic 10 glomerulonephritis, glomerular lesions associated with systemic disease, including but not limited to, systemic lupus erythematosus, Henoch-Schönlein purpura, bacterial endocarditis, diabetic glomerulosclerosis, amyloidosis, fibrillary and immunotactoid glomerulonephritis, and other systemic disorders; diseases affecting tubules and interstitium, including acute tubular necrosis and tubulointerstitial nephritis, including but not limited to, pyelonephritis and urinary 15 tract infection, acute pyelonephritis, chronic pyelonephritis and reflux nephropathy, and tubulointerstitial nephritis induced by drugs and toxins, including but not limited to, acute drug-induced interstitial nephritis, analgesic abuse nephropathy, nephropathy associated with nonsteroidal anti-inflammatory drugs, and other tubulointerstitial diseases including, but not limited to, urate nephropathy, hypercalcemia and nephrocalcinosis, and multiple myeloma; 20 diseases of blood vessels including benign nephrosclerosis, malignant hypertension and accelerated nephrosclerosis, renal artery stenosis, and thrombotic microangiopathies including, but not limited to, classic (childhood) hemolytic-uremic syndrome, adult hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura, idiopathic HUS/TTP, and other vascular disorders including, but not limited to, atherosclerotic ischemic renal disease, atheroembolic 25 renal disease, sickle cell disease nephropathy, diffuse cortical necrosis, and renal infarcts; urinary tract obstruction (obstructive uropathy); urolithiasis (renal calculi, stones); and tumors of the kidney including, but not limited to, benign tumors, such as renal papillary adenoma, renal fibroma or hamartoma (renomedullary interstitial cell tumor), angiomyolipoma, and oncocytoma, and malignant tumors, including renal cell carcinoma (hypernephroma, 30 adenocarcinoma of kidney), which includes urothelial carcinomas of renal pelvis.

Disorders involving endothelial cells include, but are not limited to, disorders characterized by aberrant, unregulated, or unwanted endothelial cell activity, e.g., proliferation, migration, angiogenesis, or vascularization; or aberrant expression of cell

surface adhesion molecules or genes associated with angiogenesis, e.g., TIE-2, FLT and FLK. Endothelial cell disorders include tumorigenesis, tumor metastasis, psoriasis, diabetic retinopathy, endometriosis, Grave's disease, ischemic disease (e.g., atherosclerosis), and chronic inflammatory diseases (e.g., rheumatoid arthritis).

- 5 Disorders involving the brain include, but are not limited to, disorders involving neurons, and disorders involving glia, such as astrocytes, oligodendrocytes, ependymal cells, and microglia; cerebral edema, raised intracranial pressure and herniation, and hydrocephalus; malformations and developmental diseases, such as neural tube defects, forebrain anomalies, posterior fossa anomalies, and syringomyelia and hydromyelia;
- 10 perinatal brain injury; cerebrovascular diseases, such as those related to hypoxia, ischemia, and infarction, including hypotension, hypoperfusion, and low-flow states--global cerebral ischemia and focal cerebral ischemia--infarction from obstruction of local blood supply, intracranial hemorrhage, including intracerebral (intraparenchymal) hemorrhage, subarachnoid hemorrhage and ruptured berry aneurysms, and vascular malformations,
- 15 hypertensive cerebrovascular disease, including lacunar infarcts, slit hemorrhages, and hypertensive encephalopathy; infections, such as acute meningitis, including acute pyogenic (bacterial) meningitis and acute aseptic (viral) meningitis, acute focal suppurative infections, including brain abscess, subdural empyema, and extradural abscess, chronic bacterial meningoencephalitis, including tuberculosis and mycobacterioses, neurosyphilis, and
- 20 neuroborreliosis (Lyme disease), viral meningoencephalitis, including arthropod-borne (Arbo) viral encephalitis, *Herpes simplex* virus Type 1, *Herpes simplex* virus Type 2, *Varicella-zoster* virus (*Herpes zoster*), cytomegalovirus, poliomyelitis, rabies, and human immunodeficiency virus 1, including HIV-1 meningoencephalitis (subacute encephalitis), vacuolar myelopathy, AIDS-associated myopathy, peripheral neuropathy, and AIDS in
- 25 children, progressive multifocal leukoencephalopathy, subacute sclerosing panencephalitis, fungal meningoencephalitis, other infectious diseases of the nervous system; transmissible spongiform encephalopathies (prion diseases); demyelinating diseases, including multiple sclerosis, multiple sclerosis variants, acute disseminated encephalomyelitis and acute necrotizing hemorrhagic encephalomyelitis, and other diseases with demyelination;
- 30 degenerative diseases, such as degenerative diseases affecting the cerebral cortex, including Alzheimer disease and Pick disease, degenerative diseases of basal ganglia and brain stem, including Parkinsonism, idiopathic Parkinson disease (paralysis agitans), progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, including

striatonigral degeneration, Shy-Drager syndrome, and olivopontocerebellar atrophy, and
 Huntington disease; spinocerebellar degenerations, including spinocerebellar ataxias,
 including Friedreich ataxia, and ataxia-telangiectasia, degenerative diseases affecting motor
 neurons, including amyotrophic lateral sclerosis (motor neuron disease), bulbospinal atrophy
 5 (Kennedy syndrome), and spinal muscular atrophy; inborn errors of metabolism, such as
 leukodystrophies, including Krabbe disease, metachromatic leukodystrophy,
 adrenoleukodystrophy, Pelizaeus-Merzbacher disease, and Canavan disease, mitochondrial
 encephalomyopathies, including Leigh disease and other mitochondrial
 encephalomyopathies; toxic and acquired metabolic diseases, including vitamin deficiencies
 10 such as thiamine (vitamin B₁) deficiency and vitamin B₁₂ deficiency, neurologic sequelae of
 metabolic disturbances, including hypoglycemia, hyperglycemia, and hepatic
 encephalopathy, toxic disorders, including carbon monoxide, methanol, ethanol, and
 radiation, including combined methotrexate and radiation-induced injury; tumors, such as
 gliomas, including astrocytoma, including fibrillary (diffuse) astrocytoma and glioblastoma
 15 multiforme, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and brain stem glioma,
 oligodendroglioma, and ependymoma and related paraventricular mass lesions, neuronal
 tumors, poorly differentiated neoplasms, including medulloblastoma, other parenchymal
 tumors, including primary brain lymphoma, germ cell tumors, and pineal parenchymal
 tumors, meningiomas, metastatic tumors, paraneoplastic syndromes, peripheral nerve sheath
 20 tumors, including schwannoma, neurofibroma, and malignant peripheral nerve sheath tumor
 (malignant schwannoma), and neurocutaneous syndromes (phakomatoses), including
 neurofibromatosis, including Type 1 neurofibromatosis (NF1) and TYPE 2
 neurofibromatosis (NF2), tuberous sclerosis, and Von Hippel-Lindau disease.

Examples of viral disorders include, but are not limited to, Hepatitis B, Hepatitis C,
 25 Herpes Simplex Virus (HSV), and HIV. Viral diseases are typically associated with cell
 death and tissue fibrosis, especially liver fibrosis, epithelial sores, or loss of white blood
 cells. In addition, viruses can cause virus-associated carcinoma, especially hepatocellular
 cancer.

30 The 21617 or 55562 protein, fragments thereof, and derivatives and other variants of
 the sequences in SEQ ID NO:2 or SEQ ID NO:5 thereof are collectively referred to as
 “polypeptides or proteins of the invention” or “21617 polypeptides or proteins” or “55562
 polypeptides or proteins”. Nucleic acid molecules encoding such polypeptides or proteins

are collectively referred to as “nucleic acids of the invention” or “21617 nucleic acids” or “55562 nucleic acids.” 21617 or 55562 molecules refer to 21617 or 55562 nucleic acids, polypeptides, and antibodies.

As used herein, the term “nucleic acid molecule” includes DNA molecules (e.g., a
 5 cDNA or genomic DNA), RNA molecules (e.g., an mRNA) and analogs of the DNA or RNA. A DNA or RNA analog can be synthesized from nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

The term “isolated nucleic acid molecule” or “purified nucleic acid molecule”
 10 includes nucleic acid molecules that are separated from other nucleic acid molecules present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term “isolated” includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5'
 15 and/or 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an “isolated” nucleic
 20 acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

As used herein, the term “hybridizes under low stringency, medium stringency, high
 stringency, or very high stringency conditions” describes conditions for hybridization and
 25 washing. Guidance for performing hybridization reactions can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, which is incorporated by reference. Aqueous and nonaqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate
 30 (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C; 3) high stringency hybridization conditions

in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C; and preferably 4) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C. Very high stringency conditions (4) are the preferred conditions and the ones that should be used
 5 unless otherwise specified.

Preferably, an isolated nucleic acid molecule of the invention that hybridizes under a stringency condition described herein to the sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, corresponds to a naturally-occurring nucleic acid molecule.

As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or
 10 DNA molecule having a nucleotide sequence that occurs in nature. For example a naturally occurring nucleic acid molecule can encode a natural protein.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules that include at least an open reading frame encoding a 21617 or 55562 protein. The gene can optionally further include non-coding sequences, e.g., regulatory sequences
 15 and introns. Preferably, a gene encodes a mammalian 21617 or 55562 protein or derivative thereof.

An "isolated" or "purified" polypeptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when
 20 chemically synthesized. "Substantially free" means that a preparation of 21617 or 55562 protein is at least 10% pure. In a preferred embodiment, the preparation of 21617 or 55562 protein has less than about 30%, 20%, 10% and more preferably 5% (by dry weight), of non-21617 or 55562 protein (also referred to herein as a "contaminating protein"), or of chemical precursors or non-21617 or 55562 chemicals. When the 21617 or 55562 protein or
 25 biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The invention includes isolated or purified preparations of at least 0.01, 0.1, 1.0, and 10 milligrams in dry weight.

30 A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of 21617 or 55562 without abolishing or substantially altering a 21617 or 55562 activity. Preferably the alteration does not substantially alter the 21617 or 55562 activity, e.g., the activity is at least 20%, 40%, 60%, 70% or 80% of wild-type. An

"essential" amino acid residue is a residue that, when altered from the wild-type sequence of 21617 or 55562, results in abolishing a 21617 or 55562 activity such that less than 20% of the wild-type activity is present. For example, conserved amino acid residues in 21617 or 55562 are predicted to be particularly unamenable to alteration.

5 A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a 21617 or 55562 protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a 21617 or 55562 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for 21617 or 55562 biological activity to identify mutants that retain activity. Following mutagenesis SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, the encoded protein can be expressed recombinationally and the activity of the protein can be determined.

As used herein, a "biologically active portion" of a 21617 or 55562 protein includes a fragment of a 21617 or 55562 protein which participates in an interaction, e.g., an intramolecular or an inter-molecular interaction. An inter-molecular interaction can be a specific binding interaction or an enzymatic interaction (e.g., the interaction can be transient and a covalent bond is formed or broken). An inter-molecular interaction can be between a 21617 or 55562 molecule and a non-21617 or 55562 molecule or between a first 21617 or 55562 molecule and a second 21617 or 55562 molecule (e.g., a dimerization interaction). Biologically active portions of a 21617 or 55562 protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the 21617 or 55562 protein, e.g., the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5, which include less amino acids than the full length 21617 or 55562 proteins, and exhibit at least one activity of a 21617 or 55562 protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the 21617 or 55562 protein,

e.g., hydrolase activity or the ability to contribute to the formation of complexes, e.g., by interacting with other tetratricopeptide proteins. A biologically active portion of a 21617 or 55562 protein can be a polypeptide which is, for example, 10, 25, 50, 100, 200 or more amino acids in length. Biologically active portions of a 21617 or 55562 protein can be used
 5 as targets for developing agents which modulate a 21617 or 55562 mediated activity, e.g., hydrolase activity or the ability to contribute to the formation of complexes, e.g., by interacting with other tetratricopeptide proteins.

Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.

10 To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for
 15 comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second
 20 sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology").

The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

25 The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) *J. Mol. Biol.* 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at
 30 <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>),

using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

5 The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

10 The nucleic acid and protein sequences described herein can be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to 21617 or 55562 nucleic acid
15 molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to 21617 or 55562 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the
20 default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

Particularly preferred 21617 or 55562 polypeptides of the present invention have an amino acid sequence substantially identical to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5. In the context of an amino acid sequence, the term "substantially identical"
25 is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity. For example, amino acid sequences that contain a common structural domain having at least
30 about 60%, or 65% identity, likely 75% identity, more likely 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:2 or SEQ ID NO:5 are termed substantially identical.

In the context of nucleotide sequence, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common

5 functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 60%, or 65% identity, likely 75% identity, more likely 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6 are termed substantially identical.

10 "Misexpression or aberrant expression", as used herein, refers to a non-wildtype pattern of gene expression at the RNA or protein level. It includes: expression at non-wild type levels, i.e., over- or under-expression; a pattern of expression that differs from wild type in terms of the time or stage at which the gene is expressed, e.g., increased or decreased expression (as compared with wild type) at a predetermined developmental period or stage;

15 a pattern of expression that differs from wild type in terms of altered, e.g., increased or decreased, expression (as compared with wild type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild type in terms of the splicing size, translated amino acid sequence, post-translational modification, or biological activity of the expressed polypeptide; a pattern of expression that differs from wild type in terms of the

20 effect of an environmental stimulus or extracellular stimulus on expression of the gene, e.g., a pattern of increased or decreased expression (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus.

"Subject," as used herein, refers to human and non-human animals. The term "non-human animals" of the invention includes all vertebrates, e.g., mammals, such as non-human

25 primates (particularly higher primates), sheep, dog, rodent (e.g., mouse or rat), guinea pig, goat, pig, cat, rabbits, cow, and non-mammals, such as chickens, amphibians, reptiles, etc. In a preferred embodiment, the subject is a human. In another embodiment, the subject is an experimental animal or animal suitable as a disease model.

A "purified preparation of cells", as used herein, refers to an in vitro preparation of

30 cells. In the case cells from multicellular organisms (e.g., plants and animals), a purified preparation of cells is a subset of cells obtained from the organism, not the entire intact organism. In the case of unicellular microorganisms (e.g., cultured cells and microbial

cells), it consists of a preparation of at least 10% and more preferably 50% of the subject cells.

Various aspects of the invention are described in further detail below.

Isolated Nucleic Acid Molecules

5 In one aspect, the invention provides, an isolated or purified, nucleic acid molecule that encodes a 21617 or 55562 polypeptide described herein, e.g., a full-length 21617 or 55562 protein or a fragment thereof, e.g., a biologically active portion of a 21617 or 55562 protein. Also included is a nucleic acid fragment suitable for use as a hybridization probe, which can be used, e.g., to identify a nucleic acid molecule encoding a polypeptide of the
10 invention, 21617 or 55562 mRNA, and fragments suitable for use as primers, e.g., PCR primers for the amplification or mutation of nucleic acid molecules.

In one embodiment, an isolated nucleic acid molecule of the invention includes the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4, or a portion of either of these nucleotide sequences. In one embodiment, the nucleic acid molecule includes sequences
15 encoding the human 21617 or 55562 protein (i.e., "the coding region" of SEQ ID NO:1 or SEQ ID NO:4, as shown in SEQ ID NO:3 and SEQ ID NO:6, respectively), as well as 5' untranslated sequences. Alternatively, the nucleic acid molecule can include only the coding region of SEQ ID NO:1 or SEQ ID NO:4 (e.g., SEQ ID NO:3 or SEQ ID NO:6, respectively) and, e.g., no flanking sequences which normally accompany the subject
20 sequence. In another embodiment, the nucleic acid molecule encodes a sequence corresponding to a fragment of a 21617 protein from about amino acid residues 37 to 249 of SEQ ID NO:2, or a fragment of a 55562 protein from about amino acid residues 40 to 73 of SEQ ID NO:5.

In another embodiment, an isolated nucleic acid molecule of the invention includes a
25 nucleic acid molecule which is a full complement of the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, or a portion of any of these nucleotide sequences. In other embodiments, the nucleic acid molecule of the invention is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, such that it can hybridize (e.g., under a stringency
30 condition described herein) to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, thereby forming a stable duplex.

In one embodiment, an isolated nucleic acid molecule of the present invention includes a nucleotide sequence which is at least about: 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the entire length of the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or
 5 SEQ ID NO:6, or a portion, preferably of the same length, of any of these nucleotide sequences.

21617 Nucleic Acid Fragments

A nucleic acid molecule of the invention can include only a portion of the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:3. For example, such a nucleic acid
 10 molecule can include a fragment which can be used as a probe or primer or a fragment encoding a portion of a 21617 protein, e.g., an immunogenic or biologically active portion of a 21617 protein. A fragment can comprise those nucleotides of SEQ ID NO:1, which encode a short chain dehydrogenase domain of human 21617. The nucleotide sequence determined from the cloning of the 21617 gene allows for the generation of probes and
 15 primers designed for use in identifying and/or cloning other 21617 family members, or fragments thereof, as well as 21617 homologues, or fragments thereof, from other species.

In another embodiment, a nucleic acid includes a nucleotide sequence that includes part, or all, of the coding region and extends into either (or both) the 5' or 3' noncoding region. Other embodiments include a fragment which includes a nucleotide sequence encoding an
 20 amino acid fragment described herein. Nucleic acid fragments can encode a specific domain or site described herein or fragments thereof, particularly fragments thereof which are at least 50 amino acids in length, preferably 70, 80, 90, 100, 125, 150, 200, 250, 300, or 325 amino acids in length. Fragments also include nucleic acid sequences corresponding to specific amino acid sequences described above or fragments thereof. Nucleic acid fragments should not to be
 25 construed as encompassing those fragments that may have been disclosed prior to the invention.

A nucleic acid fragment can include a sequence corresponding to a domain, region, or functional site described herein. A nucleic acid fragment can also include one or more domains, regions, or functional sites described herein. Thus, for example, a 21617 nucleic acid
 30 fragment can include a sequence corresponding to a short chain dehydrogenase domain, a dehydrogenase family signature motif, or a signal peptide domain.

21617 probes and primers are provided. Typically a probe/primer is an isolated or purified oligonucleotide. The oligonucleotide typically includes a region of nucleotide sequence that hybridizes under a stringency condition described herein to at least about 7, 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense or antisense sequence of SEQ ID NO:1 or SEQ ID NO:3, or of a naturally occurring allelic variant or mutant of SEQ ID NO:1 or SEQ ID NO:3. Preferably, an oligonucleotide is less than about 200, 150, 120, or 100 nucleotides in length.

In one embodiment, the probe or primer is attached to a solid support, e.g., a solid support described herein.

One exemplary kit of primers includes a forward primer that anneals to the coding strand and a reverse primer that anneals to the non-coding strand. The forward primer can anneal to the start codon, e.g., the nucleic acid sequence encoding amino acid residue 1 of SEQ ID NO:2. The reverse primer can anneal to the ultimate codon, e.g., the codon immediately before the stop codon, e.g., the codon encoding amino acid residue 341 of SEQ ID NO:2. In a preferred embodiment, the annealing temperatures of the forward and reverse primers differ by no more than 5, 4, 3, or 2°C.

In a preferred embodiment the nucleic acid is a probe which is at least 10, 12, 15, 18, 20 and less than 200, more preferably less than 100, or less than 50, nucleotides in length. It should be identical, or differ by 1, or 2, or less than 5 or 10 nucleotides, from a sequence disclosed herein. If alignment is needed for this comparison the sequences should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.

A probe or primer can be derived from the sense or anti-sense strand of a nucleic acid which encodes a short chain dehydrogenase domain, e.g., the domain at about amino acid 37 to 249 of SEQ ID NO:2.

In another embodiment a set of primers is provided, e.g., primers suitable for use in a PCR, which can be used to amplify a selected region of a 21617 sequence, e.g., a domain, region, site or other sequence described herein. The primers should be at least 5, 10, or 50 base pairs in length and less than 100, or less than 200, base pairs in length. The primers should be identical, or differs by one base from a sequence disclosed herein or from a naturally occurring variant. For example, primers suitable for amplifying all or a portion of any of the following regions are provided: a short chain dehydrogenase domain from about amino acid 37 to 249 of SEQ ID NO:2.

A nucleic acid fragment can encode an epitope bearing region of a polypeptide described herein.

A nucleic acid fragment encoding a "biologically active portion of a 21617 polypeptide" can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, which encodes a polypeptide having a 21617 biological activity (e.g., the biological activities of the 21617 proteins are described herein), expressing the encoded portion of the 21617 protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the 21617 protein. For example, a nucleic acid fragment encoding a biologically active portion of 21617 includes a short chain dehydrogenase domain, e.g., amino acid residues about 37 to 249 of SEQ ID NO:2. A nucleic acid fragment encoding a biologically active portion of a 21617 polypeptide, may comprise a nucleotide sequence which is greater than 300 or more nucleotides in length.

In preferred embodiments, a nucleic acid includes a nucleotide sequence which is about 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2200, 2400, 2600, 2800, 3000, 3200, 3400, 3600, or more nucleotides in length and hybridizes under a stringency condition described herein to a nucleic acid molecule of SEQ ID NO:1, or SEQ ID NO:3.

In a preferred embodiment, a nucleic acid fragment differs by at least 1, 2, 3, 10, 20, or more nucleotides from the sequence of Genbank accession number AF286885, G28278, G29385, or G25914. In some preferred embodiments, a nucleic acid fragment differs by at least 1, 2, 3, 10, 20, or more nucleotides from a sequence disclosed in one or more of WO 00/09552, WO 01/51628, WO 01/55301, WO 01/55364, WO 01/77289, WO 01/5719, EP1033401 or WO 01/02568. Differences can include differing in length or sequence identity. For example, a nucleic acid fragment can: include one or more nucleotides from SEQ ID NO: 1 or SEQ ID NO:3 located outside the region of nucleotides 475-3607; not include all of the nucleotides of Genbank accession number AF286885, G28278, G29385, or G25914 and a sequence disclosed in one or more of WO 00/09552, WO 01/51628, WO 01/55301, WO 01/55364, WO 01/77289, WO 01/5719, EP1033401 or WO 01/02568, e.g., can be one or more nucleotides shorter (at one or both ends) than a sequence disclosed in Genbank accession number AF286885, G28278, G29385, or G25914 or a sequence disclosed in one or more of WO 00/09552, WO 01/51628, WO 01/55301, WO 01/55364, WO 01/77289, WO 01/5719, EP1033401 or WO 01/02568; or can differ by one or more nucleotides in the region of overlap.

55562 Nucleic Acid Fragments

A nucleic acid molecule of the invention can include only a portion of the nucleic acid sequence of SEQ ID NO:4 or SEQ ID NO:6. For example, such a nucleic acid molecule can include a fragment that can be used as a probe or primer or a fragment
 5 encoding a portion of a 55562 protein, e.g., an immunogenic or biologically active portion of a 55562 protein. A fragment can comprise those nucleotides of SEQ ID NO:4 or SEQ ID NO:6, which encode a tetratricopeptide repeat domain of human 55562. The nucleotide sequence determined from the cloning of the 55562 gene allows for the generation of probes and primers designed for use in identifying and/or cloning other 55562 family members, or
 10 fragments thereof, as well as 55562 homologues, or fragments thereof, from other species.

In another embodiment, a nucleic acid includes a nucleotide sequence that includes part, or all, of the coding region and extends into either (or both) the 5' or 3' noncoding region. Other embodiments include a fragment that includes a nucleotide sequence encoding an amino acid fragment described herein. Nucleic acid fragments can encode a specific domain or site
 15 described herein or fragments thereof, particularly fragments thereof which are at least 50, 79, 91, 100, 111, or more amino acids in length. Fragments also include nucleic acid sequences corresponding to specific amino acid sequences described above or fragments thereof. Nucleic acid fragments should not be construed as encompassing those fragments that may have been disclosed prior to the invention.

20 A nucleic acid fragment can include a sequence corresponding to a domain, region, or functional site described herein. A nucleic acid fragment can also include one or more domains, regions, or functional sites described herein. Thus, for example, a 55562 nucleic acid fragment can include a sequence corresponding to a tetratricopeptide repeat domain, or a PD314595 homology domain.

25 55562 probes and primers are provided. Typically a probe/primer is an isolated or purified oligonucleotide. The oligonucleotide typically includes a region of nucleotide sequence that hybridizes under a stringency condition described herein to at least about 7, 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense or antisense sequence of SEQ ID NO:4 or SEQ ID NO:6,
 30 or of a naturally occurring allelic variant or mutant of SEQ ID NO:4 or SEQ ID NO:6. Preferably, an oligonucleotide is less than about 200, 150, 120, or 100 nucleotides in length.

In one embodiment, the probe or primer is attached to a solid support, e.g., a solid support described herein.

One exemplary kit of primers includes a forward primer that anneals to the coding strand and a reverse primer that anneals to the non-coding strand. The forward primer can anneal to the start codon, e.g., the nucleic acid sequence encoding amino acid residue 1 of SEQ ID NO:5. The reverse primer can anneal to the ultimate codon, e.g., the codon
 5 immediately before the stop codon, e.g., the codon encoding amino acid residue 274 of SEQ ID NO:5. In a preferred embodiment, the annealing temperatures of the forward and reverse primers differ by no more than 5, 4, 3, or 2°C.

In a preferred embodiment the nucleic acid is a probe which is at least 10, 12, 15, 18, 20 and less than 200, more preferably less than 100, or less than 50, nucleotides in length. It
 10 should be identical, or differ by 1, or 2, or less than 5 or 10 nucleotides, from a sequence disclosed herein. If alignment is needed for this comparison the sequences should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.

A probe or primer can be derived from the sense or anti-sense strand of a nucleic acid
 15 which encodes a tetratricopeptide repeat domain, e.g., a tetratricopeptide domain of human 55562, e.g., about amino acid residues 40 to 73 of SEQ ID NO:5, or a PD314595 homology domain, e.g., a PD314595 homology domain of human 55562, e.g., about amino acid residues 40 to 266 of SEQ ID NO:5.

In another embodiment a set of primers is provided, e.g., primers suitable for use in a
 20 PCR, which can be used to amplify a selected region of a 21617 or 55562 sequence, e.g., a domain, region, site or other sequence described herein. The primers should be at least 5, 10, or 50 base pairs in length and less than 100, or less than 200, base pairs in length. The primers should be identical, or differs by one base from a sequence disclosed herein or from a naturally occurring variant. For example, primers suitable for amplifying all or a portion
 25 of any of the following regions are provided: a tetratricopeptide repeat domain, e.g., a tetratricopeptide domain of human 55562, e.g., about amino acid residues 40 to 73 of SEQ ID NO:5, or a PD314595 homology domain, e.g., a PD314595 homology domain of human 55562, e.g., about amino acid residues 40 to 266 of SEQ ID NO:5.

A nucleic acid fragment can encode an epitope bearing region of a polypeptide
 30 described herein.

A nucleic acid fragment encoding a "biologically active portion of a 55562 polypeptide" can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO:4 or SEQ ID NO:6, which encodes a polypeptide having a 55562 biological activity

(e.g., the biological activities of the 55562 proteins are described herein), expressing the encoded portion of the 55562 protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the 55562 protein. For example, a nucleic acid fragment encoding a biologically active portion of 21617 or 55562 includes a

5 tetratricopeptide repeat domain, e.g., amino acid residues about 40 to 73 of SEQ ID NO:5. A nucleic acid fragment encoding a biologically active portion of a 55562 polypeptide may comprise a nucleotide sequence which is greater than 240, 275, 300, 331, or more nucleotides in length.

In preferred embodiments, a nucleic acid includes a nucleotide sequence which is
10 about 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, or more nucleotides in length and hybridizes under a stringency condition described herein to a nucleic acid molecule of SEQ ID NO:4 or SEQ ID NO:6.

In a preferred embodiment, a nucleic acid fragment differs by at least 1, 2, 3, 10, 20, or more nucleotides from the sequence of Genbank accession number AC092587 or
15 AL161992. In some preferred embodiments, a nucleic acid fragment differs by at least 1, 2, 3, 10, 20, or more nucleotides from a sequence disclosed in one or more of WO 01/70979 (e.g., SEQ ID NO:17485), WO 01/22920 (e.g., SEQ ID NO:338), EP 1033401 (e.g., SEQ ID NO:13112), WO 00/55174 (e.g., SEQ ID NO:213), and WO 01/57182 (e.g., SEQ ID NO:33456). Differences can include differing in length or sequence identity. For example,
20 a nucleic acid fragment can: include one or more nucleotides from SEQ ID NO: 4 located outside the region of nucleotides 401 to 594 and 672 to 1001; not include all of the nucleotides of Genbank accession number AC092587 or AL161992 and a sequence disclosed in one or more of WO 01/70979, WO 01/22920, EP 1033401, WO 00/55174, and WO 01/57182; or can differ by one or more nucleotides in the region of overlap.

25 21617 or 55562 Nucleic Acid Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6. Such differences can be due to degeneracy of the genetic code (and result in a nucleic acid which encodes the same 21617 or 55562 proteins as those encoded by the
30 nucleotide sequence disclosed herein. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence which differs, by at least 1, but less than 5, 10, 20, 50, or 100 amino acid

residues that shown in SEQ ID NO:2 or SEQ ID NO:5. If alignment is needed for this comparison the sequences should be aligned for maximum homology. The encoded protein can differ by no more than 5, 4, 3, 2, or 1 amino acid. “Looped” out sequences from deletions or insertions, or mismatches, are considered differences.

5 Nucleic acids of the inventor can be chosen for having codons, which are preferred, or non-preferred, for a particular expression system. E.g., the nucleic acid can be one in which at least one codon, at preferably at least 10%, or 20% of the codons has been altered such that the sequence is optimized for expression in *E. coli*, yeast, human, insect, or CHO cells.

10 Nucleic acid variants can be naturally occurring, such as allelic variants (same locus), homologs (different locus), and orthologs (different organism) or can be non naturally occurring. Non-naturally occurring variants can be made by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. The variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the
15 coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions (as compared in the encoded product).

In a preferred embodiment, the nucleic acid differs from that of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6, e.g., as follows: by at least one but less than 10, 20, 30, or 40 nucleotides; at least one but less than 1%, 5%, 10% or 20% of the nucleotides in the
20 subject nucleic acid. The nucleic acid can differ by no more than 5, 4, 3, 2, or 1 nucleotide. If necessary for this analysis the sequences should be aligned for maximum homology. “Looped” out sequences from deletions or insertions, or mismatches, are considered differences.

Orthologs, homologs, and allelic variants can be identified using methods known in the art. These variants comprise a nucleotide sequence encoding a polypeptide that is 50%, at least
25 about 55%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more identical to the nucleotide sequence shown in SEQ ID NO:2 or SEQ ID NO:5 or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under a stringency condition described herein, to the nucleotide sequence shown in SEQ ID NO:2 or SEQ ID NO:5, or a fragment of the sequence.
30 Nucleic acid molecules corresponding to orthologs, homologs, and allelic variants of the 21617 or 55562 cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the 21617 or 55562 gene.

Preferred 21617 variants include those that are correlated with the ability to oxidize an alcohol group or reduce a carbonyl group present in a small molecule, e.g., a steroid, lipid, toxin, or xenobiotic compound, or a protein substrate.

Allelic variants of 21617, e.g., human 21617, include both functional and non-
 5 functional proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the 21617 protein within a population that maintain the ability to bind a substrate, e.g., an alcohol or steroid. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID NO:2, or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein. Non-
 10 functional allelic variants are naturally-occurring amino acid sequence variants of the 21617, e.g., human 21617, protein within a population that do not have the ability to bind or otherwise act upon a substrate. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion, or premature truncation of the amino acid sequence of SEQ ID NO:2, or a substitution, insertion, or deletion in critical residues or
 15 critical regions of the protein.

Preferred 55562 variants include those that are correlated with either the ability to stimulate the formation of a complex, e.g., with other tetratricopeptide repeat containing molecules or, conversely, the ability to disrupt the formation of such a complex.

Allelic variants of 55562, e.g., human 21617 or 55562, include both functional and
 20 non-functional proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the 21617 or 55562 protein within a population that maintain the ability to bind to human 55562-interacting proteins. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID NO:5, or substitution, deletion or insertion of non-critical residues in non-critical regions of the
 25 protein. Non-functional allelic variants are naturally-occurring amino acid sequence variants of the 55562, e.g., human 55562, protein within a population that do not have the ability human 55562-interacting proteins. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion, or premature truncation of the amino acid sequence of SEQ ID NO:5, or a substitution, insertion, or deletion in critical
 30 residues or critical regions of the protein.

Moreover, nucleic acid molecules encoding other 21617 or 55562 family members and, thus, which have a nucleotide sequence which differs from the 21617 or 55562

sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6 are intended to be within the scope of the invention.

Antisense Nucleic Acid Molecules, Ribozymes and Modified 21617 or 55562 Nucleic Acid Molecules

5 In another aspect, the invention features, an isolated nucleic acid molecule which is antisense to 21617 or 55562. An "antisense" nucleic acid can include a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. The antisense nucleic acid can be complementary to an entire 21617 or 55562
10 coding strand, or to only a portion thereof (e.g., the coding region of human 21617 or 55562 corresponding to SEQ ID NO:3 and SEQ ID NO:6, respectively). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding 21617 or 55562 (e.g., the 5' and 3' untranslated regions).

An antisense nucleic acid can be designed such that it is complementary to the entire
15 coding region of 21617 or 55562 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of 21617 or 55562 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of 21617 or 55562 mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for
20 example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length.

An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized
25 using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. The antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been
30 subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject (e.g., by direct injection at a tissue site), or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a 21617 or 55562 protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation.

5 Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can
10 also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an
15 α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids. Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue
20 (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. A ribozyme having specificity for a 21617 or 55562-encoding nucleic acid can include one or more sequences complementary to the nucleotide sequence of a 21617 or 55562 cDNA disclosed herein (i.e., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6), and a
25 sequence having known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach (1988) *Nature* 334:585-591). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a 21617 or 55562-encoding mRNA. See, e.g., Cech *et al.* U.S. Patent No. 4,987,071; and
30 Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, 21617 or 55562 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

21617 or 55562 gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the 21617 or 55562 (e.g., the 21617 or 55562 promoter and/or enhancers) to form triple helical structures that prevent transcription of the 21617 or 55562 gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6:569-84; Helene, C. i (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14:807-15. The potential sequences that can be targeted for triple helix formation can be increased by creating a so-called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

The invention also provides detectably labeled oligonucleotide primer and probe molecules. Typically, such labels are chemiluminescent, fluorescent, radioactive, or colorimetric.

A 21617 or 55562 nucleic acid molecule can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For non-limiting examples of synthetic oligonucleotides with modifications see Toulmé (2001) *Nature Biotech.* 19:17 and Faria *et al.* (2001) *Nature Biotech.* 19:40-44. Such phosphoramidite oligonucleotides can be effective antisense agents.

For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4: 5-23). As used herein, the terms "peptide nucleic acid" or "PNA" refers to a nucleic acid mimic, e.g., a DNA mimic, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of a PNA can allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. *et al.* (1996) *supra* and Perry-O'Keefe *et al.* *Proc. Natl. Acad. Sci.* 93: 14670-675.

PNAs of 21617 or 55562 nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of 21617 or 55562 nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in combination with

other enzymes, (e.g., S1 nucleases (Hyrup B. *et al.* (1996) *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *supra*).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or intercalating agents. (see, e.g., Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

The invention also includes molecular beacon oligonucleotide primer and probe molecules having at least one region which is complementary to a 21617 or 55562 nucleic acid of the invention, two complementary regions one having a fluorophore and one a quencher such that the molecular beacon is useful for quantitating the presence of the 21617 or 55562 nucleic acid of the invention in a sample. Molecular beacon nucleic acids are described, for example, in Lizardi *et al.*, U.S. Patent No. 5,854,033; Nazarenko *et al.*, U.S. Patent No. 5,866,336, and Livak *et al.*, U.S. Patent 5,876,930.

20 Isolated 21617 Polypeptides

In another aspect, the invention features an isolated 21617 protein or fragments thereof, e.g., biologically active portions, for use as immunogens or antigens to raise or test (or more generally to bind) anti-21617 antibodies. 21617 protein can be isolated from cells or tissue sources using standard protein purification techniques. 21617 protein or fragments thereof can be produced by recombinant DNA techniques or synthesized chemically.

Polypeptides of the invention include those which arise as a result of the existence of multiple genes, alternative transcription events, alternative RNA splicing events, and alternative translational and post-translational events. The polypeptide can be expressed in systems, e.g., cultured cells, which result in substantially the same post-translational modifications present when expressed the polypeptide is expressed in a native cell, or in systems which result in the alteration or omission of post-translational modifications, e.g., glycosylation or cleavage, present when expressed in a native cell.

In a preferred embodiment, a 21617 polypeptide has one or more of the following characteristics:

- (i) it has the ability to oxidize an alcohol group on a substrate molecule;
- (ii) it has the ability to reduce a carbonyl group on a substrate molecule;
- 5 (iii) it has the ability bind a co-enzyme;
- (iv) it participates in the metabolism of a substrate, e.g., a small molecule substrate, e.g., an alcohol, steroid, or fatty acid molecule;
- (v) it has a molecular weight, e.g., a deduced molecular weight (preferably ignoring any contribution of post translational modifications), amino acid composition, or other
- 10 physical characteristic of a 21617 polypeptide, e.g., the protein described in SEQ ID NO:2;
- (vi) it has an overall sequence similarity of at least 60%, more preferably at least 70%, 80%, 90%, or 95%, with a polypeptide of SEQ ID NO:2; or
- (vii) it has a short chain dehydrogenase domain which is preferably about 70%, 80%, 90%, 95%, 98%, 99%, or more homologous with amino acid residues about 37 to 249 of
- 15 SEQ ID NO:2;
- (viii) it can be found in a tumor cell or tissue, e.g., a colon, colorectal, breast, lung, cervical, or liver tumor cell or tissue;
- (ix) it has a dehydrogenase family signature motif (PS00061);
- (x) it has a predicted signal peptide;
- 20 (xi) it has at least one, preferable two dileucine motifs;
- (xii) it has at least one predicted glycosaminoglycan attachment site (PS00002);
- (xiii) it has at least one, two, preferably three predicted Protein Kinase C phosphorylation sites (PS00005);
- (xiv) it has at least one, preferable two predicted Casein Kinase II phosphorylation
- 25 sites (PS00006);
- (xv) it has at least one, two, three, four, five, preferably six predicted N-myristoylation sites (PS00008); and
- (xvi) it has at least one predicted amidation site (PS00009).

In a preferred embodiment the 21617 protein, or fragment thereof, differs from the

30 corresponding sequence in SEQ ID NO:2. In one embodiment it differs by at least one but by less than 15, 10 or 5 amino acid residues. In another it differs from the corresponding sequence in SEQ ID NO:2 by at least one residue but less than 20%, 15%, 10% or 5% of the residues in it differ from the corresponding sequence in SEQ ID NO:2. (If this comparison

requires alignment the sequences should be aligned for maximum homology. “Looped” out sequences from deletions or insertions, or mismatches, are considered differences.) The differences are, preferably, differences or changes at a non essential residue or a conservative substitution. In a preferred embodiment the differences are not in the short chain dehydrogenase domain. For example, the differences are in the region of amino acid residues 1-36 and 250-341 of SEQ ID NO:2. In another preferred embodiment one or more differences are in the short chain dehydrogenase domain, e.g., residues 37-249 of SEQ ID NO:2.

Other embodiments include a protein that contain one or more changes in amino acid sequence, e.g., a change in an amino acid residue which is not essential for activity. Such 21617 proteins differ in amino acid sequence from SEQ ID NO:2, yet retain biological activity.

In one embodiment, the protein includes an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more homologous to SEQ ID NO:2.

A 21617 protein or fragment is provided which varies from the sequence of SEQ ID NO:2 in regions defined by amino acids about 1-36 and 250-341 by at least one but by less than 15, 10 or 5 amino acid residues in the protein or fragment but which does not differ from SEQ ID NO:2 in regions defined by amino acids about 37-249 of SEQ ID NO:2. (If this comparison requires alignment the sequences should be aligned for maximum homology. “Looped” out sequences from deletions or insertions, or mismatches, are considered differences.) In some embodiments the difference is at a non-essential residue or is a conservative substitution, while in others the difference is at an essential residue or is a non-conservative substitution.

In one embodiment, a biologically active portion of a 21617 protein includes a short chain dehydrogenase domain. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native 21617 protein.

In a preferred embodiment, the 21617 protein has an amino acid sequence shown in SEQ ID NO:2. In other embodiments, the 21617 protein is substantially identical to SEQ ID NO:2. In yet another embodiment, the 21617 protein is substantially identical to SEQ ID NO:2 and retains the functional activity of the protein of SEQ ID NO:2, as described in detail in the subsections above.

In a preferred embodiment, a fragment differs by at least 1, 2, 3, 10, 20, or more amino acid residues encoded by a sequence present in Genbank accession number AF286885, G28278, G29385, or G25914 or a sequence disclosed in one or more of WO 00/09552, WO 01/51628, WO 01/55301, WO 01/55364, WO 01/77289, WO 01/5719, EP1033401 or WO 01/02568. Differences can include differing in length or sequence identity. For example, a fragment can: include one or more amino acid residues from SEQ ID NO: 2 outside the region encoded by nucleotides 475-3607; not include all of the amino acid residues encoded by a nucleotide sequence in Genbank accession number AF286885, G28278, G29385, or G25914, or a sequence disclosed in WO 00/09552, WO 01/51628, WO 01/55301, WO 01/55364, WO 01/77289, WO 01/5719, EP1033401 or WO 01/02568, e.g., can be one or more amino acid residues shorter (at one or both ends) than a sequence encoded by the nucleotide sequence in Genbank accession number AF286885, G28278, G29385, or G25914 or a sequence disclosed in one or more of WO 00/09552, WO 01/51628, WO 01/55301, WO 01/55364, WO 01/77289, WO 01/5719, EP1033401 or WO 01/02568; or can differ by one or more amino acid residues in the region of overlap.

Isolated 55562 Polypeptides

In another aspect, the invention features an isolated 5562 protein or fragments thereof, e.g., biologically active portions, for use as immunogens or antigens to raise or test (or more generally to bind) anti- 55562 antibodies. 55562 protein can be isolated from cells or tissue sources using standard protein purification techniques. 55562 protein or fragments thereof can be produced by recombinant DNA techniques or synthesized chemically.

Polypeptides of the invention include those that arise as a result of the existence of multiple genes, alternative transcription events, alternative RNA splicing events, and alternative translational and post-translational events. The polypeptide can be expressed in systems, e.g., cultured cells, which result in substantially the same post-translational modifications present when expressed the polypeptide is expressed in a native cell, or in systems which result in the alteration or omission of post-translational modifications, e.g., glycosylation or cleavage, present when expressed in a native cell.

In a preferred embodiment, a 55562 polypeptide has one or more of the following characteristics:

(i) it has the ability to facilitate the formation of a protein complex, e.g., a protein complex containing at least one other tetratricopeptide repeat containing protein;

(ii) it has a molecular weight, e.g., a deduced molecular weight (preferably ignoring any contribution of post translational modifications), amino acid composition, or other physical characteristic of a 55562 polypeptide, e.g., the protein of SEQ ID NO:5;

(iii) it has an overall sequence similarity of at least 60%, more preferably at least 70%, 80%, 90%, 95%, 98%, 99%, or more with a polypeptide of SEQ ID NO:5;

(iv) it has a tetratricopeptide repeat domain which is preferably about 70%, 80%, 90%, 95%, 98%, 99%, or more homologous with amino acid residues about 40 to 73 of SEQ ID NO:5;

(v) it has conserved TPR features, e.g., an alanine corresponding to residue 47 of SEQ ID NO:5, an alanine corresponding to residue 58 of SEQ ID NO:5; and a tyrosine corresponding to residue 55 of SEQ ID NO:5;

(vi) it has a PD314595 homology domain which is preferably about 70%, 80%, 90%, 95%, 98%, 99%, or more homologous with amino acid residues about 40 to 266 of SEQ ID NO:5;

(vii) it has the ability to modulate intracellular transport;

(viii) it has the ability to modulate an enzyme activity, e.g., in response to a second messenger;

(viii) it has at least one, two three, preferably four predicted Protein Kinase C phosphorylation sites (PS00005);

(ix) it has at least one, two, three, preferably four predicted Casein Kinase II phosphorylation sites (PS00006);

(x) it has at least one, two, preferably three predicted cAMP/cGMP-dependent protein kinase phosphorylation sites (PS00004);

(xi) it has at least one, preferably two predicted N-glycosylation sites (PS00001); or

(xii) it has at least one predicted N-myristylation sites (PS00008).

In a preferred embodiment the 55562 protein, or fragment thereof, differs from the corresponding sequence in SEQ ID NO:5. In one embodiment it differs by at least one but by less than 15, 10 or 5 amino acid residues. In another it differs from the corresponding sequence in SEQ ID NO:5 by at least one residue but less than 20%, 15%, 10% or 5% of the residues in it differ from the corresponding sequence in SEQ ID NO:5. (If this comparison requires alignment the sequences should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.) The differences are, preferably, differences or changes at a non-essential residue or a

conservative substitution. In a preferred embodiment the differences are not in the tetratricopeptide repeat domain. In another preferred embodiment one or more differences are in the tetratricopeptide repeat domain.

Other embodiments include a protein that contain one or more changes in amino acid sequence, e.g., a change in an amino acid residue which is not essential for activity. Such 55562 proteins differ in amino acid sequence from SEQ ID NO:5, yet retain biological activity.

In one embodiment, the protein includes an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or more homologous to SEQ ID NO:5.

10 A 55562 protein or fragment is provided which varies from the sequence of SEQ ID NO:5 in regions defined by amino acids about 1 to 39 and 74 to 274 by at least one but by less than 15, 10 or 5 amino acid residues in the protein or fragment but which does not differ from SEQ ID NO:5 in regions defined by amino acids about 40 to 73 of SEQ ID NO:5. (If this comparison requires alignment the sequences should be aligned for maximum 15 homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.) In some embodiments the difference is at a non-essential residue or is a conservative substitution, while in others the difference is at an essential residue or is a non-conservative substitution.

In one embodiment, a biologically active portion of a 55562 protein includes a 20 tetratricopeptide repeat domain. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native 55562 protein.

In a preferred embodiment, the 55562 protein has an amino acid sequence shown in SEQ ID NO:5. In other embodiments, the 55562 protein is substantially identical to SEQ ID 25 NO:5. In yet another embodiment, the 55562 protein is substantially identical to SEQ ID NO:5 and retains the functional activity of the protein of SEQ ID NO:5, as described in detail in the subsections above.

In a preferred embodiment, a 55562 protein fragment differs by at least 1, 2, 3, 10, 20, or more amino acids from protein sequence encoded by the sequence of Genbank 30 accession number AC092587, AL161992, or AK005342. In some preferred embodiments, a 55562 protein fragment differs by at least 1, 2, 3, 10, 20, or more amino acids from a protein sequence encoded by a sequence disclosed in one or more of WO 01/70979 (e.g., SEQ ID NO:17485), WO 01/22920 (e.g., SEQ ID NO:338), EP 1033401 (e.g., SEQ ID NO:13112),

WO 00/55174 (e.g., SEQ ID NO:213), and WO 01/57182 (e.g., SEQ ID NO:33456).

Differences can include differing in length or sequence identity. For example, a 55562 protein fragment can: include one or more amino acid residues of SEQ ID NO:5 located outside the region encoded by nucleotides 401 to 594 and 672 to 1001 of SEQ ID NO:4; not
5 include all of the amino acid encoded by the nucleic acid molecules of Genbank accession number AC092587, AL161992 or AK005342, or a sequence disclosed in one or more of WO 01/70979, WO 01/22920, EP 1033401, WO 00/55174, and WO 01/57182, e.g., can be one or more amino acid residues shorter (at one or both ends) than a sequence encoded by the nucleotide sequence in Genbank accession number AC092587, AL161992 or
10 AK005342, or a sequence disclosed in one or more of WO 01/70979, WO 01/22920, EP 1033401, WO 00/55174, and WO 01/57182; or can differ by one or more amino acid in the region of overlap.

21617 or 55562 Chimeric or Fusion Proteins

In another aspect, the invention provides 21617 or 55562 chimeric or fusion proteins.

15 As used herein, a 21617 or 55562 "chimeric protein" or "fusion protein" includes a 21617 or 55562 polypeptide linked to a non-21617 or non-55562 polypeptide, respectively. A "non-21617 polypeptide" or "non-55562 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the 21617 or 55562 protein, e.g., a protein which is different from the 21617 or 55562 protein
20 and which is derived from the same or a different organism. The 21617 or 55562 polypeptide of the fusion protein can correspond to all or a portion e.g., a fragment described herein of a 21617 or 55562 amino acid sequence. In a preferred embodiment, a 21617 or 55562 fusion protein includes at least one (or two) biologically active portion of a 21617 or 55562 protein. The non-21617 or 55562 polypeptide can be fused to the N-
25 terminus or C-terminus of the 21617 or 55562 polypeptide.

The fusion protein can include a moiety which has a high affinity for a ligand. For example, the fusion protein can be a GST-21617 or 55562 fusion protein in which the 21617 or 55562 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant 21617 or 55562. Alternatively, the fusion
30 protein can be a 21617 or 55562 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of 21617 or 55562 can be increased through use of a heterologous signal sequence.

Fusion proteins can include all or a part of a serum protein, e.g., an IgG constant region, or human serum albumin.

The 21617 or 55562 fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. The 21617 or 55562 fusion proteins can be used to affect the bioavailability of a 21617 or 55562 substrate. 21617 or 55562 fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a 21617 or 55562 protein; (ii) mis-regulation of the 21617 or 55562 gene; and (iii) aberrant post-translational modification of a 21617 or 55562 protein.

Moreover, the 21617 or 55562-fusion proteins of the invention can be used as immunogens to produce anti-21617 or 55562 antibodies in a subject, to purify 21617 or 55562 ligands and in screening assays to identify molecules which inhibit the interaction of 21617 or 55562 with a 21617 or 55562 substrate.

Expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A 21617 or 55562-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the 21617 or 55562 protein.

Variants of 21617 or 55562 Proteins

In another aspect, the invention also features a variant of a 21617 or 55562 polypeptide, e.g., which functions as an agonist (mimetics) or as an antagonist. Variants of the 21617 or 55562 proteins can be generated by mutagenesis, e.g., discrete point mutation, the insertion or deletion of sequences or the truncation of a 21617 or 55562 protein. An agonist of the 21617 or 55562 proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a 21617 or 55562 protein. An antagonist of a 21617 or 55562 protein can inhibit one or more of the activities of the naturally occurring form of the 21617 or 55562 protein by, for example, competitively modulating a 21617 or 55562-mediated activity of a 21617 or 55562 protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Preferably, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the 21617 or 55562 protein.

Variants of a 21617 or 55562 protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a 21617 or 55562 protein for agonist or antagonist activity.

Libraries of fragments e.g., N-terminal, C-terminal, or internal fragments, of a 21617
5 or 55562 protein coding sequence can be used to generate a variegated population of fragments for screening and subsequent selection of variants of a 21617 or 55562 protein. Variants in which a cysteine residues is added or deleted or in which a residue which is glycosylated is added or deleted are particularly preferred.

Methods for screening gene products of combinatorial libraries made by point
10 mutations or truncation, and for screening cDNA libraries for gene products having a selected property are known in the art. Such methods are adaptable for rapid screening of the gene libraries generated by combinatorial mutagenesis of 21617 or 55562 proteins. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to
15 identify 21617 or 55562 variants (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6:327-331).

Cell based assays can be exploited to analyze a variegated 21617 or 55562 library. For example, a library of expression vectors can be transfected into a cell line, e.g., a cell line, which ordinarily responds to 21617 or 55562 in a substrate-dependent manner. The
20 transfected cells are then contacted with 21617 or 55562 and the effect of the expression of the mutant on signaling by the 21617 or 55562 substrate can be detected, e.g., by measuring an activity associated with 21617 or 55562 expression, e.g., cellular proliferation and/or differentiation. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of signaling by the 21617 or 55562 substrate, and
25 the individual clones further characterized.

In another aspect, the invention features a method of making a 21617 or 55562 polypeptide, e.g., a peptide having a non-wild type activity, e.g., an antagonist, agonist, or super agonist of a naturally occurring 21617 or 55562 polypeptide, e.g., a naturally occurring 21617 or 55562 polypeptide. The method includes: altering the sequence of a
30 21617 or 55562 polypeptide, e.g., altering the sequence, e.g., by substitution or deletion of one or more residues of a non-conserved region, a domain or residue disclosed herein, and testing the altered polypeptide for the desired activity.

In another aspect, the invention features a method of making a fragment or analog of a 21617 or 55562 polypeptide a biological activity of a naturally occurring 21617 or 55562 polypeptide. The method includes: altering the sequence, e.g., by substitution or deletion of one or more residues, of a 21617 or 55562 polypeptide, e.g., altering the sequence of a non-conserved region, or a domain or residue described herein, and testing the altered polypeptide for the desired activity.

Anti-21617 or 55562 Antibodies

In another aspect, the invention provides an anti-21617 or 55562 antibody, or a fragment thereof (e.g., an antigen-binding fragment thereof). The term "antibody" as used herein refers to an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. As used herein, the term "antibody" refers to a protein comprising at least one, and preferably two, heavy (H) chain variable regions (abbreviated herein as VH), and at least one and preferably two light (L) chain variable regions (abbreviated herein as VL). The VH and VL regions can be further subdivided into regions of hypervariability, termed "complementarity determining regions" ("CDR"), interspersed with regions that are more conserved, termed "framework regions" (FR). The extent of the framework region and CDR's has been precisely defined (see, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. *et al.* (1987) *J. Mol. Biol.* 196:901-917, which are incorporated herein by reference). Each VH and VL is composed of three CDR's and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The anti-21617 or 55562 antibody can further include a heavy and light chain constant region, to thereby form a heavy and light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are interconnected by, e.g., disulfide bonds. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. The light chain constant region is comprised of one domain, CL. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune

system (e.g., effector cells) and the first component (Clq) of the classical complement system.

As used herein, the term "immunoglobulin" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized human immunoglobulin genes include the kappa, lambda, alpha (IgA1 and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin "light chains" (about 25 KDa or 214 amino acids) are encoded by a variable region gene at the NH₂-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COOH--terminus. Full-length immunoglobulin "heavy chains" (about 50 KDa or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids).

The term "antigen-binding fragment" of an antibody (or simply "antibody portion," or "fragment"), as used herein, refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to the antigen, e.g., 21617 or 55562 polypeptide or fragment thereof. Examples of antigen-binding fragments of the anti-21617 or 55562 antibody include, but are not limited to: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see *e.g.*, Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also encompassed within the term "antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

The anti-21617 or 55562 antibody can be a polyclonal or a monoclonal antibody. In other embodiments, the antibody can be recombinantly produced, e.g., produced by phage display or by combinatorial methods.

Phage display and combinatorial methods for generating anti-21617 or 55562 antibodies are known in the art (as described in, e.g., Ladner et al. U.S. Patent No. 5,223,409; Kang et al. International Publication No. WO 92/18619; Dower et al. International Publication No. WO 91/17271; Winter et al. International Publication WO 92/20791; Markland et al. International Publication No. WO 92/15679; Breitling et al. International Publication WO 93/01288; McCafferty et al. International Publication No. WO 92/01047; Garrard et al. International Publication No. WO 92/09690; Ladner et al. International Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum Antibod Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J* 12:725-734; Hawkins et al. (1992) *J Mol Biol* 226:889-896; Clackson et al. (1991) *Nature* 352:624-628; Gram et al. (1992) *PNAS* 89:3576-3580; Garrad et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al. (1991) *Nuc Acid Res* 19:4133-4137; and Barbas et al. (1991) *PNAS* 88:7978-7982, the contents of all of which are incorporated by reference herein).

In one embodiment, the anti-21617 or 55562 antibody is a fully human antibody (e.g., an antibody made in a mouse which has been genetically engineered to produce an antibody from a human immunoglobulin sequence), or a non-human antibody, e.g., a rodent (mouse or rat), goat, primate (e.g., monkey), camel antibody. Preferably, the non-human antibody is a rodent (mouse or rat antibody). Method of producing rodent antibodies are known in the art.

Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. International Application WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. International Application WO 92/03918; Kay et al. International Application 92/03917; Lonberg, N. et al. 1994 *Nature* 368:856-859; Green, L.L. et al. 1994 *Nature Genet.* 7:13-21; Morrison, S.L. et al. 1994 *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. 1993 *Year Immunol* 7:33-40; Tuailon et al. 1993 *PNAS* 90:3720-3724; Bruggeman et al. 1991 *Eur J Immunol* 21:1323-1326).

An anti-21617 or 55562 antibody can be one in which the variable region, or a portion thereof, e.g., the CDR's, are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibodies generated in a non-human organism, e.g., a rat or mouse, and then modified, e.g.,

5 in the variable framework or constant region, to decrease antigenicity in a human are within the invention.

Chimeric antibodies can be produced by recombinant DNA techniques known in the art. For example, a gene encoding the Fc constant region of a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the region

10 encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567;

15 Cabilly et al., European Patent Application 125,023; Better et al. (1988 *Science* 240:1041-1043); Liu et al. (1987) *PNAS* 84:3439-3443; Liu et al., 1987, *J. Immunol.* 139:3521-3526; Sun et al. (1987) *PNAS* 84:214-218; Nishimura et al., 1987, *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al., 1988, *J. Natl Cancer Inst.* 80:1553-1559).

A humanized or CDR-grafted antibody will have at least one or two but generally all

20 three recipient CDR's (of heavy and or light immunoglobulin chains) replaced with a donor CDR. The antibody may be replaced with at least a portion of a non-human CDR or only some of the CDR's may be replaced with non-human CDR's. It is only necessary to replace the number of CDR's required for binding of the humanized antibody to a 21617 or 55562 or a fragment thereof. Preferably, the donor will be a rodent antibody, e.g., a rat or mouse

25 antibody, and the recipient will be a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDR's is called the "donor" and the immunoglobulin providing the framework is called the "acceptor." In one embodiment, the donor immunoglobulin is a non-human (e.g., rodent). The acceptor framework is a naturally-occurring (e.g., a human) framework or a consensus framework, or a sequence

30 about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.

As used herein, the term "consensus sequence" refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnaker, *From Genes to Clones* (Verlagsgesellschaft, Weinheim, Germany 1987). In a

family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A "consensus framework" refers to the framework region in the consensus immunoglobulin sequence.

5 An antibody can be humanized by methods known in the art. Humanized antibodies can be generated by replacing sequences of the Fv variable region which are not directly involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for generating humanized antibodies are provided by Morrison, S. L., 1985, *Science* 229:1202-1207, by Oi et al., 1986, *BioTechniques* 4:214, and by Queen et al.
10 US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of which are hereby incorporated by reference. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or light chain. Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from a hybridoma producing an
15 antibody against a 21617 or 55562 polypeptide or fragment thereof. The recombinant DNA encoding the humanized antibody, or fragment thereof, can then be cloned into an appropriate expression vector.

 Humanized or CDR-grafted antibodies can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDR's of an immunoglobulin chain can be replaced.
20 See e.g., U.S. Patent 5,225,539; Jones et al. 1986 *Nature* 321:552-525; Verhoeven et al. 1988 *Science* 239:1534; Beidler et al. 1988 *J. Immunol.* 141:4053-4060; Winter US 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on March
25 26, 1987; Winter US 5,225,539), the contents of which is expressly incorporated by reference.

 Also within the scope of the invention are humanized antibodies in which specific amino acids have been substituted, deleted or added. Preferred humanized antibodies have amino acid substitutions in the framework region, such as to improve binding to the antigen.
30 For example, a humanized antibody will have framework residues identical to the donor framework residue or to another amino acid other than the recipient framework residue. To generate such antibodies, a selected, small number of acceptor framework residues of the humanized immunoglobulin chain can be replaced by the corresponding donor amino acids.

Preferred locations of the substitutions include amino acid residues adjacent to the CDR, or which are capable of interacting with a CDR (see e.g., US 5,585,089). Criteria for selecting amino acids from the donor are described in US 5,585,089, e.g., columns 12-16 of US 5,585,089, the e.g., columns 12-16 of US 5,585,089, the contents of which are hereby
 5 incorporated by reference. Other techniques for humanizing antibodies are described in Padlan et al. EP 519596 A1, published on December 23, 1992.

In preferred embodiments an antibody can be made by immunizing with purified 21617 or 55562 antigen, or a fragment thereof, e.g., a fragment described herein, membrane associated antigen, tissue, e.g., crude tissue preparations, whole cells, preferably living cells,
 10 lysed cells, or cell fractions, e.g., membrane fractions or cytosolic fractions.

A full-length 21617 or 55562 protein or, antigenic peptide fragment of 21617 or 55562 can be used as an immunogen or can be used to identify anti-21617 or 55562 antibodies made with other immunogens, e.g., cells, membrane preparations, and the like. The antigenic peptide of 21617 or 55562 should include at least 8 amino acid residues of the
 15 amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5 and encompasses an epitope of 21617 or 55562. Preferably, the antigenic peptide includes at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

Fragments of 21617 can be used, e.g., to characterize the specificity of an antibody
 20 or to make immunogens. For example, fragments of 21617 which include, e.g., residues about 68 to 77, 222 to 236, or 325 to 340 of SEQ ID NO:2 can be used to make antibodies against hydrophilic regions of the 21617 protein. Similarly, fragments of 21617 which include, e.g., residues 1 to 20, 191 to 203, or 293 to 310 of SEQ ID NO:2 can be used to make an antibody against a hydrophobic region of the 21617 protein; a fragment of 21617
 25 which includes, e.g., residues about 37 to 249 of SEQ ID NO:2 can be used to make an antibody against the short chain dehydrogenase region of the 21617 protein; and a fragment of 21617 which includes, e.g., about amino acid residues 210 to 220 of SEQ ID NO:2 can be used to make an antibody against the dehydrogenase family signature motif of the 21617 protein.

30 Fragments of 55562 can be used, e.g., to characterize the specificity of an antibody or to make immunogens. For example, fragments of 55562 which include, e.g., residues about 2 to 9, 95 to 110, or 259 to 273 of SEQ ID NO:5 can be used to make antibodies against hydrophilic regions of the 55562 protein. Similarly, fragments of 55562 which include

residues from about amino acid 39 to 44, 66 to 76, or 156 to 167 of SEQ ID NO:5 can be used to make an antibody against a hydrophobic region of the 55562 protein; a fragment of 55562 which include residues about 40 to 73 can be used to make an antibody against the TPR region of the 55562 protein; and fragments of 55562 which include about amino acid
5 residues 40 to 266 can be used to make an antibody against the PD314595 homology domain of the 55562 protein.

Antibodies reactive with, or specific for, any of these regions, or other regions or domains described herein are provided.

Antibodies which bind only native 21617 or 55562 protein, only denatured or
10 otherwise non-native 21617 or 55562 protein, or which bind both, are within the invention. Antibodies with linear or conformational epitopes are within the invention. Conformational epitopes can sometimes be identified by identifying antibodies which bind to native but not denatured 21617 or 55562 protein.

Preferred epitopes encompassed by the antigenic peptide are regions of 21617 or
15 55562 are located on the surface of the protein, e.g., hydrophilic regions, as well as regions with high antigenicity. For example, an Emini surface probability analysis of the human 21617 or 55562 protein sequence can be used to indicate the regions that have a particularly high probability of being localized to the surface of the 21617 or 55562 protein and are thus likely to constitute surface residues useful for targeting antibody production.

20 In preferred embodiments the antibodies can bind one or more of purified antigen, membrane associated antigen, tissue, e.g., tissue sections, whole cells, preferably living cells, lysed cells, cell fractions, e.g., membrane fractions or cytosolic fractions.

The anti-21617 or 55562 antibody can be a single chain antibody. A single-chain antibody (scFV) may be engineered (see, for example, Colcher, D. *et al.* (1999) *Ann N Y Acad Sci* 880:263-80; and Reiter, Y. (1996) *Clin Cancer Res* 2:245-52). The single chain
25 antibody can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target 21617 or 55562 protein.

In a preferred embodiment the antibody has effector function and/or can fix complement. In other embodiments the antibody does not recruit effector cells; or fix
30 complement.

In a preferred embodiment, the antibody has reduced or no ability to bind an Fc receptor. For example, it is a isotype or subtype, fragment or other mutant, which does not

support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.

In a preferred embodiment, an anti-21617 antibody alters (e.g., increases or decreases) the dehydrogenase activity of a 21617 polypeptide. For example, the antibody
5 can bind at or in proximity to the active site, e.g., to an epitope that includes a residue located from about amino acid 210 to 220 of SEQ ID NO:2.

In a preferred embodiment, an anti-21617 or 55562 antibody alters (e.g., increases or decreases) the activity of a 55562 polypeptide. For example, the antibody can bind at or in proximity to the tetratricopeptide repeat domain of 55562, e.g., to an epitope that includes a
10 residue located from about 40 to 73 of SEQ ID NO:5.

The antibody can be coupled to a toxin, e.g., a polypeptide toxin, e.g., ricin or diphtheria toxin or active fragment hereof, or a radioactive nucleus, or imaging agent, e.g. a radioactive, enzymatic, or other, e.g., imaging agent, e.g., a NMR contrast agent. Labels that produce detectable radioactive emissions or fluorescence are preferred.

15 An anti-21617 or 55562 antibody (e.g., monoclonal antibody) can be used to isolate 21617 or 55562 by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, an anti-21617 or 55562 antibody can be used to detect 21617 or 55562 protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the protein. Anti-21617 or 55562 antibodies can be
20 used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance (i.e., antibody labelling). Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive
25 materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a
30 luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

The invention also includes a nucleic acid which encodes an anti-21617 or 55562 antibody, e.g., an anti-21617 or 55562 antibody described herein. Also included are vectors which include the nucleic acid and cells transformed with the nucleic acid, particularly cells which are useful for producing an antibody, e.g., mammalian cells, e.g. CHO or lymphatic cells.

The invention also includes cell lines, e.g., hybridomas, which make an anti-21617 or 55562 antibody, e.g., an antibody described herein, and method of using said cells to make a 21617 or 55562 antibody.

Recombinant Expression Vectors, Host Cells and Genetically Engineered Cells

In another aspect, the invention includes, vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide described herein. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid or viral vector. The vector can be capable of autonomous replication or it can integrate into a host DNA. Viral vectors include, e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses.

A vector can include a 21617 or 55562 nucleic acid in a form suitable for expression of the nucleic acid in a host cell. Preferably the recombinant expression vector includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or polypeptides, including fusion proteins or polypeptides, encoded by nucleic acids as described herein (e.g., 21617 or 55562 proteins, mutant forms of 21617 or 55562 proteins, fusion proteins, and the like).

The recombinant expression vectors of the invention can be designed for expression of 21617 or 55562 proteins in prokaryotic or eukaryotic cells. For example, polypeptides of the invention can be expressed in *E. coli*, insect cells (e.g., using baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, (1990) *Gene Expression Technology: Methods in Enzymology* 185, Academic

Press, San Diego, CA. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors
 5 containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the
 10 recombinant protein by acting as a ligand in affinity purification. Often, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include
 15 pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be used in 21617 or 55562 activity assays, (e.g., direct
 20 assays or competitive assays described in detail below), or to generate antibodies specific for 21617 or 55562 proteins. In a preferred embodiment, a fusion protein expressed in a retroviral expression vector of the present invention can be used to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six weeks).

25 To maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., (1990) *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the
 30 individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

The 21617 or 55562 expression vector can be a yeast expression vector, a vector for expression in insect cells, e.g., a baculovirus expression vector or a vector suitable for expression in mammalian cells.

When used in mammalian cells, the expression vector's control functions can be provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.

In another embodiment, the promoter is an inducible promoter, e.g., a promoter regulated by a steroid hormone, by a polypeptide hormone (e.g., by means of a signal transduction pathway), or by a heterologous polypeptide (e.g., the tetracycline-inducible systems, "Tet-On" and "Tet-Off"; see, e.g., Clontech Inc., CA, Gossen and Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547, and Paillard (1989) *Human Gene Therapy* 9:983).

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example, the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. Regulatory sequences (e.g., viral promoters and/or enhancers) operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus.

Another aspect the invention provides a host cell which includes a nucleic acid molecule described herein, e.g., a 21617 or 55562 nucleic acid molecule within a recombinant expression vector or a 21617 or 55562 nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. Such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a 21617 or 55562 protein can be expressed in bacterial cells (such as *E. coli*), insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells (African green monkey kidney cells CV-1 origin SV40 cells; Gluzman (1981) *Cell* 23:175-182)). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into host cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride coprecipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation.

A host cell of the invention can be used to produce (i.e., express) a 21617 or 55562 protein. Accordingly, the invention further provides methods for producing a 21617 or 55562 protein using the host cells of the invention. In one embodiment, the method includes culturing the host cell of the invention (into which a recombinant expression vector encoding a 21617 or 55562 protein has been introduced) in a suitable medium such that a 21617 or 55562 protein is produced. In another embodiment, the method further includes isolating a 21617 or 55562 protein from the medium or the host cell.

In another aspect, the invention features, a cell or purified preparation of cells which include a 21617 or 55562 transgene, or which otherwise misexpress 21617 or 55562. The cell preparation can consist of human or non-human cells, e.g., rodent cells, e.g., mouse or rat cells, rabbit cells, or pig cells. In preferred embodiments, the cell or cells include a 21617 or 55562 transgene, e.g., a heterologous form of a 21617 or 55562, e.g., a gene derived from humans (in the case of a non-human cell). The 21617 or 55562 transgene can be misexpressed, e.g., overexpressed or underexpressed. In other preferred embodiments,

the cell or cells include a gene that mis-expresses an endogenous 21617 or 55562, e.g., a gene the expression of which is disrupted, e.g., a knockout. Such cells can serve as a model for studying disorders that are related to mutated or mis-expressed 21617 or 55562 alleles or for use in drug screening.

5 In another aspect, the invention features, a human cell, e.g., a hematopoietic, hepatic, neural, or muscle stem cell, transformed with nucleic acid which encodes a subject 21617 or 55562 polypeptide.

Also provided are cells, preferably human cells, e.g., human hematopoietic, hepatic, neural, or muscle cells, fibroblast cells, or tumor-derived cells in which an endogenous
10 21617 or 55562 is under the control of a regulatory sequence that does not normally control the expression of the endogenous 21617 or 55562 gene. The expression characteristics of an endogenous gene within a cell, e.g., a cell line or microorganism, can be modified by inserting a heterologous DNA regulatory element into the genome of the cell such that the inserted regulatory element is operably linked to the endogenous 21617 or 55562 gene. For
15 example, an endogenous 21617 or 55562 gene which is "transcriptionally silent," e.g., not normally expressed, or expressed only at very low levels, may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, e.g., Chappel, US 5,272,071; WO
20 91/06667, published in May 16, 1991.

In a preferred embodiment, recombinant cells described herein can be used for replacement therapy in a subject. For example, a nucleic acid encoding a 21617 or 55562 polypeptide operably linked to an inducible promoter (e.g., a steroid hormone receptor-regulated promoter) is introduced into a human or nonhuman, e.g., mammalian, e.g., porcine
25 recombinant cell. The cell is cultivated and encapsulated in a biocompatible material, such as poly-lysine alginate, and subsequently implanted into the subject. See, e.g., Lanza (1996) *Nat. Biotechnol.* 14:1107; Joki *et al.* (2001) *Nat. Biotechnol.* 19:35; and U.S. Patent No. 5,876,742. Production of 21617 or 55562 polypeptide can be regulated in the subject by administering an agent (e.g., a steroid hormone) to the subject. In another preferred
30 embodiment, the implanted recombinant cells express and secrete an antibody specific for a 21617 or 55562 polypeptide. The antibody can be any antibody or any antibody derivative described herein.

Transgenic Animals

The invention provides non-human transgenic animals. Such animals are useful for studying the function and/or activity of a 21617 or 55562 protein and for identifying and/or evaluating modulators of 21617 or 55562 activity. As used herein, a "transgenic animal" is

5 a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like. A transgene is exogenous DNA or a rearrangement, e.g., a deletion of endogenous chromosomal DNA, which preferably is integrated into or occurs in

10 the genome of the cells of a transgenic animal. A transgene can direct the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal, other transgenes, e.g., a knockout, reduce expression. Thus, a transgenic animal can be one in which an endogenous 21617 or 55562 gene has been altered by, e.g., by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced

15 into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to a transgene of the invention to direct expression of a

20 21617 or 55562 protein to particular cells. A transgenic founder animal can be identified based upon the presence of a 21617 or 55562 transgene in its genome and/or expression of 21617 or 55562 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding a 21617 or 55562 protein can further be bred to other

25 transgenic animals carrying other transgenes.

21617 or 55562 proteins or polypeptides can be expressed in transgenic animals or plants, e.g., a nucleic acid encoding the protein or polypeptide can be introduced into the genome of an animal. In preferred embodiments the nucleic acid is placed under the control of a tissue specific promoter, e.g., a milk or egg specific promoter, and recovered from the


30 milk or eggs produced by the animal. Suitable animals are mice, pigs, cows, goats, and sheep.

The invention also includes a population of cells from a transgenic animal, as discussed, e.g., below.

Uses

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics); and c) methods of treatment (e.g., therapeutic and prophylactic).

In addition, 21617 proteins of the invention can be used in vitro, e.g., for the oxidation or reduction of substrate molecules in a synthetic or diagnostic process. Dehydrogenase and/or reductase activity is widely used for the quantitation of ethanol in biological fluids. It can also be used in coupled enzyme reactions for determination of metabolites in biological fluids. Dehydrogenases catalyzes the oxidation of alcohol and the reduction of aldehydes as shown below:



As carried out by yeasts, this fermentation generates the alcohol in alcoholic beverages. Yeasts used in baking also carry out the alcoholic fermentation; the CO₂ produced by pyruvate decarboxylation causes bread to rise, and the ethanol produced evaporates during baking.

The isolated nucleic acid molecules of the invention can be used, for example, to express a 21617 or 55562 protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect a 21617 or 55562 mRNA (e.g., in a biological sample) or a genetic alteration in a 21617 or 55562 gene, and to modulate 21617 or 55562 activity, as described further below. The 21617 or 55562 proteins can be used to treat disorders characterized by insufficient or excessive production of a 21617 or 55562 substrate or production of 21617 or 55562 inhibitors. In addition, the 21617 or 55562 proteins can be used to screen for naturally occurring 21617 or 55562 substrates, to screen for drugs or compounds which modulate 21617 or 55562 activity, as well as to treat disorders characterized by insufficient or excessive production of 21617 or 55562 protein or production of 21617 or 55562 protein forms which have decreased, aberrant or unwanted activity compared to 21617 or 55562 wild type protein (e.g., cellular proliferation and/or differentiation disorders, metabolic disorders, kidney disorders, endothelial cell disorders, neural disorders, and viral disorders). Moreover, the anti-21617 or 55562 antibodies of the

invention can be used to detect and isolate 21617 or 55562 proteins, regulate the bioavailability of 21617 or 55562 proteins, and modulate 21617 or 55562 activity.

A method of evaluating a compound for the ability to interact with, e.g., bind, a subject 21617 or 55562 polypeptide is provided. The method includes: contacting the compound with the subject 21617 or 55562 polypeptide; and evaluating ability of the compound to interact with, e.g., to bind or form a complex with the subject 21617 or 55562 polypeptide. This method can be performed in vitro, e.g., in a cell free system, or in vivo, e.g., in a two-hybrid interaction trap assay. This method can be used to identify naturally occurring molecules that interact with subject 21617 or 55562 polypeptide. It can also be used to find natural or synthetic inhibitors of subject 21617 or 55562 polypeptide. Screening methods are discussed in more detail below.

Screening Assays

The invention provides methods (also referred to herein as "screening assays") for identifying modulators, i.e., candidate or test compounds or agents (e.g., proteins, peptides, peptidomimetics, peptoids, small molecules or other drugs) which bind to 21617 or 55562 proteins, have a stimulatory or inhibitory effect on, for example, 21617 or 55562 expression or 21617 or 55562 activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of a 21617 or 55562 substrate. Compounds thus identified can be used to modulate the activity of target gene products (e.g., 21617 or 55562 genes) in a therapeutic protocol, to elaborate the biological function of the target gene product, or to identify compounds that disrupt normal target gene interactions.

In one embodiment, the invention provides assays for screening candidate or test compounds which are substrates of a 21617 or 55562 protein or polypeptide or a biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds that bind to or modulate an activity of a 21617 or 55562 protein or polypeptide or a biologically active portion thereof.

In one embodiment, an activity of a 21617 protein can be assayed as follows: (a) contact a test substrate molecule (e.g., a steroid or alcohol) with a 21617 protein or functional fragment thereof in the presence of a coenzyme, e.g., NAD; and (b) evaluate the ability the 21617 protein or functional fragment thereof to catalyze a reaction, e.g., oxidize an alcohol group or reduce a carbonyl group present on the test substrate. In an exemplary embodiment, the ability of a 21617 molecule to catalyze a reaction is evaluated by

evaluating the presence or absence of the substrate or the enzymatic product of the reaction at the end of the assay, e.g., by evaluating the slope of absorbance of the substrate or end product through the assay period.

The test compounds of the present invention can be obtained using any of the
 5 numerous approaches in combinatorial library methods known in the art, including:
 biological libraries; peptoid libraries (libraries of molecules having the functionalities of
 peptides, but with a novel, non-peptide backbone which are resistant to enzymatic
 degradation but which nevertheless remain bioactive; see, e.g., Zuckermann, R.N. *et al.*
 (1994) *J. Med. Chem.* 37:2678-85); spatially addressable parallel solid phase or solution
 10 phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-
 compound' library method; and synthetic library methods using affinity chromatography
 selection. The biological library and peptoid library approaches are limited to peptide
 libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or
 small molecule libraries of compounds (Lam (1997) *Anticancer Drug Des.* 12:145).

15 Examples of methods for the synthesis of molecular libraries can be found in the art,
 for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994)
Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678;
 Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.*
 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop *et al.* (1994)
 20 *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten (1992)
Biotechniques 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor
 (1993) *Nature* 364:555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner
 U.S. Patent No. 5,223,409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-
 25 1869) or on phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science*
 249:404-406; Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382; Felici (1991) *J.*
Mol. Biol. 222:301-310; Ladner *supra.*).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a
 21617 or 55562 protein or biologically active portion thereof is contacted with a test
 30 compound, and the ability of the test compound to modulate 21617 or 55562 activity is
 determined. Determining the ability of the test compound to modulate 21617 or 55562
 activity can be accomplished by monitoring, for example, cellular proliferation and/or
 differentiation. The cell, for example, can be of mammalian origin, e.g., human.

The ability of the test compound to modulate 21617 or 55562 binding to a compound, e.g., a 21617 or 55562 substrate, or to bind to 21617 or 55562 can also be evaluated. This can be accomplished, for example, by coupling the compound, e.g., the substrate, with a radioisotope or enzymatic label such that binding of the compound, e.g., the substrate, to 21617 or 55562 can be determined by detecting the labeled compound, e.g., substrate, in a complex. Alternatively, 21617 or 55562 could be coupled with a radioisotope or enzymatic label to monitor the ability of a test compound to modulate 21617 or 55562 binding to a 21617 or 55562 substrate in a complex. For example, compounds (e.g., 21617 or 55562 substrates) can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

The ability of a compound (e.g., a 21617 or 55562 substrate) to interact with 21617 or 55562 with or without the labeling of any of the interactants can be evaluated. For example, a microphysiometer can be used to detect the interaction of a compound with 21617 or 55562 without the labeling of either the compound or the 21617 or 55562. McConnell, H. M. *et al.* (1992) *Science* 257:1906-1912. As used herein, a "microphysiometer" (e.g., Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and 21617 or 55562.

In yet another embodiment, a cell-free assay is provided in which a 21617 or 55562 protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the 21617 or 55562 protein or biologically active portion thereof is evaluated. Preferred biologically active portions of the 21617 or 55562 proteins to be used in assays of the present invention include fragments which participate in interactions with non-21617 or 55562 molecules, e.g., fragments with high surface probability scores.

Soluble and/or membrane-bound forms of isolated proteins (e.g., 21617 or 55562 proteins or biologically active portions thereof) can be used in the cell-free assays of the invention. When membrane-bound forms of the protein are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic

detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

Cell-free assays involve preparing a reaction mixture of the target gene protein and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex that can be removed and/or detected.

The interaction between two molecules can also be detected, e.g., using fluorescence energy transfer (FET) (see, for example, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos, *et al.*, U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

In another embodiment, determining the ability of the 21617 or 55562 protein to bind to a target molecule can be accomplished using real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705). "Surface plasmon resonance" or "BIA" detects biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

In one embodiment, the target gene product or the test substance is anchored onto a solid phase. The target gene product/test compound complexes anchored on the solid phase

can be detected at the end of the reaction. Preferably, the target gene product can be anchored onto a solid surface, and the test compound, (which is not anchored), can be labeled, either directly or indirectly, with detectable labels discussed herein.

It may be desirable to immobilize either 21617 or 55562, an anti-21617 or 55562
 5 antibody or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a 21617 or 55562 protein, or interaction of a 21617 or 55562 protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels
 10 include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/21617 or 55562 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter
 15 plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or 21617 or 55562 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined
 20 either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of 21617 or 55562 binding or activity determined using standard techniques.

Other techniques for immobilizing either a 21617 or 55562 protein or a target molecule on matrices include using conjugation of biotin and streptavidin. Biotinylated
 25 21617 or 55562 protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).

In order to conduct the assay, the non-immobilized component is added to the coated
 30 surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously non-

immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the immobilized component (the antibody, in turn, can be directly labeled or indirectly labeled with, e.g., a labeled anti-Ig antibody).

In one embodiment, this assay is performed utilizing antibodies reactive with 21617 or 55562 protein or target molecules but which do not interfere with binding of the 21617 or 55562 protein to its target molecule. Such antibodies can be derivatized to the wells of the plate, and unbound target or 21617 or 55562 protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the 21617 or 55562 protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the 21617 or 55562 protein or target molecule.

Alternatively, cell free assays can be conducted in a liquid phase. In such an assay, the reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (see, for example, Rivas, G., and Minton, A.P., (1993) *Trends Biochem Sci* 18:284-7); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis (see, e.g., Ausubel, F. *et al.*, eds. *Current Protocols in Molecular Biology* 1999, J. Wiley: New York.); and immunoprecipitation (see, for example, Ausubel, F. *et al.*, eds. (1999) *Current Protocols in Molecular Biology*, J. Wiley: New York). Such resins and chromatographic techniques are known to one skilled in the art (see, e.g., Heegaard, N.H., (1998) *J Mol Recognit* 11:141-8; Hage, D.S., and Tweed, S.A. (1997) *J Chromatogr B Biomed Sci Appl.* 699:499-525). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.

In a preferred embodiment, the assay includes contacting the 21617 or 55562 protein or biologically active portion thereof with a known compound which binds 21617 or 55562 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a 21617 or 55562 protein, wherein determining the ability of the test compound to interact with a 21617 or 55562 protein includes determining the ability of the test compound to preferentially bind to 21617

or 55562 or biologically active portion thereof, or to modulate the activity of a target molecule, as compared to the known compound.

The target gene products of the invention can, *in vivo*, interact with one or more cellular or extracellular macromolecules, such as proteins. For the purposes of this discussion, such cellular and extracellular macromolecules are referred to herein as "binding partners." Compounds that disrupt such interactions can be useful in regulating the activity of the target gene product. Such compounds can include, but are not limited to molecules such as antibodies, peptides, and small molecules. The preferred target genes/products for use in this embodiment are the 21617 or 55562 genes herein identified. In an alternative embodiment, the invention provides methods for determining the ability of the test compound to modulate the activity of a 21617 or 55562 protein through modulation of the activity of a downstream effector of a 21617 or 55562 target molecule. For example, the activity of the effector molecule on an appropriate target can be determined, or the binding of the effector to an appropriate target can be determined, as previously described.

To identify compounds that interfere with the interaction between the target gene product and its cellular or extracellular binding partner(s), a reaction mixture containing the target gene product and the binding partner is prepared, under conditions and for a time sufficient, to allow the two products to form complex. In order to test an inhibitory agent, the reaction mixture is provided in the presence and absence of the test compound. The test compound can be initially included in the reaction mixture, or can be added at a time subsequent to the addition of the target gene and its cellular or extracellular binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the target gene product and the cellular or extracellular binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the target gene product and the interactive binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal target gene product can also be compared to complex formation within reaction mixtures containing the test compound and mutant target gene product. This comparison can be important in those cases wherein it is desirable to identify compounds that disrupt interactions of mutant but not normal target gene products.

These assays can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the target gene product or the binding

partner onto a solid phase, and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere
 5 with the interaction between the target gene products and the binding partners, e.g., by competition, can be identified by conducting the reaction in the presence of the test substance. Alternatively, test compounds that disrupt preformed complexes, e.g., compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes
 10 have been formed. The various formats are briefly described below.

In a heterogeneous assay system, either the target gene product or the interactive cellular or extracellular binding partner, is anchored onto a solid surface (e.g., a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored species can be immobilized by non-covalent or covalent attachments. Alternatively, an
 15 immobilized antibody specific for the species to be anchored can be used to anchor the species to the solid surface.

In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain
 20 immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, can be directly labeled or indirectly labeled
 25 with, e.g., a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components,
 30 and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of

addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

In an alternate embodiment of the invention, a homogeneous assay can be used. For example, a preformed complex of the target gene product and the interactive cellular or
 5 extracellular binding partner product is prepared in that either the target gene products or their binding partners are labeled, but the signal generated by the label is quenched due to complex formation (see, e.g., U.S. Patent No. 4,109,496 that utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above
 10 background. In this way, test substances that disrupt target gene product-binding partner interaction can be identified.

In yet another aspect, the 21617 or 55562 proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.*
 15 (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with 21617 or 55562 ("21617 or 55562-binding proteins" or "21617 or 55562-bp") and are involved in 21617 or 55562 activity. Such 21617 or 55562-bps can be activators or inhibitors of signals by the 21617 or 55562 proteins or 21617 or 55562 targets as, for example, downstream elements of
 20 a 21617 or 55562-mediated signaling pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a 21617 or 55562 protein is fused to a gene encoding the DNA binding domain of a known transcription factor
 25 (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. (Alternatively the: 21617 or 55562 protein can be the fused to the activator domain.) If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a 21617 or 55562-dependent complex, the DNA-binding
 30 and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., lacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor

can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the 21617 or 55562 protein.

In another embodiment, modulators of 21617 or 55562 expression are identified. For example, a cell or cell free mixture is contacted with a candidate compound and the expression of 21617 or 55562 mRNA or protein evaluated relative to the level of expression of 21617 or 55562 mRNA or protein in the absence of the candidate compound. When expression of 21617 or 55562 mRNA or protein is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of 21617 or 55562 mRNA or protein expression. Alternatively, when expression of 21617 or 55562 mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of 21617 or 55562 mRNA or protein expression. The level of 21617 or 55562 mRNA or protein expression can be determined by methods described herein for detecting 21617 or 55562 mRNA or protein.

In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell free assay, and the ability of the agent to modulate the activity of a 21617 or 55562 protein can be confirmed *in vivo*, e.g., in an animal such as an animal model for a cellular proliferation and/or differentiation disorder, metabolic disorder, kidney disorder, endothelial cell disorder, neural disorder, or viral disorder.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein (e.g., a 21617 or 55562 modulating agent, an antisense 21617 or 55562 nucleic acid molecule, a 21617 or 55562-specific antibody, or a 21617 or 55562-binding partner) in an appropriate animal model to determine the efficacy, toxicity, side effects, or mechanism of action, of treatment with such an agent. Furthermore, novel agents identified by the above-described screening assays can be used for treatments as described herein.

Detection Assays

Portions or fragments of the nucleic acid sequences identified herein can be used as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome e.g., to locate gene regions associated with genetic

disease or to associate 21617 or 55562 with a disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

Chromosome Mapping

5 The 21617 or 55562 nucleotide sequences or portions thereof can be used to map the location of the 21617 or 55562 genes on a chromosome. This process is called chromosome mapping. Chromosome mapping is useful in correlating the 21617 or 55562 sequences with genes associated with disease.

Briefly, 21617 or 55562 genes can be mapped to chromosomes by preparing PCR
10 primers (preferably 15-25 bp in length) from the 21617 or 55562 nucleotide sequences. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the 21617 or 55562 sequences will yield an amplified fragment.

A panel of somatic cell hybrids in which each cell line contains either a single human
15 chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, can allow easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. *et al.* (1983) *Science* 220:919-924).

Other mapping strategies e.g., in situ hybridization (described in Fan, Y. *et al.* (1990) *Proc. Natl. Acad. Sci. USA*, 87:6223-27), pre-screening with labeled flow-sorted
20 chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries can be used to map 21617 or 55562 to a chromosomal location.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases.
25 However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma *et al.*, *Human Chromosomes: A Manual of Basic Techniques* ((1988) Pergamon Press, New York).

30 Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding

regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical
5 position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between a gene and a disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example,
10 Egeland, J. *et al.* (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the 21617 or 55562 gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease.
15 Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

20 Tissue Typing

21617 or 55562 sequences can be used to identify individuals from biological samples using, e.g., restriction fragment length polymorphism (RFLP). In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, the fragments separated, e.g., in a Southern blot, and probed to yield bands for identification. The
25 sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the 21617 or 55562 nucleotide sequences described herein can be used to prepare two PCR
30 primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it. Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual

identifications, as each individual will have a unique set of such DNA sequences due to allelic differences.

Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO:1 OR SEQ ID NO:4 can provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:3 OR SEQ ID NO:6 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from 21617 or 55562 nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

Use of Partial 21617 or 55562 Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic biology. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO:1 or SEQ ID NO:4 (e.g., fragments derived from the noncoding regions of SEQ ID NO:1 or SEQ ID NO:4

having a length of at least 20 bases, preferably at least 30 bases) are particularly appropriate for this use.

The 21617 or 55562 nucleotide sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such 21617 or 55562 probes can be used to identify tissue by species and/or by organ type.

In a similar fashion, these reagents, e.g., 21617 or 55562 primers or probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a culture).

Predictive Medicine

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual.

Generally, the invention provides, a method of determining if a subject is at risk for a disorder related to a lesion in or the misexpression of a gene which encodes 21617 or 55562.

Such disorders include, e.g., a disorder associated with the misexpression of 21617 or 55562 gene; a cellular proliferation and/or differentiation disorder, e.g., cancer, e.g., colon, colorectal, breast, lung, cervical, ovarian or liver cancer.

The method includes one or more of the following:

detecting, in a tissue of the subject, the presence or absence of a mutation which affects the expression of the 21617 or 55562 gene, or detecting the presence or absence of a mutation in a region which controls the expression of the gene, e.g., a mutation in the 5' control region;

detecting, in a tissue of the subject, the presence or absence of a mutation which alters the structure of the 21617 or 55562 gene;

detecting, in a tissue of the subject, the misexpression of the 21617 or 55562 gene, at the mRNA level, e.g., detecting a non-wild type level of a mRNA ;

detecting, in a tissue of the subject, the misexpression of the gene, at the protein level, e.g., detecting a non-wild type level of a 21617 or 55562 polypeptide.

In preferred embodiments the method includes: ascertaining the existence of at least one of: a deletion of one or more nucleotides from the 21617 or 55562 gene; an insertion of one or more nucleotides into the gene, a point mutation, e.g., a substitution of one or more nucleotides of the gene, a gross chromosomal rearrangement of the gene, e.g., a translocation, inversion, or deletion.

For example, detecting the genetic lesion can include: (i) providing a probe/primer including an oligonucleotide containing a region of nucleotide sequence which hybridizes to a sense or antisense sequence from SEQ ID NO:1 or SEQ ID NO:4, or naturally occurring mutants thereof or 5' or 3' flanking sequences naturally associated with the 21617 or 55562 gene; (ii) exposing the probe/primer to nucleic acid of the tissue; and detecting, by hybridization, e.g., *in situ* hybridization, of the probe/primer to the nucleic acid, the presence or absence of the genetic lesion.

In preferred embodiments detecting the misexpression includes ascertaining the existence of at least one of: an alteration in the level of a messenger RNA transcript of the 21617 or 55562 gene; the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; or a non-wild type level of 21617 or 55562.

Methods of the invention can be used prenatally or to determine if a subject's offspring will be at risk for a disorder.

In preferred embodiments the method includes determining the structure of a 21617 or 55562 gene, an abnormal structure being indicative of risk for the disorder.

In preferred embodiments the method includes contacting a sample from the subject with an antibody to the 21617 or 55562 protein or a nucleic acid, which hybridizes specifically with the gene. These and other embodiments are discussed below.

Diagnostic and Prognostic Assays

Diagnostic and prognostic assays of the invention include method for assessing the expression level of 21617 or 55562 molecules and for identifying variations and mutations in the sequence of 21617 or 55562 molecules.

Expression Monitoring and Profiling. The presence, level, or absence of 21617 or 55562 protein or nucleic acid in a biological sample can be evaluated by obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting 21617 or 55562 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes 21617 or 55562 protein such that the presence of 21617 or

55562 protein or nucleic acid is detected in the biological sample. The term "biological sample" includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. A preferred biological sample is serum. The level of expression of the 21617 or 55562 gene can be measured in a number of ways, including, but not limited to: measuring the mRNA encoded by the 21617 or 55562 genes; measuring the amount of protein encoded by the 21617 or 55562 genes; or measuring the activity of the protein encoded by the 21617 or 55562 genes.

The level of mRNA corresponding to the 21617 or 55562 gene in a cell can be determined both by *in situ* and by *in vitro* formats.

The isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays. One preferred diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe can be, for example, a full-length 21617 or 55562 nucleic acid, such as the nucleic acid of SEQ ID NO:1 or SEQ ID NO:4, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to 21617 or 55562 mRNA or genomic DNA. The probe can be disposed on an address of an array, e.g., an array described below. Other suitable probes for use in the diagnostic assays are described herein.

In one format, mRNA (or cDNA) is immobilized on a surface and contacted with the probes, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probes are immobilized on a surface and the mRNA (or cDNA) is contacted with the probes, for example, in a two-dimensional gene chip array described below. A skilled artisan can adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the 21617 or 55562 genes.

The level of mRNA in a sample that is encoded by one of 21617 or 55562 can be evaluated with nucleic acid amplification, e.g., by rtPCR (Mullis (1987) U.S. Patent No. 4,683,202), ligase chain reaction (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189-193), self sustained sequence replication (Guatelli *et al.*, (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.*, (1989), *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*, (1988) *Bio/Technology* 6:1197),

rolling circle replication (Lizardi *et al.*, U.S. Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques known in the art. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

For *in situ* methods, a cell or tissue sample can be prepared/processed and immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the 21617 or 55562 gene being analyzed.

In another embodiment, the methods further contacting a control sample with a compound or agent capable of detecting 21617 or 55562 mRNA, or genomic DNA, and comparing the presence of 21617 or 55562 mRNA or genomic DNA in the control sample with the presence of 21617 or 55562 mRNA or genomic DNA in the test sample. In still another embodiment, serial analysis of gene expression, as described in U.S. Patent No. 5,695,937, is used to detect 21617 or 55562 transcript levels.

A variety of methods can be used to determine the level of protein encoded by 21617 or 55562. In general, these methods include contacting an agent that selectively binds to the protein, such as an antibody with a sample, to evaluate the level of protein in the sample. In a preferred embodiment, the antibody bears a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with a detectable substance. Examples of detectable substances are provided herein.

The detection methods can be used to detect 21617 or 55562 protein in a biological sample *in vitro* as well as *in vivo*. *In vitro* techniques for detection of 21617 or 55562 protein include enzyme linked immunosorbent assays (ELISAs), immunoprecipitations, immunofluorescence, enzyme immunoassay (EIA), radioimmunoassay (RIA), and Western blot analysis. *In vivo* techniques for detection of 21617 or 55562 protein include introducing

into a subject a labeled anti-21617 or 55562 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. In another embodiment, the sample is labeled, e.g., biotinylated and then contacted to the antibody, e.g., an anti-21617 or 55562 antibody
 5 positioned on an antibody array (as described below). The sample can be detected, e.g., with avidin coupled to a fluorescent label.

In another embodiment, the methods further include contacting the control sample with a compound or agent capable of detecting 21617 or 55562 protein, and comparing the presence of 21617 or 55562 protein in the control sample with the presence of 21617 or
 10 55562 protein in the test sample.

The invention also includes kits for detecting the presence of 21617 or 55562 in a biological sample. For example, the kit can include a compound or agent capable of detecting 21617 or 55562 protein or mRNA in a biological sample; and a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise
 15 instructions for using the kit to detect 21617 or 55562 protein or nucleic acid.

For antibody-based kits, the kit can include: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can include: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide corresponding to a marker of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker of the invention. The kit can also include a buffering agent, a preservative, or a protein stabilizing agent. The kit can
 20 also include components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed
 25 using the kit.
 30

The diagnostic methods described herein can identify subjects having, or at risk of developing, a disease or disorder associated with misexpressed or aberrant or unwanted 21617 or 55562 expression or activity. As used herein, the term "unwanted" includes an

unwanted phenomenon involved in a biological response such as a cellular proliferation and/or differentiation disorder, metabolic disorder, kidney disorder, endothelial cell disorder, neural disorder, or viral disorder.

In one embodiment, a disease or disorder associated with aberrant or unwanted
 5 21617 or 55562 expression or activity is identified. A test sample is obtained from a subject and 21617 or 55562 protein or nucleic acid (e.g., mRNA or genomic DNA) is evaluated, wherein the level, e.g., the presence or absence, of 21617 or 55562 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant or unwanted 21617 or 55562 expression or activity. As used herein, a "test sample"
 10 refers to a biological sample obtained from a subject of interest, including a biological fluid (e.g., serum), cell sample, or tissue.

The prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder
 15 associated with aberrant or unwanted 21617 or 55562 expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a cellular proliferative and/or differentiative disorder, metabolic disorder, kidney disorder, endothelial cell disorder, neural disorder, or viral disorder.

In another aspect, the invention features a computer medium having a plurality of
 20 digitally encoded data records. Each data record includes a value representing the level of expression of 21617 or 55562 in a sample, and a descriptor of the sample. The descriptor of the sample can be an identifier of the sample, a subject from which the sample was derived (e.g., a patient), a diagnosis, or a treatment (e.g., a preferred treatment). In a preferred embodiment, the data record further includes values representing the level of expression of
 25 genes other than 21617 or 55562 (e.g., other genes associated with a 21617 or 55562-disorder, or other genes on an array). The data record can be structured as a table, e.g., a table that is part of a database such as a relational database (e.g., a SQL database of the Oracle or Sybase database environments).

Also featured is a method of evaluating a sample. The method includes providing a
 30 sample, e.g., from the subject, and determining a gene expression profile of the sample, wherein the profile includes a value representing the level of 21617 or 55562 expression. The method can further include comparing the value or the profile (i.e., multiple values) to a reference value or reference profile. The gene expression profile of the sample can be

obtained by any of the methods described herein (e.g., by providing a nucleic acid from the sample and contacting the nucleic acid to an array). The method can be used to diagnose a cellular proliferation and/or differentiation disorders, metabolic disorders, kidney disorders, endothelial cell disorders, neural disorders, and viral disorders disorder in a subject wherein
5 an increase or decrease in 21617 or 55562 expression is an indication that the subject has or is disposed to having such a disorder. For example, an increase in 21617 expression can be an indication that the subject has or is disposed to having a cellular proliferation and/or differentiation disorder, e.g., colon, colorectal, breast, lung, cervical, ovarian or liver cancer. The method can be used to monitor a treatment for a cellular proliferation and/or
10 differentiation disorder, metabolic disorder, kidney disorder, endothelial cell disorder, neural disorder, or viral disorder in a subject. For example, the gene expression profile can be determined for a sample from a subject undergoing treatment. The profile can be compared to a reference profile or to a profile obtained from the subject prior to treatment or prior to onset of the disorder (see, e.g., Golub *et al.* (1999) *Science* 286:531).

15 In yet another aspect, the invention features a method of evaluating a test compound (see also, "Screening Assays", above). The method includes providing a cell and a test compound; contacting the test compound to the cell; obtaining a subject expression profile for the contacted cell; and comparing the subject expression profile to one or more reference profiles. The profiles include a value representing the level of 21617 or 55562 expression.
20 In a preferred embodiment, the subject expression profile is compared to a target profile, e.g., a profile for a normal cell or for desired condition of a cell. The test compound is evaluated favorably if the subject expression profile is more similar to the target profile than an expression profile obtained from an uncontacted cell.

In another aspect, the invention features, a method of evaluating a subject. The
25 method includes: a) obtaining a sample from a subject, e.g., from a caregiver, e.g., a caregiver who obtains the sample from the subject; b) determining a subject expression profile for the sample. Optionally, the method further includes either or both of steps: c) comparing the subject expression profile to one or more reference expression profiles; and d) selecting the reference profile most similar to the subject reference profile. The subject
30 expression profile and the reference profiles include a value representing the level of 21617 or 55562 expression. A variety of routine statistical measures can be used to compare two reference profiles. One possible metric is the length of the distance vector that is the

difference between the two profiles. Each of the subject and reference profile is represented as a multi-dimensional vector, wherein each dimension is a value in the profile.

The method can further include transmitting a result to a caregiver. The result can be the subject expression profile, a result of a comparison of the subject expression profile with another profile, a most similar reference profile, or a descriptor of any of the aforementioned. The result can be transmitted across a computer network, e.g., the result can be in the form of a computer transmission, e.g., a computer data signal embedded in a carrier wave.

Also featured is a computer medium having executable code for effecting the following steps: receive a subject expression profile; access a database of reference expression profiles; and either i) select a matching reference profile most similar to the subject expression profile or ii) determine at least one comparison score for the similarity of the subject expression profile to at least one reference profile. The subject expression profile, and the reference expression profiles each include a value representing the level of 21617 or 55562 expression.

Arrays and Uses Thereof

In another aspect, the invention features an array that includes a substrate having a plurality of addresses. At least one address of the plurality includes a capture probe that binds specifically to a 21617 or 55562 molecule (e.g., a 21617 or 55562 nucleic acid or a 21617 or 55562 polypeptide). The array can have a density of at least 10, 50, 100, 200, 500, 1,000, 2,000, or 10,000 or more addresses/cm², and ranges between. In a preferred embodiment, the plurality of addresses includes at least 10, 100, 500, 1,000, 5,000, 10,000, 50,000 addresses. In a preferred embodiment, the plurality of addresses includes equal to or less than 10, 100, 500, 1,000, 5,000, 10,000, or 50,000 addresses. The substrate can be a two-dimensional substrate such as a glass slide, a wafer (e.g., silica or plastic), a mass spectroscopy plate, or a three-dimensional substrate such as a gel pad. Addresses in addition to address of the plurality can be disposed on the array.

In a preferred embodiment, at least one address of the plurality includes a nucleic acid capture probe that hybridizes specifically to a 21617 or 55562 nucleic acid, e.g., the sense or anti-sense strand. In one preferred embodiment, a subset of addresses of the plurality of addresses has a nucleic acid capture probe for 21617 or 55562. Each address of the subset can include a capture probe that hybridizes to a different region of a 21617 or

55562 nucleic acid. In another preferred embodiment, addresses of the subset include a capture probe for a 21617 or 55562 nucleic acid. Each address of the subset is unique, overlapping, and complementary to a different variant of 21617 or 55562 (e.g., an allelic variant, or all possible hypothetical variants). The array can be used to sequence 21617 or
 5 55562 by hybridization (see, e.g., U.S. Patent No. 5,695,940).

An array can be generated by various methods, e.g., by photolithographic methods (see, e.g., U.S. Patent Nos. 5,143,854; 5,510,270; and 5,527,681), mechanical methods (e.g., directed-flow methods as described in U.S. Patent No. 5,384,261), pin-based methods (e.g., as described in U.S. Pat. No. 5,288,514), and bead-based techniques (e.g., as described in
 10 PCT US/93/04145).

In another preferred embodiment, at least one address of the plurality includes a polypeptide capture probe that binds specifically to a 21617 or 55562 polypeptide or fragment thereof. The polypeptide can be a naturally-occurring interaction partner of 21617 or 55562 polypeptide. Preferably, the polypeptide is an antibody, e.g., an antibody
 15 described herein (see "Anti-21617 or 55562 Antibodies," above), such as a monoclonal antibody or a single-chain antibody.

In another aspect, the invention features a method of analyzing the expression of 21617 or 55562. The method includes providing an array as described above; contacting the array with a sample and detecting binding of a 21617 or 55562-molecule (e.g., nucleic acid
 20 or polypeptide) to the array. In a preferred embodiment, the array is a nucleic acid array. Optionally the method further includes amplifying nucleic acid from the sample prior or during contact with the array.

In another embodiment, the array can be used to assay gene expression in a tissue to ascertain tissue specificity of genes in the array, particularly the expression of 21617 or
 25 55562. If a sufficient number of diverse samples is analyzed, clustering (e.g., hierarchical clustering, k-means clustering, Bayesian clustering and the like) can be used to identify other genes which are co-regulated with 21617 or 55562. For example, the array can be used for the quantitation of the expression of multiple genes. Thus, not only tissue specificity, but also the level of expression of a battery of genes in the tissue is ascertained.
 30 Quantitative data can be used to group (e.g., cluster) genes on the basis of their tissue expression *per se* and level of expression in that tissue.

For example, array analysis of gene expression can be used to assess the effect of cell-cell interactions on 21617 or 55562 expression. A first tissue can be perturbed and

nucleic acid from a second tissue that interacts with the first tissue can be analyzed. In this context, the effect of one cell type on another cell type in response to a biological stimulus can be determined, e.g., to monitor the effect of cell-cell interaction at the level of gene expression.

5 In another embodiment, cells are contacted with a therapeutic agent. The expression profile of the cells is determined using the array, and the expression profile is compared to the profile of like cells not contacted with the agent. For example, the assay can be used to determine or analyze the molecular basis of an undesirable effect of the therapeutic agent. If an agent is administered therapeutically to treat one cell type but has an undesirable effect
10 on another cell type, the invention provides an assay to determine the molecular basis of the undesirable effect and thus provides the opportunity to co-administer a counteracting agent or otherwise treat the undesired effect. Similarly, even within a single cell type, undesirable biological effects can be determined at the molecular level. Thus, the effects of an agent on expression of other than the target gene can be ascertained and counteracted.

15 In another embodiment, the array can be used to monitor expression of one or more genes in the array with respect to time. For example, samples obtained from different time points can be probed with the array. Such analysis can identify and/or characterize the development of a 21617 or 55562-associated disease or disorder; and processes, such as a cellular transformation associated with a 21617 or 55562-associated disease or disorder.

20 The method can also evaluate the treatment and/or progression of a 21617 or 55562-associated disease or disorder

The array is also useful for ascertaining differential expression patterns of one or more genes in normal and abnormal cells. This provides a battery of genes (e.g., including 21617 or 55562) that could serve as a molecular target for diagnosis or therapeutic
25 intervention.

In another aspect, the invention features an array having a plurality of addresses. Each address of the plurality includes a unique polypeptide. At least one address of the plurality has disposed thereon a 21617 or 55562 polypeptide or fragment thereof. Methods of producing polypeptide arrays are described in the art, e.g., in De Wildt *et al.* (2000).
30 *Nature Biotech.* 18, 989-994; Lueking *et al.* (1999). *Anal. Biochem.* 270, 103-111; Ge, H. (2000). *Nucleic Acids Res.* 28, e3, I-VII; MacBeath, G., and Schreiber, S.L. (2000). *Science* 289, 1760-1763; and WO 99/51773A1. In a preferred embodiment, each addresses of the plurality has disposed thereon a polypeptide at least 60, 70, 80,85, 90, 95 or 99 % identical

to a 21617 or 55562 polypeptide or fragment thereof. For example, multiple variants of a 21617 or 55562 polypeptide (e.g., encoded by allelic variants, site-directed mutants, random mutants, or combinatorial mutants) can be disposed at individual addresses of the plurality. Addresses in addition to the address of the plurality can be disposed on the array.

5 The polypeptide array can be used to detect a 21617 or 55562 binding compound, e.g., an antibody in a sample from a subject with specificity for a 21617 or 55562 polypeptide or the presence of a 21617 or 55562-binding protein or ligand.

 The array is also useful for ascertaining the effect of the expression of a gene on the expression of other genes in the same cell or in different cells (*e.g.*, ascertaining the effect of 10 21617 or 55562 expression on the expression of other genes). This provides, for example, for a selection of alternate molecular targets for therapeutic intervention if the ultimate or downstream target cannot be regulated.

 In another aspect, the invention features a method of analyzing a plurality of probes. The method is useful, e.g., for analyzing gene expression. The method includes: providing 15 a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality having a unique capture probe, e.g., wherein the capture probes are from a cell or subject which express 21617 or 55562 or from a cell or subject in which a 21617 or 55562 mediated response has been elicited, e.g., by contact of the cell with 21617 or 55562 nucleic acid or protein, or 20 administration to the cell or subject 21617 or 55562 nucleic acid or protein; providing a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality, and each address of the plurality having a unique capture probe, e.g., wherein the capture probes are from a cell or subject which does not express 21617 or 55562 (or does not express as highly as in the case 25 of the 21617 or 55562 positive plurality of capture probes) or from a cell or subject which in which a 21617 or 55562 mediated response has not been elicited (or has been elicited to a lesser extent than in the first sample); contacting the array with one or more inquiry probes (which is preferably other than a 21617 or 55562 nucleic acid, polypeptide, or antibody), and thereby evaluating the plurality of capture probes. Binding, e.g., in the case of a nucleic 30 acid, hybridization with a capture probe at an address of the plurality, is detected, e.g., by signal generated from a label attached to the nucleic acid, polypeptide, or antibody.

 In another aspect, the invention features a method of analyzing a plurality of probes or a sample. The method is useful, e.g., for analyzing gene expression. The method

includes: providing a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality having a unique capture probe, contacting the array with a first sample from a cell or subject which express or mis-express 21617 or 55562 or from a cell or subject in which a 21617 or 55562-mediated response has been elicited, e.g., by contact of the cell with 21617 or 55562 nucleic acid or protein, or administration to the cell or subject 21617 or 55562 nucleic acid or protein; providing a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality, and each address of the plurality having a unique capture probe, and contacting the array with a second sample from a cell or subject which does not express 21617 or 55562 (or does not express as highly as in the case of the 21617 or 55562 positive plurality of capture probes) or from a cell or subject which in which a 21617 or 55562 mediated response has not been elicited (or has been elicited to a lesser extent than in the first sample); and comparing the binding of the first sample with the binding of the second sample. Binding, e.g., in the case of a nucleic acid, hybridization with a capture probe at an address of the plurality, is detected, e.g., by signal generated from a label attached to the nucleic acid, polypeptide, or antibody. The same array can be used for both samples or different arrays can be used. If different arrays are used the plurality of addresses with capture probes should be present on both arrays.

In another aspect, the invention features a method of analyzing 21617 or 55562, e.g., analyzing structure, function, or relatedness to other nucleic acid or amino acid sequences. The method includes: providing a 21617 or 55562 nucleic acid or amino acid sequence; comparing the 21617 or 55562 sequence with one or more preferably a plurality of sequences from a collection of sequences, e.g., a nucleic acid or protein sequence database; to thereby analyze 21617 or 55562.

Detection of Variations or Mutations

The methods of the invention can also be used to detect genetic alterations in a 21617 or 55562 gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by misregulation in 21617 or 55562 protein activity or nucleic acid expression, such as a cellular proliferation and/or differentiation disorders, metabolic disorders, kidney disorders, endothelial cell disorders, neural disorders, and viral disorders. In preferred embodiments, the methods include detecting, in a sample from the subject, the presence or

absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding a 21617 or 55562-protein, or the mis-expression of the 21617 or 55562 gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a 21617 or 55562 gene; 2) an addition of one or more nucleotides to a 21617 or 55562 gene; 3) a substitution of one or more nucleotides of a 21617 or 55562 gene, 4) a chromosomal rearrangement of a 21617 or 55562 gene; 5) an alteration in the level of a messenger RNA transcript of a 21617 or 55562 gene, 6) aberrant modification of a 21617 or 55562 gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a 21617 or 55562 gene, 8) a non-wild type level of a 21617 or 55562-protein, 9) allelic loss of a 21617 or 55562 gene, and 10) inappropriate post-translational modification of a 21617 or 55562-protein.

An alteration can be detected without a probe/primer in a polymerase chain reaction, such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR), the latter of which can be particularly useful for detecting point mutations in the 21617 or 55562-gene. This method can include the steps of collecting a sample of cells from a subject, isolating nucleic acid (e.g., genomic, mRNA or both) from the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a 21617 or 55562 gene under conditions such that hybridization and amplification of the 21617 or 55562-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein. Alternatively, other amplification methods described herein or known in the art can be used.

In another embodiment, mutations in a 21617 or 55562 gene from a sample cell can be identified by detecting alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined, e.g., by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in 21617 or 55562 can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, two-dimensional arrays, e.g., chip based arrays. Such arrays include a plurality of addresses, each of which is positionally distinguishable from the other. A different probe is located at each address of the plurality. A probe can be complementary to a region of a 21617 or 55562 nucleic acid or a putative variant (e.g., allelic variant) thereof. A probe can have one or more mismatches to a region of a 21617 or 55562 nucleic acid (e.g., a destabilizing mismatch). The arrays can have a high density of addresses, e.g., can contain hundreds or thousands of oligonucleotide probes (Cronin, M.T. *et al.* (1996) *Human Mutation* 7: 244-255; Kozal, M.J. *et al.* (1996) *Nature Medicine* 2: 753-759). For example, genetic mutations in 21617 or 55562 can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin, M.T. *et al. supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the 21617 or 55562 gene and detect mutations by comparing the sequence of the sample 21617 or 55562 with the corresponding wild-type (control) sequence. Automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry.

Other methods for detecting mutations in the 21617 or 55562 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242; Cotton *et al.* (1988) *Proc. Natl Acad Sci USA* 85:4397; Saleeba *et al.* (1992) *Methods Enzymol.* 217:286-295).

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in 21617 or 55562 cDNAs obtained from samples of cells. For example, the mutY enzyme of

E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662; U.S. Patent No. 5,459,039).

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in 21617 or 55562 genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita *et al.* (1989) *Proc Natl. Acad. Sci USA*: 86:2766, see also Cotton (1993) *Mutat. Res.* 285:125-144; and Hayashi (1992) *Genet. Anal. Tech. Appl.* 9:73-79). Single-stranded DNA fragments of sample and control 21617 or 55562 nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet* 7:5).

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc. Natl Acad. Sci USA* 86:6230). A further method of detecting point mutations is the chemical ligation of oligonucleotides as described in Xu *et al.* ((2001) *Nature Biotechnol.* 19:148). Adjacent oligonucleotides, one of which selectively anneals to the query site, are ligated together if the nucleotide at the query site of the sample nucleic acid is complementary to the query

oligonucleotide; ligation can be monitored, e.g., by fluorescent dyes coupled to the oligonucleotides.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used
 5 as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site
 10 in the region of the mutation to create cleavage-based detection (Gasparini *et al.* (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site
 15 by looking for the presence or absence of amplification.

In another aspect, the invention features a set of oligonucleotides. The set includes a plurality of oligonucleotides, each of which is at least partially complementary (e.g., at least 50%, 60%, 70%, 80%, 90%, 92%, 95%, 97%, 98%, or 99% complementary) to a 21617 or 55562 nucleic acid.

20 In a preferred embodiment the set includes a first and a second oligonucleotide. The first and second oligonucleotide can hybridize to the same or to different locations of SEQ ID NO:1 or SEQ ID NO:4 or the complement of SEQ ID NO:1 or SEQ ID NO:4. Different locations can be different but overlapping, or non-overlapping on the same strand. The first and second oligonucleotide can hybridize to sites on the same or on different strands.

25 The set can be useful, e.g., for identifying SNP's, or identifying specific alleles of 21617 or 55562. In a preferred embodiment, each oligonucleotide of the set has a different nucleotide at an interrogation position. In one embodiment, the set includes two oligonucleotides, each complementary to a different allele at a locus, e.g., a biallelic or polymorphic locus.

30 In another embodiment, the set includes four oligonucleotides, each having a different nucleotide (e.g., adenine, guanine, cytosine, or thymidine) at the interrogation position. The interrogation position can be a SNP or the site of a mutation. In another preferred embodiment, the oligonucleotides of the plurality are identical in sequence to one

another (except for differences in length). The oligonucleotides can be provided with differential labels, such that an oligonucleotide that hybridizes to one allele provides a signal that is distinguishable from an oligonucleotide that hybridizes to a second allele. In still another embodiment, at least one of the oligonucleotides of the set has a nucleotide change at a position in addition to a query position, e.g., a destabilizing mutation to decrease the T_m of the oligonucleotide. In another embodiment, at least one oligonucleotide of the set has a non-natural nucleotide, e.g., inosine. In a preferred embodiment, the oligonucleotides are attached to a solid support, e.g., to different addresses of an array or to different beads or nanoparticles.

In a preferred embodiment the set of oligo nucleotides can be used to specifically amplify, e.g., by PCR, or detect, a 21617 or 55562 nucleic acid.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a 21617 or 55562 gene.

Use of 21617 or 55562 Molecules as Surrogate Markers

The 21617 or 55562 molecules of the invention are also useful as markers of disorders or disease states, as markers for precursors of disease states, as markers for predisposition of disease states, as markers of drug activity, or as markers of the pharmacogenomic profile of a subject. Using the methods described herein, the presence, absence and/or quantity of the 21617 or 55562 molecules of the invention may be detected, and may be correlated with one or more biological states in vivo. For example, the 21617 or 55562 molecules of the invention may serve as surrogate markers for one or more disorders or disease states or for conditions leading up to disease states. As used herein, a “surrogate marker” is an objective biochemical marker which correlates with the absence or presence of a disease or disorder, or with the progression of a disease or disorder (e.g., with the presence or absence of a tumor). The presence or quantity of such markers is independent of the disease. Therefore, these markers may serve to indicate whether a particular course of treatment is effective in lessening a disease state or disorder. Surrogate markers are of particular use when the presence or extent of a disease state or disorder is difficult to assess through standard methodologies (e.g., early stage tumors), or when an assessment of disease

progression is desired before a potentially dangerous clinical endpoint is reached (e.g., an assessment of cardiovascular disease may be made using cholesterol levels as a surrogate marker, and an analysis of HIV infection may be made using HIV RNA levels as a surrogate marker, well in advance of the undesirable clinical outcomes of myocardial infarction or fully-developed AIDS). Examples of the use of surrogate markers in the art include: Koomen *et al.* (2000) *J. Mass. Spectrom.* 35: 258-264; and James (1994) *AIDS Treatment News Archive* 209.

The 21617 or 55562 molecules of the invention are also useful as pharmacodynamic markers. As used herein, a “pharmacodynamic marker” is an objective biochemical marker which correlates specifically with drug effects. The presence or quantity of a pharmacodynamic marker is not related to the disease state or disorder for which the drug is being administered; therefore, the presence or quantity of the marker is indicative of the presence or activity of the drug in a subject. For example, a pharmacodynamic marker may be indicative of the concentration of the drug in a biological tissue, in that the marker is either expressed or transcribed or not expressed or transcribed in that tissue in relationship to the level of the drug. In this fashion, the distribution or uptake of the drug may be monitored by the pharmacodynamic marker. Similarly, the presence or quantity of the pharmacodynamic marker may be related to the presence or quantity of the metabolic product of a drug, such that the presence or quantity of the marker is indicative of the relative breakdown rate of the drug in vivo. Pharmacodynamic markers are of particular use in increasing the sensitivity of detection of drug effects, particularly when the drug is administered in low doses. Since even a small amount of a drug may be sufficient to activate multiple rounds of marker (e.g., a 21617 or 55562 marker) transcription or expression, the amplified marker may be in a quantity which is more readily detectable than the drug itself. Also, the marker may be more easily detected due to the nature of the marker itself; for example, using the methods described herein, anti-21617 or 55562 antibodies may be employed in an immune-based detection system for a 21617 or 55562 protein marker, or 21617 or 55562-specific radiolabeled probes may be used to detect a 21617 or 55562 mRNA marker. Furthermore, the use of a pharmacodynamic marker may offer mechanism-based prediction of risk due to drug treatment beyond the range of possible direct observations. Examples of the use of pharmacodynamic markers in the art include: Matsuda *et al.* US 6,033,862; Hattis *et al.* (1991) *Env. Health Perspect.* 90: 229-238;

Schentag (1999) *Am. J. Health-Syst. Pharm.* 56 Suppl. 3: S21-S24; and Nicolau (1999) *Am. J. Health-Syst. Pharm.* 56 Suppl. 3: S16-S20.

The 21617 or 55562 molecules of the invention are also useful as pharmacogenomic markers. As used herein, a "pharmacogenomic marker" is an objective biochemical marker which correlates with a specific clinical drug response or susceptibility in a subject (see, e.g., McLeod *et al.* (1999) *Eur. J. Cancer* 35:1650-1652). The presence or quantity of the pharmacogenomic marker is related to the predicted response of the subject to a specific drug or class of drugs prior to administration of the drug. By assessing the presence or quantity of one or more pharmacogenomic markers in a subject, a drug therapy which is most appropriate for the subject, or which is predicted to have a greater degree of success, may be selected. For example, based on the presence or quantity of RNA, or protein (e.g., 21617 or 55562 protein or RNA) for specific tumor markers in a subject, a drug or course of treatment may be selected that is optimized for the treatment of the specific tumor likely to be present in the subject. Similarly, the presence or absence of a specific sequence mutation in 21617 or 55562 DNA may correlate 21617 or 55562 drug response. The use of pharmacogenomic markers therefore permits the application of the most appropriate treatment for each subject without having to administer the therapy.

Pharmaceutical Compositions

The nucleic acid and polypeptides, fragments thereof, as well as anti-21617 or 55562 antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions. Such compositions typically include the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols,

glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.

- 5 pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- 10
- 15
- 20
- 25

- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the
- 30

active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be

obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and

even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The protein or polypeptide can be administered one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. The skilled artisan
 5 will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of
 10 treatments.

For antibodies, the preferred dosage is 0.1 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies.
 15 Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank *et al.* ((1997) *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193).

20 The present invention encompasses agents which modulate expression or activity. An agent may, for example, be a small molecule. For example, such small molecules include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic
 25 compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

30 Exemplary doses include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is

furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a

5 physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the

10 route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

An antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D,

15 ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, maytansinoids, *e.g.*, maytansinol (see US Patent No. 5,208,020), CC-1065 (see US Patent Nos. 5,475,092, 5,585,499, 5,846,545) and analogs or

20 homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepa chlorambucil, CC-1065, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin),

25 anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine, vinblastine, taxol and maytansinoids). Radioactive ions include, but are not limited to iodine, yttrium and praseodymium.

The conjugates of the invention can be used for modifying a given biological

30 response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -

interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant or unwanted 21617 or 55562 expression or activity. As used herein, the term "treatment" is defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease. A therapeutic agent includes, but is not limited to, small molecules, peptides, antibodies, ribozymes and antisense oligonucleotides.

With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics", as used herein, refers to the application

of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or "drug response genotype".) Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the 21617 or 55562 molecules of the present invention or 21617 or 55562 modulators according to that individual's drug response genotype.

Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant or unwanted 21617 or 55562 expression or activity, by administering to the subject a 21617 or 55562 or an agent which modulates 21617 or 55562 expression or at least one 21617 or 55562 activity. Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted 21617 or 55562 expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the 21617 or 55562 aberrance, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of 21617 or 55562 aberrance, for example, a 21617 or 55562, 21617 or 55562 agonist or 21617 or 55562 antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

It is possible that some 21617 or 55562 disorders can be caused, at least in part, by an abnormal level of gene product, or by the presence of a gene product exhibiting abnormal activity. As such, the reduction in the level and/or activity of such gene products would bring about the amelioration of disorder symptoms.

The 21617 or 55562 molecules can act as novel diagnostic targets and therapeutic agents for controlling one or more of cellular proliferative and/or differentiative disorders, metabolic disorders, viral disorders, kidney disorders, endothelial cell disorders, neural disorders (e.g., brain disorders), and viral disorders, as discussed above, as well as disorders associated with bone metabolism, immune disorders, cardiovascular disorders, liver disorders, and pain disorders.

Disorders associated with bone metabolism refers to disorders in the formation or degeneration of bone structures, e.g., bone formation, bone resorption, etc., which may ultimately affect the concentrations in serum of calcium and phosphate. The disorders may involve bone cells, e.g. osteoclasts and osteoblasts, and may result in bone formation or
5 degeneration. Disorders effecting bone metabolism can also involve monocytes and mononuclear phagocytes, which differentiate to form osteoclasts. Accordingly, 21617 or 55562 molecules that modulate the production of bone cells can influence bone formation and degeneration, and thus may be used to treat bone disorders. Examples of such disorders include, but are not limited to, osteoporosis, osteodystrophy, osteomalacia, rickets, osteitis
10 fibrosa cystica, renal osteodystrophy, osteosclerosis, anti-convulsant treatment, osteopenia, fibrogenesis-imperfecta ossium, secondary hyperparathyroidism, hypoparathyroidism, hyperparathyroidism, cirrhosis, obstructive jaundice, drug induced metabolism, medullary carcinoma, chronic renal disease, rickets, sarcoidosis, glucocorticoid antagonism, malabsorption syndrome, steatorrhea, tropical sprue, idiopathic hypercalcemia and milk
15 fever.

Examples of immune disorders or diseases include, but are not limited to, autoimmune diseases (including, for example, diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus, autoimmune
20 thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute
25 necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis), graft-versus-host disease, cases of
30 transplantation, and allergy such as, atopic allergy.

As used herein, disorders involving the heart, or "cardiovascular disease" or a "cardiovascular disorder" includes a disease or disorder which affects the cardiovascular system, e.g., the heart, the blood vessels, and/or the blood. A cardiovascular disorder can be

caused by an imbalance in arterial pressure, a malfunction of the heart, or an occlusion of a blood vessel, *e.g.*, by a thrombus. A cardiovascular disorder includes, but is not limited to disorders such as arteriosclerosis, atherosclerosis, cardiac hypertrophy, ischemia reperfusion injury, restenosis, arterial inflammation, vascular wall remodeling, ventricular remodeling,

5 rapid ventricular pacing, coronary microembolism, tachycardia, bradycardia, pressure overload, aortic bending, coronary artery ligation, vascular heart disease, valvular disease, including but not limited to, valvular degeneration caused by calcification, rheumatic heart disease, endocarditis, or complications of artificial valves; atrial fibrillation, long-QT syndrome, congestive heart failure, sinus node dysfunction, angina, heart failure,

10 hypertension, atrial fibrillation, atrial flutter, pericardial disease, including but not limited to, pericardial effusion and pericarditis; cardiomyopathies, *e.g.*, dilated cardiomyopathy or idiopathic cardiomyopathy, myocardial infarction, coronary artery disease, coronary artery spasm, ischemic disease, arrhythmia, sudden cardiac death, and cardiovascular developmental disorders (*e.g.*, arteriovenous malformations, arteriovenous fistulae,

15 raynaud's syndrome, neurogenic thoracic outlet syndrome, causalgia/reflex sympathetic dystrophy, hemangioma, aneurysm, cavernous angioma, aortic valve stenosis, atrial septal defects, atrioventricular canal, coarctation of the aorta, ebsteins anomaly, hypoplastic left heart syndrome, interruption of the aortic arch, mitral valve prolapse, ductus arteriosus, patent foramen ovale, partial anomalous pulmonary venous return, pulmonary atresia with

20 ventricular septal defect, pulmonary atresia without ventricular septal defect, persistence of the fetal circulation, pulmonary valve stenosis, single ventricle, total anomalous pulmonary venous return, transposition of the great vessels, tricuspid atresia, truncus arteriosus, ventricular septal defects). A cardiovascular disease or disorder can also include an endothelial cell disorder and a hematological disorder.

25 A hematological disorder can include thrombosis. Thrombosis can result from platelet dysfunction, *e.g.*, seen in myocardial infarction, angina, hypertension, lipid disorders, diabetes mellitus; myelodysplastic syndromes; myeloproliferative syndromes (including polycythemia vera and thrombocythemia); thrombotic thrombocytopenic purpuras; HIV-induced platelet disorders (AIDS-Thrombocytopenia); heparin induced

30 thrombocytopenia; mural cell alterations/interactions leading to platelet aggregation/degranulation, vascular endothelial cell activation/injury, monocyte/macrophage extravasation and smooth muscle cell proliferation; autoimmune disorders such as, but not limited to vasculitis, antiphospholipid syndromes, systemic lupus erythromatosis;

inflammatory diseases, such as, but not limited to immune activation; graft vs. host disease; radiation induced hypercoagulation; clotting factor dysregulation either hereditary (autosomal dominant or recessive) such as, but not limited to clotting factor pathways including protein C/S, Anti-thrombin III deficiency, and the Factor V Leiden mutation or
5 acquired such as but not limited to autoimmune, cancer -associated and drug-induced dysregulation of clotting factors.

Disorders which may be treated or diagnosed by methods described herein include, but are not limited to, disorders associated with an accumulation in the liver of fibrous tissue, such as that resulting from an imbalance between production and degradation of the
10 extracellular matrix accompanied by the collapse and condensation of preexisting fibers. The methods described herein can be used to diagnose or treat hepatocellular necrosis or injury induced by a wide variety of agents including processes which disturb homeostasis, such as an inflammatory process, tissue damage resulting from toxic injury or altered hepatic blood flow, and infections (e.g., bacterial, viral and parasitic). For example, the
15 methods can be used for the early detection of hepatic injury, such as portal hypertension or hepatic fibrosis. In addition, the methods can be employed to detect liver fibrosis attributed to inborn errors of metabolism, for example, fibrosis resulting from a storage disorder such as Gaucher's disease (lipid abnormalities) or a glycogen storage disease, A1-antitrypsin deficiency; a disorder mediating the accumulation (e.g., storage) of an exogenous substance,
20 for example, hemochromatosis (iron-overload syndrome) and copper storage diseases (Wilson's disease), disorders resulting in the accumulation of a toxic metabolite (e.g., tyrosinemia, fructosemia and galactosemia) and peroxisomal disorders (e.g., Zellweger syndrome). Additionally, the methods described herein may be useful for the early detection and treatment of liver injury associated with the administration of various chemicals or
25 drugs, such as for example, methotrexate, isoniazid, oxyphenisatin, methyldopa, chlorpromazine, tolbutamide or alcohol, or which represents a hepatic manifestation of a vascular disorder such as obstruction of either the intrahepatic or extrahepatic bile flow or an alteration in hepatic circulation resulting, for example, from chronic heart failure, veno-occlusive disease, portal vein thrombosis or Budd-Chiari syndrome.

30 Additionally, 21617 or 55562 may play an important role in the regulation of pain disorders. Examples of pain disorders include, but are not limited to, pain response elicited during various forms of tissue injury, e.g., inflammation, infection, and ischemia, usually referred to as hyperalgesia (described in, for example, Fields, H.L. (1987) *Pain*, New

York:McGraw-Hill); pain associated with musculoskeletal disorders, e.g., joint pain; tooth pain; headaches; pain associated with surgery; pain related to irritable bowel syndrome; or chest pain.

As discussed, successful treatment of 21617 or 55562 disorders can be brought about by techniques that serve to inhibit the expression or activity of target gene products. For example, compounds, e.g., an agent identified using an assays described above, that proves to exhibit negative modulatory activity, can be used in accordance with the invention to prevent and/or ameliorate symptoms of 21617 or 55562 disorders. Such molecules can include, but are not limited to peptides, phosphopeptides, small organic or inorganic molecules, or antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')₂ and Fab expression library fragments, scFV molecules, and epitope-binding fragments thereof).

Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used in accordance with the invention to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. Antisense, ribozyme and triple helix molecules are discussed above.

It is possible that the use of antisense, ribozyme, and/or triple helix molecules to reduce or inhibit mutant gene expression can also reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles, such that the concentration of normal target gene product present can be lower than is necessary for a normal phenotype. In such cases, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy method. Alternatively, in instances in that the target gene encodes an extracellular protein, it can be preferable to co-administer normal target gene protein into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.

Another method by which nucleic acid molecules may be utilized in treating or preventing a disease characterized by 21617 or 55562 expression is through the use of aptamer molecules specific for 21617 or 55562 protein. Aptamers are nucleic acid molecules having a tertiary structure which permits them to specifically bind to protein ligands (see, e.g., Osborne, *et al.* (1997) *Curr. Opin. Chem Biol.* 1: 5-9; and Patel, D.J. (1997) *Curr Opin Chem Biol* 1:32-46). Since nucleic acid molecules may in many cases be

more conveniently introduced into target cells than therapeutic protein molecules may be, aptamers offer a method by which 21617 or 55562 protein activity may be specifically decreased without the introduction of drugs or other molecules which may have pluripotent effects.

5 Antibodies can be generated that are both specific for target gene product and that reduce target gene product activity. Such antibodies may, therefore, be administered in instances whereby negative modulatory techniques are appropriate for the treatment of 21617 or 55562 disorders. For a description of antibodies, see the Antibody section above.

10 In circumstances wherein injection of an animal or a human subject with a 21617 or 55562 protein or epitope for stimulating antibody production is harmful to the subject, it is possible to generate an immune response against 21617 or 55562 through the use of anti-idiotypic antibodies (see, for example, Herlyn, D. (1999) *Ann Med* 31:66-78; and Bhattacharya-Chatterjee, M., and Foon, K.A. (1998) *Cancer Treat Res.* 94:51-68). If an anti-idiotypic antibody is introduced into a mammal or human subject, it should stimulate
15 the production of anti-anti-idiotypic antibodies, which should be specific to the 21617 or 55562 protein. Vaccines directed to a disease characterized by 21617 or 55562 expression may also be generated in this fashion.

20 In instances where the target antigen is intracellular and whole antibodies are used, internalizing antibodies may be preferred. Lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region that binds to the target antigen into cells. Where fragments of the antibody are used, the smallest inhibitory fragment that binds to the target antigen is preferred. For example, peptides having an amino acid sequence corresponding to the Fv region of the antibody can be used. Alternatively, single chain neutralizing antibodies that bind to intracellular target antigens can also be administered.
25 Such single chain antibodies can be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population (see e.g., Marasco *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:7889-7893).

30 The identified compounds that inhibit target gene expression, synthesis and/or activity can be administered to a patient at therapeutically effective doses to prevent, treat or ameliorate 21617 or 55562 disorders. A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms of the disorders. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures as described above.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography. Another example of determination of effective dose for an individual is the ability to directly assay levels of “free” and “bound” compound in the serum of the test subject. Such assays may utilize antibody mimics and/or “biosensors” that have been created through molecular imprinting techniques. The compound which is able to modulate 21617 or 55562 activity is used as a template, or “imprinting molecule”, to spatially organize polymerizable monomers prior to their polymerization with catalytic reagents. The subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated “negative image” of the compound and is able to selectively rebind the molecule under biological assay conditions. A detailed review of this technique can be seen in Ansell, R. J. *et al* (1996) *Current Opinion in Biotechnology* 7:89-94 and in Shea, K.J. (1994) *Trends in Polymer Science* 2:166-173. Such “imprinted” affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix. An example of the use of such matrixes in this way can be seen in Vlatakis, G. *et al* (1993) *Nature* 361:645-647. Through the use of isotope-labeling, the “free” concentration of compound which modulates the expression or activity of 21617 or 55562 can be readily monitored and used in calculations of IC₅₀. Such “imprinted” affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties measurably change upon local and selective binding of target compound. These changes can be readily assayed in real time using appropriate fiberoptic devices, in turn allowing the dose in a test subject to be quickly optimized based on its individual IC₅₀. An rudimentary example of such a “biosensor” is discussed in Kriz, D. *et al* (1995) *Analytical Chemistry* 67:2142-2144.

Another aspect of the invention pertains to methods of modulating 21617 or 55562 expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell with a 21617 or 55562 or agent that modulates one or more of the activities of 21617 or 55562 protein activity
5 associated with the cell. An agent that modulates 21617 or 55562 protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of a 21617 or 55562 protein (e.g., a 21617 or 55562 substrate or receptor), a 21617 or 55562 antibody, a 21617 or 55562 agonist or antagonist, a peptidomimetic of a 21617 or 55562 agonist or antagonist, or other small molecule.

10 In one embodiment, the agent stimulates one or 21617 or 55562 activities. Examples of such stimulatory agents include active 21617 or 55562 protein and a nucleic acid molecule encoding 21617 or 55562. In another embodiment, the agent inhibits one or more 21617 or 55562 activities. Examples of such inhibitory agents include antisense 21617 or 55562 nucleic acid molecules, anti-21617 or 55562 antibodies, and 21617 or 55562
15 inhibitors. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of a 21617 or 55562 protein or nucleic acid molecule. In one embodiment, the method involves
20 administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up regulates or down regulates) 21617 or 55562 expression or activity. In another embodiment, the method involves administering a 21617 or 55562 protein or nucleic acid molecule as therapy to compensate for reduced, aberrant, or unwanted 21617 or 55562 expression or activity.

25 Stimulation of 21617 or 55562 activity is desirable in situations in which 21617 or 55562 is abnormally downregulated and/or in which increased 21617 or 55562 activity is likely to have a beneficial effect. For example, stimulation of 21617 or 55562 activity is desirable in situations in which a 21617 or 55562 is downregulated and/or in which increased 21617 or 55562 activity is likely to have a beneficial effect. Likewise, inhibition
30 of 21617 or 55562 activity is desirable in situations in which 21617 or 55562 is abnormally upregulated and/or in which decreased 21617 or 55562 activity is likely to have a beneficial effect.

Pharmacogenomics

The 21617 or 55562 molecules of the present invention, as well as agents, or modulators which have a stimulatory or inhibitory effect on 21617 or 55562 activity (e.g., 21617 or 55562 gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) 21617 or 55562 associated disorders (e.g., cellular proliferation and/or differentiation disorders, metabolic disorders, kidney disorders, endothelial cell disorders, neural disorders, or viral disorders) associated with aberrant or unwanted 21617 or 55562 activity. In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a 21617 or 55562 molecule or 21617 or 55562 modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with a 21617 or 55562 molecule or 21617 or 55562 modulator.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, for example, Eichelbaum, M. *et al.* (1996) *Clin. Exp. Pharmacol. Physiol.* 23:983-985 and Linder, M.W. *et al.* (1997) *Clin. Chem.* 43:254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (e.g., a "bi-allelic" gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two variants.) Such a high-resolution genetic map can be

compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.

Alternatively, a method termed the "candidate gene approach," can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drug's target is known (e.g., a 21617 or 55562 protein of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

Alternatively, a method termed the "gene expression profiling," can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (e.g., a 21617 or 55562 molecule or 21617 or 55562 modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.

Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment of an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a 21617 or 55562 molecule or 21617 or 55562 modulator, such as a modulator identified by one of the exemplary screening assays described herein.

The present invention further provides methods for identifying new agents, or combinations, that are based on identifying agents that modulate the activity of one or more of the gene products encoded by one or more of the 21617 or 55562 genes of the present

invention, wherein these products may be associated with resistance of the cells to a therapeutic agent. Specifically, the activity of the proteins encoded by the 21617 or 55562 genes of the present invention can be used as a basis for identifying agents for overcoming agent resistance. By blocking the activity of one or more of the resistance proteins, target cells, e.g., human cells, will become sensitive to treatment with an agent that the unmodified target cells were resistant to.

Monitoring the influence of agents (e.g., drugs) on the expression or activity of a 21617 or 55562 protein can be applied in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase 21617 or 55562 gene expression, protein levels, or upregulate 21617 or 55562 activity, can be monitored in clinical trials of subjects exhibiting decreased 21617 or 55562 gene expression, protein levels, or downregulated 21617 or 55562 activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease 21617 or 55562 gene expression, protein levels, or downregulate 21617 or 55562 activity, can be monitored in clinical trials of subjects exhibiting increased 21617 or 55562 gene expression, protein levels, or upregulated 21617 or 55562 activity. In such clinical trials, the expression or activity of a 21617 or 55562 gene, and preferably, other genes that have been implicated in, for example, a 21617 or 55562-associated disorder can be used as a "read out" or markers of the phenotype of a particular cell.

21617 or 55562 Informatics

The sequence of a 21617 or 55562 molecule is provided in a variety of media to facilitate use thereof. A sequence can be provided as a manufacture, other than an isolated nucleic acid or amino acid molecule, which contains a 21617 or 55562. Such a manufacture can provide a nucleotide or amino acid sequence, e.g., an open reading frame, in a form which allows examination of the manufacture using means not directly applicable to examining the nucleotide or amino acid sequences, or a subset thereof, as they exists in nature or in purified form. The sequence information can include, but is not limited to, 21617 or 55562 full-length nucleotide and/or amino acid sequences, partial nucleotide and/or amino acid sequences, polymorphic sequences including single nucleotide polymorphisms (SNPs), epitope sequence, and the like. In a preferred embodiment, the manufacture is a machine-readable medium, e.g., a magnetic, optical, chemical or mechanical information storage device.

As used herein, "machine-readable media" refers to any medium that can be read and accessed directly by a machine, e.g., a digital computer or analogue computer. Non-limiting examples of a computer include a desktop PC, laptop, mainframe, server (e.g., a web server, network server, or server farm), handheld digital assistant, pager, mobile telephone, and the like. The computer can be stand-alone or connected to a communications network, e.g., a local area network (such as a VPN or intranet), a wide area network (e.g., an Extranet or the Internet), or a telephone network (e.g., a wireless, DSL, or ISDN network). Machine-readable media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM, ROM, EPROM, EEPROM, flash memory, and the like; and hybrids of these categories such as magnetic/optical storage media.

A variety of data storage structures are available to a skilled artisan for creating a machine-readable medium having recorded thereon a nucleotide or amino acid sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. The skilled artisan can readily adapt any number of data processor structuring formats (e.g., text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention.

In a preferred embodiment, the sequence information is stored in a relational database (such as Sybase or Oracle). The database can have a first table for storing sequence (nucleic acid and/or amino acid sequence) information. The sequence information can be stored in one field (e.g., a first column) of a table row and an identifier for the sequence can be stored in another field (e.g., a second column) of the table row. The database can have a second table, e.g., storing annotations. The second table can have a field for the sequence identifier, a field for a descriptor or annotation text (e.g., the descriptor can refer to a functionality of the sequence, a field for the initial position in the sequence to which the annotation refers, and a field for the ultimate position in the sequence to which the annotation refers. Non-limiting examples for annotation to nucleic acid sequences include

polymorphisms (e.g., SNP's) translational regulatory sites and splice junctions. Non-limiting examples for annotations to amino acid sequence include polypeptide domains, e.g., a domain described herein; active sites and other functional amino acids; and modification sites.

5 By providing the nucleotide or amino acid sequences of the invention in computer readable form, the skilled artisan can routinely access the sequence information for a variety of purposes. For example, one skilled in the art can use the nucleotide or amino acid sequences of the invention in computer readable form to compare a target sequence or target structural motif with the sequence information stored within the data storage means. A
10 search is used to identify fragments or regions of the sequences of the invention which match a particular target sequence or target motif. The search can be a BLAST search or other routine sequence comparison, e.g., a search described herein.

Thus, in one aspect, the invention features a method of analyzing 21617 or 55562, e.g., analyzing structure, function, or relatedness to one or more other nucleic acid or amino
15 acid sequences. The method includes: providing a 21617 or 55562 nucleic acid or amino acid sequence; comparing the 21617 or 55562 sequence with a second sequence, e.g., one or more preferably a plurality of sequences from a collection of sequences, e.g., a nucleic acid or protein sequence database to thereby analyze 21617 or 55562. The method can be performed in a machine, e.g., a computer, or manually by a skilled artisan.

20 The method can include evaluating the sequence identity between a 21617 or 55562 sequence and a database sequence. The method can be performed by accessing the database at a second site, e.g., over the Internet.

As used herein, a "target sequence" can be any DNA or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan can readily recognize that
25 the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. Typical sequence lengths of a target sequence are from about 10 to 100 amino acids or from about 30 to 300 nucleotide residues. However, it is well recognized that commercially important fragments, such as sequence fragments involved in gene expression and protein processing, may be of shorter length.

30 Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium for analysis and comparison to other sequences. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the

computer-based systems of the present invention. Examples of such software include, but are not limited to, MacPattern (EMBL), BLASTN and BLASTX (NCBI).

Thus, the invention features a method of making a computer readable record of a sequence of a 21617 or 55562 sequence which includes recording the sequence on a computer readable matrix. In a preferred embodiment the record includes one or more of the following: identification of an ORF; identification of a domain, region, or site; identification of the start of transcription; identification of the transcription terminator; the full length amino acid sequence of the protein, or a mature form thereof; the 5' end of the translated region.

In another aspect, the invention features, a method of analyzing a sequence. The method includes: providing a 21617 or 55562 sequence, or record, in machine-readable form; comparing a second sequence to the 21617 or 55562 sequence; thereby analyzing a sequence. Comparison can include comparing to sequences for sequence identity or determining if one sequence is included within the other, e.g., determining if the 21617 or 55562 sequence includes a sequence being compared. In a preferred embodiment the 21617 or 55562 or second sequence is stored on a first computer, e.g., at a first site and the comparison is performed, read, or recorded on a second computer, e.g., at a second site. E.g., the 21617 or 55562 or second sequence can be stored in a public or proprietary database in one computer, and the results of the comparison performed, read, or recorded on a second computer. In a preferred embodiment the record includes one or more of the following: identification of an ORF; identification of a domain, region, or site; identification of the start of transcription; identification of the transcription terminator; the full length amino acid sequence of the protein, or a mature form thereof; the 5' end of the translated region.

In another aspect, the invention provides a machine-readable medium for holding instructions for performing a method for determining whether a subject has a 21617 or 55562-associated disease or disorder or a pre-disposition to a 21617 or 55562-associated disease or disorder, wherein the method comprises the steps of determining 21617 or 55562 sequence information associated with the subject and based on the 21617 or 55562 sequence information, determining whether the subject has a 21617 or 55562-associated disease or disorder or a pre-disposition to a 21617 or 55562-associated disease or disorder and/or recommending a particular treatment for the disease, disorder or pre-disease condition.

The invention further provides in an electronic system and/or in a network, a method for determining whether a subject has a 21617 or 55562-associated disease or disorder or a pre-disposition to a disease associated with a 21617 or 55562 wherein the method comprises the steps of determining 21617 or 55562 sequence information associated with the subject, and based on the 21617 or 55562 sequence information, determining whether the subject has a 21617 or 55562-associated disease or disorder or a pre-disposition to a 21617 or 55562-associated disease or disorder, and/or recommending a particular treatment for the disease, disorder or pre-disease condition. In a preferred embodiment, the method further includes the step of receiving information, e.g., phenotypic or genotypic information, associated with the subject and/or acquiring from a network phenotypic information associated with the subject. The information can be stored in a database, e.g., a relational database. In another embodiment, the method further includes accessing the database, e.g., for records relating to other subjects, comparing the 21617 or 55562 sequence of the subject to the 21617 or 55562 sequences in the database to thereby determine whether the subject as a 21617 or 55562-associated disease or disorder, or a pre-disposition for such.

The present invention also provides in a network, a method for determining whether a subject has a 21617 or 55562 associated disease or disorder or a pre-disposition to a 21617 or 55562-associated disease or disorder associated with 21617 or 55562, said method comprising the steps of receiving 21617 or 55562 sequence information from the subject and/or information related thereto, receiving phenotypic information associated with the subject, acquiring information from the network corresponding to 21617 or 55562 and/or corresponding to a 21617 or 55562-associated disease or disorder (e.g., a cellular proliferation and/or differentiation disorder, metabolic disorder, kidney disorder, endothelial cell disorder, neural disorder, or viral disorder), and based on one or more of the phenotypic information, the 21617 or 55562 information (e.g., sequence information and/or information related thereto), and the acquired information, determining whether the subject has a 21617 or 55562-associated disease or disorder or a pre-disposition to a 21617 or 55562-associated disease or disorder. The method may further comprise the step of recommending a particular treatment for the disease, disorder or pre-disease condition.

The present invention also provides a method for determining whether a subject has a 21617 or 55562 -associated disease or disorder or a pre-disposition to a 21617 or 55562-associated disease or disorder, said method comprising the steps of receiving information related to 21617 or 55562 (e.g., sequence information and/or information related thereto),

receiving phenotypic information associated with the subject, acquiring information from the network related to 21617 or 55562 and/or related to a 21617 or 55562-associated disease or disorder, and based on one or more of the phenotypic information, the 21617 or 55562 information, and the acquired information, determining whether the subject has a 21617 or 55562-associated disease or disorder or a pre-disposition to a 21617 or 55562-associated disease or disorder. The method may further comprise the step of recommending a particular treatment for the disease, disorder or pre-disease condition.

This invention is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

This invention is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

15

EXAMPLES

Example 1: Identification and Characterization of Human 21617 or 55562 cDNA

The human 21617 nucleic acid sequence is recited as follows:

TAGTCTAACTCGCGGCTGTCACCGCCACTGCAGCGGAGCCGGCCGGGCGCTGCGGG
 20 ACGGGCGGGCGGCTGCCGGCAGGAGGCGCCGAGCCGGGTGACTGCCGCGGCGGGCACAGT
 CCGGGGCCACAGCGCCGAGCCCGGGCGGGAGTGGCCCCGCGCAGGCAGGGAGCGGCGCCG
 CGCACTCCAACCCGGCGGGCACCTCGGGGGCGGGCGCGGGGCGCAGCCTTCTCGTCCCGG
 CCTCTGTGACAAGCGCCCCGAGCCGGGAGCCCCGATTGCCGGGCTCGGGGTGGGCGCGGA
 CGCAGGCACTGGGCTCGTGCGGGGCCCCGGGCGTTCGCGATGAACATCGTGGTGGAGTTCT
 25 TCGTGGTCACTTTCAAAGTGCTCTGGGCGTTCTGTGCTGGCCGCGGCGCGCTGGCTGGTGC
 GGCCCAAGGAGAAGAGCGTGCGGGGCCAGGTGTGCCTCATCACCGGCGCCGGCAGCGGCC
 TGGGCCGCCTCTTCGCGCTGGAGTTGCCCCGGCGTGGGCGCTGCTGGTGTGTGGGACA
 TCAACACGCAAAGCAACGAGGAGACGGCTGGCATGGTGCGCCACATCTACCGCGACCTGG
 AGGCGGCCGACGCCGCTGCGCTGCAAGCTGGGAATGGTGAGGAAGAAATTCTGCCCCACT
 30 GTAACCTGCAGGTTTTTACCTACACCTGTGACGTGGGGAAGAGGGAGAACGTCTACCTGA
 CGGCTGAAAGAGTCCGCAAGGAGGTTGGCGAAGTCTCAGTCCTGGTCAATAATGCTGGTG
 TGGTCTCTGGGCATCACCTTCTGGAATGTCCTGATGAGCTCATTGAGAGAACCATGATGG
 TCAATTGCCATGCACACTTCTGGACCACTAAGGCTTTTCTTCTTACGATGCTGGAGATTA
 ATCATGGTCATATTGTGACAGTTGCAAGTTCCTTGGGATTGTTTCTCAGTACTGCCGGAGTTG
 35 AGGATTACTGTGCCAGTAAATTTGGAGTTGTGGGTTTTCATGAATCCCTGAGCCATGAAC

TAAAGGCTGCTGAAAAGGATGGAATTAAAACAACCTTGGTTTGCCCTTATCTTGTAGACA
CTGGCATGTTTCAGAGGCTGCCGAATCAGGAAAGAAATTGAGCCTTTTCTGCCACCTCTGA
AGCCTGATTACTGTGTGAAGCAGGCCATGAAGGCCATCCTCACTGACCAGCCCATGATCT
GCACTCCCCGCTCATGTACATCGTGACCTTCATGAAGAGCATCCTACCATTTGAAGCAG
5 TTGTGTGCATGTATCGGTTCCTAGGAGCGGACAAGTGTATGTACCCCTTTATTGCTCAAA
GAAAGCAAGCCACAAACAATAATGAAGCAAAAAATGGAATCTAAGAATCTTTTTGTATGG
AATATTACTTCTATCAGAAGATGATCAAGATGTTTCAGTCCAGTGCACATCAGCATTGCT
GACATTTTATGGATTCTAAACTTGTGTTGTTTCTTTTTTAAATCAACTTTTTAAAAAAT
AAAGTGTAATTAACCGACTAGAGTACTTGGAATGTGATCAGTACAAGTGAAGTTAGG
10 TTGTTGCCAACAGGGTCCTTTTAGGCAGAACCCAGAAACCAGTCAAATCTGTAGAGAAGC
AGTGTGACATCTTCAGGTTACCATTTATTTTTTAATGAGCAGGAAGTCTAGAAATGATAAC
TAGACTGTATGTTTCATGTGTGTGATTTTTTCAAGATTCCCAGAGTTTACTCATTCTTGTT
ATTAAACTCTAGCCAGTTGACATCTTCGCAATTTCAAGGACTGATAGTGCTGTATTTTCT
CACGTTTTCTAAGTTTTCCGTTTTGCAAGGCCTAGGTGACTTTTTTCATGGTGTGTTGTATGT
15 TTAGCTCTTTTGAAAAGGAATTTTGAAATCTCCATCAACTGAAGTAAATGATGTCTGAGT
GTTACAGTWAAGGTGACCAAGTCTCTTTCTTAAAGTCACAATGACTAAAGTATTAGTTGA
ATTTTTTTTTTTTTTTTTTGATGGAGTCTCGCTCTGTCACCAGGCTGGAGTGCAGTAGCAC
AATCACGGCTCACTGCAATCTCTGCCTCCCRGTTTCAAGTGATTCTGCTGTCTCAGCCTC
CCAAGTAGCTGGGACTACAGGCATGCGCCACCACGCCAGCTAATTTTTGTATTTTAGT
20 AGAGACGGGGTTTCACCATGTTGGTCAGGATGGTCTCCATCTCTTGACATTGTGATCCAC
CTGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACTGCACCCAGCCTTGAA
TTTTTAATTTTATCTCTGATATACTTCATTAAGTGTCTGGAGACCTAATTATCCTAAAAG
ATCATACATTTTCTACCTATGAATTTTGCTGCATACAGAAAGTGCCCTTTCCTCAGGAAG
TTGCTGTGTTTCATTTCTTTGGATGGACTCTTATCTAGAATACATAGCAGCTCTGCAAAG
25 AAACAGTTTTTAAAAATGGGAACCTTCTACATTGAAAAGTCCCCATTTTTGTGCCAACTAT
GATTAGTGAGAGGAAGAAATCTTATTCTATGGCATATGTATGGAAGGGTGTAAGATTCT
TTTGAAAGGTTTATTCACATTGTAGAACAGCAAATGACATTTTACAGTATTTTTTTGTA
AAGCAAATATTTTGTGCCTTGAATTTGGTATATGTGTATTAGTGAAACATTGTAAAGGT
GAACCTTCTACCTCTGTATCTAAATGTATACCATCCACTTGTAATGACTATAAACTATTA
30 TGTGATTGCTTTTTTTTTTAGAATGTCTTGTTTAAATAGTGGCCAATGTTTAAGGCTGTT
AAAATAAGCCAACCTTTTACTAATTGGGGAGTTTTATAAATGACTGATTAAATTTAAAGAA
TTAACTTACATGCAATTGTGTGATTATTAGTTATCAGCAGTGTTGTAAGGAAAATTATTG
TGTTTTTTTTTATGATCATTTATCCCACTTTAGGTAAAGAAAAATATTGGAATGGAATAGT
GTTGGGAAACAGACATTAACAACCTAGGGTGCCTGCACTCAAATAGCCGATGTTACTGTC
35 CCTAGATTAGAGACTTGATTAAAGGGCTTGTTTGTACCAAAGTGGGGAAACAATGCCATG
ACCTGTGTTTTAGTTTGGCTGCACCACAGATCAAATCTGCACTGTGCTACATATAGGAA
AGGTCCTGGTGTGTGCTAATGTTCCCAATGCAGGACTTGAGGAAGAGCTCTGTTATATGT
TTCCATTTCTCTTTATCAAAGATAACCAAACCTTATGGCCCTTATAACAATGGAGGCACT

GGCTGCCTCTTAATTTTCAATCATGGACCTAAAGAAGTACTCTGAAGGGTCTCAACAATG
 CCAGGTGGGGACAGATATACTCAGAGATTATCCAGGTCTGCCTCCCAGCGAGCCTGGAGT
 ACACCAGACCCTCCTAGAGAAATCTGTTATAATTTAACAACCCACTTATCCACCTTAAAA
 CTGAGGAAAGTCGTCTTTACATCTAATTTTATTCTTGTGTGTTATAACTTAAACCTATTT
 5 CTATTTTGTGTTGTTATTGCCCTTATAAGGGTGTCCATCTCCAAGTTCAATAAACTAATT
 CATTTAAAAAAAAAAAAAAAAAAAAA (SEQ ID NO:1, SEQ ID NO:4).

The human 21617 sequence (SEQ ID NO:1, SEQ ID NO:4) is approximately 3624
 nucleotides long. The nucleic acid sequence includes an initiation codon (ATG) and a
 termination codon (TAA), which are indicated in bold and underscored above. The region
 10 between and inclusive of the initiation codon and the termination codon is a methionine-
 initiated coding sequence of about 1026 nucleotides, including the termination codon
 (nucleotides 339 to 1364 of SEQ ID NO:1, SEQ ID NO:4; SEQ ID NO:3, AND SEQ ID
 NO:6). The coding sequence encodes a 341 amino acid protein (SEQ ID NO:2 AND SEQ
 ID NO:5), which is recited as follows:

15 MNIVVEFFVVTFKVLWAFVLAARWLVRPKEKSVAGQVCLITGAGSGLGRLFALEFARRR
 ALLVLWDINTQSNEETAGMVRHIYRDLEAADAALQAGNGEEEILPHCNLQVFTYTCDBG
 KRENVYLTAERVVRKEVGSVLVNNAGVVSQHLLLECPDELIERTMMVNCHAHFWTTKAF
 LPTMLEINHGHIVTVASSLGLFSTAGVEDYCASKFGVVGFHESLSHELKAAEKDGIKTTL
 VCPYLVDVTGMFRGCRIRKEIEPFLPLKPDYCVKQAMKAILTDQPMICTPRLMYIVTFMK
 20 SILPFEAVVCMYRFLGADKCMYPIAQRKQATNNNEAKNGI (SEQ ID NO:2 AND SEQ
 ID NO:5).

The human 55562 nucleic acid sequence is recited as follows:

25 CCTGCTGCAATGGCTTACGGGAGCCAATGTGACGGGATCAGGGCAGACCCATTTAGGGTTTC
 GTAACCGGCCAATTACGTACGCAATAGGGAAAATCAATTAGGATCTGCAGAGGGTTCCCGGA
 TACACCTTGCGAAGAATGCCGCACTCTCCGCCACTCATTTCCCACTACCCGGCACCCGCTAA
 ACCTTCAGCCTGAAATTTTCTCCGAAGGAAGCAGAGCAGAGGAAGAATACTACCAAGTGCTAC
 ACTCAAAGCCTGCCGTGCGAGTGAGCGCGACCTCCAACTGAGGCATTTTTGTTCCGGCGAA
 ATCCCTCCCACTCAGGAAAGTCCCTAGAAAGAGAGCGCAGGCGCCTGGGGTATCACATGACC
 30 ACTTCCCGGAAGCGCAGCAGACCCGCTCAACTTCATCCTGGGTGAGGCGGAGGAGAACTTC
 CAGAATTATGGCGAAGTCCGGGCTGAGGCAGGACCCGAGAGCACAGCTGCAGCCACTGTGC
 TAAAGCGGGCAGTAGAACTAGATTTCGGAGTCGCGGTATCCGCAGGCTCTGGTGTGTTACCAA
 GAGGGGATTGATCTGCTCCTGCAGGTTCTGAAAGGTACCAAAGATAATACTAAGAGATGTAA
 TCTCAGAGAAAAAATTTCCAAATACATGGACAGAGCGGAAAACATAAAGAAGTACTTGGACC
 35 AAGAAAAAGAAGATGGAATAATCACAAGCAAATTAATAAGAGAATGCAACAGGTTTC
 AGTTATGAGTCACTTTTTTCGCGAATACCTTAATGAGACAGTTACAGAAGTTTGGATAGAAGA

TCCTTATATTAGACATACTCATCAGCTGTATAACTTTCTTCGATTTTGTGAGATGCTTATTA
 AGAGACCATGTAAAGTAAAACTATTCACCTTCTCACCTCTCTGGATGAAGGCATTGAGCAA
 GTGCAGCAAAGTAGAGGCCTGCAAGAAATAGAAGAGTCACTCAGGAGTCACGGAGTGCTGTT
 GGAAGTTCAATACTCTTCTTCAATACATGACCGAGAAATTAGGTTCAACAATGGATGGATGA
 5 TTAAGATTGGAAGGGGACTTGATTATTTTAAGAAACCACAGAGTCGTTTTTCCCTTGGATAT
 TGTGATTTTGATTTAAGACCATGTCATGAAACAACAGTAGACATTTTTCATAAGAAGCATAAC
 AAAAAATATAT**TGA**TGGGTGGTAGCCTAATTTGTATTATGTCTACTTTAAGTGAATATTGGAT
 TTTTTTTAAAAGATCACTTTTATAATGTATGAATTTAACAATAAACTTTTATATTCTACTA
 AAAAAAAAAAAAAAAAAAAAAAAAAA (SEQ ID NO:4).

10 The human 55562 sequence (SEQ ID NO:4) is approximately 1327 nucleotides long.
 The nucleic acid sequence includes an initiation codon (ATG) and a termination codon
 (TGA), which are indicated in bold and underscored above. The region between and
 inclusive of the initiation codon and the termination codon is a methionine-initiated coding
 sequence of about 825 nucleotides, including the termination codon (nucleotides 367 to
 15 1191 of SEQ ID NO:4; SEQ ID NO:6). The coding sequence encodes a 274 amino acid
 protein (SEQ ID NO:5), which is recited as follows:

MTTSRKRSRPAQLHPGLRRRRTSRIMAKSGLRQDPQSTAAATVLKRAVELDSESRYPQAL
 VCYQEGIDLLQVLKGTKDNTKRCNLREKISKYMDRAENIKKYLDQEKEDGKYHKQIKIE
 ENATGFSYESLRFREYLNETHVTEVWIEDPYIRHTHQLYNFLRFCEMLIKRPCKVKTIHLLT
 20 SLDEGIEQVQQSRGLQEIEESLRSHGVLLEVQYSSSIHDREIRFNNGWMIKIGRGLDYFK
 KPQSRFSLGYCDFDLRPFCHETTVDFHKKHTKNI (SEQ ID NO:5).

Example 2: Tissue Distribution of 21617 or 55562 mRNA

Northern blot hybridizations with various RNA samples can be performed under
 25 standard conditions and washed under stringent conditions, i.e., 0.2xSSC at 65°C. A DNA
 probe corresponding to all or a portion of the 21617 or 55562 cDNA (SEQ ID NO:1 or SEQ
 ID NO:4, respectively) can be used. The DNA can be radioactively labeled with ³²P-dCTP
 using the Prime-It Kit (Stratagene, La Jolla, CA) according to the instructions of the
 supplier. Filters containing mRNA from mouse hematopoietic and endocrine tissues, and
 30 cancer cell lines (Clontech, Palo Alto, CA) can be probed in ExpressHyb hybridization
 solution (Clontech) and washed at high stringency according to manufacturer's
 recommendations.

Endogenous human 21617 or 55562 gene expression can also be determined using
 the Perkin-Elmer/ABI 7700 Sequence Detection System which employs TaqMan
 35 technology. Briefly, TaqMan technology relies on standard RT-PCR with the addition of a

third gene-specific oligonucleotide (referred to as a probe) which has a fluorescent dye coupled to its 5' end (typically 6-FAM) and a quenching dye at the 3' end (typically TAMRA). When the fluorescently tagged oligonucleotide is intact, the fluorescent signal from the 5' dye is quenched. As PCR proceeds, the 5' to 3' nucleolytic activity of Taq polymerase digests the labeled primer, producing a free nucleotide labeled with 6-FAM, which is now detected as a fluorescent signal. The PCR cycle where fluorescence is first released and detected is directly proportional to the starting amount of the gene of interest in the test sample, thus providing a quantitative measure of the initial template concentration. Samples can be internally controlled by the addition of a second set of primers/probe specific for a housekeeping gene such as GAPDH which has been labeled with a different fluorophore on the 5' end (typically VIC).

To determine the level of 21617 in various human tissues a primer/probe set was designed. Total RNA was prepared from a series of human tissues using an RNeasy kit from Qiagen. First strand cDNA was prepared from 1 µg total RNA using an oligo-dT primer and Superscript II reverse transcriptase (Gibco/BRL). cDNA obtained from approximately 50 ng total RNA was used per TaqMan reaction. Tissues tested include the human tissues and several cell lines shown in Tables 1-5. 21617 mRNA was detected in colon cancer cell lines and samples (Tables 1, 2, 5). 21617 mRNA expression was also found in breast, lung, and cervical carcinoma cell lines (Tables 1-5).

TABLE 1: In vitro Expression in Synchronized Cell Cycle Panel

Tissue Type	Expression
HCT 116 Aphidl t=0	63.6
HCT 116 Aphidl t=3	66.3
HCT 116 Aphidl t=6	43.0
HCT 116 Aphidl t=9	70.3
HCT 116 Aphidl t=12	57.1
HCT 116 Aphidl t=15	39.4
HCT 116 Aphidl t=18	57.1
HCT 116 Aphidl t=21	65.2
HCT 116 Aphidl t=24	58.9
HCT 116 Noc t=0	78.8
HCT 116 Noc t=3	92.5
HCT 116 Noc t=6	90.6
HCT 116 Noc t=9	75.1
HCT 116 Noc t=15	86.0
HCT 116 Noc t=18	89.6
HCT 116 Noc t=21	56.9
HCT 116 Noc t=24	66.5
DLD noc t=0	105.5

DLD noc t=3	236.5
DLD noc t=6	216.1
DLD noc t=9	251.7
DLD noc t=12	1117.3
DLD noc t=15	129.4
DLD noc t=18	196.1
DLD noc t=21	170.8
A549 Mimo t=0	110.3
A549 Mimo t=3	160.4
A549 Mimo t=6	64.5
A549 Mimo t=9	54.4
A549 Mimo t=15	48.5
A549 Mimo t=18	62.7
A549 Mimo t=21	53.7
A549 Mimo t=24	69.1
MCF10A Mimo t=0	110.0
MCF10A Mimo t=3	73.6
MCF10A Mimo t=6	49.4
MCF10A Mimo t=9	62.7
MCF10A Mimo t=12	65.8
MCF10A Mimo t=18	42.0
MCF10A Mimo t=21	31.8
MCF10A Mimo t=24	25.0

Expression of 21617 mRNA in synchronized cells grown in culture is shown in Table 1. Colon cancer cell lines HCT 116 and DLD, human lung carcinoma cell line A549 and human mammary epithelial cell line MCF10A all show expression of 21617 mRNA.

- 5 The highest level of expression is shown at the mid pint of the cell cycle in DLD cells (colorectal carcinoma cell line).

TABLE 2: 21617 Expression In Colon Metastasis Panel

Tissue Type	Expression
CHT 371 Colon N	0.45
CHT 523 Colon N	0.10
NDR 104 Colon N	0.16
CHT 520 Colonic ACA-C	0.41
CHT 1365 Colonic ACA-C	0.04
CHT 382 Colonic ACA-B	2.76
CHT 122 Adenocarcinoma	0.91
CHT 077 Liver-Colon Mets	2.76
CHT 739 Liver-Colon Mets	0.79
CHT 755 Liver-Colon Mets	6.43
CHT001 Liver-Colon Mets	2.90
CHT 084 Liver-Colon Mets	1.50
CHT 113 Liver-Colon Mets	0.16
CHT 114 Liver-Colon Mets	35.65
CHT 127 Liver-Colon Mets	4.07

CHT 137 Liver-Colon Mets	2.07
CHT 218 Liver-Colon Mets	0.13
CHT 220 Liver-Colon Mets	1.98
CHT 324 Liver-Colon Mets	0.54
CHT 340 Liver-Colon Met	7.24
CHT 530 Liver -Colon Met	0.65
CHT 849 Liver-Colon Met	4.76
CHT 1637 Liver-Colon Met	1.46
CHT131 Liver-Colon Met	11.72
NDR 165 Liver Normal	0.79
NDR 150 Liver Normal	1.80
PIT 236 Liver Normal	1.00

- Expression of 21617 mRNA in a colon tumor metastasis panel is shown in Table 2. One of the colon cancer cell lines displays elevated expression of 21617 mRNA, while a subset of the Liver-Colon metastases express elevated levels of 21617 mRNA, suggesting that 21617 is a marker of cancer of the colon and liver-colon metastases. The highest level of expression is found in a liver metastasis sample.

Table 3: 21617 Expression in Expanded Breast Panel

Tissue Type	Expression
CHT 2242 Breast Normal	0.00
CHT 2251 Breast Normal	2.80
NDR824 Breast Normal	2.68
CHT 1744 Breast-ILC	3.77
NDR 133 Breast-ILC	4.58
CLN 662 Breast-ILC	0.84
CHT 1985 Breast-ILC	0.34
CLN 658 Breast-AC IDC II	1.74
CLN 732 Breast-AC IDC II	4.52
CHT 1828 Breast-Tumor IDC II	0.15
CHT 2012 Breast-Tumor IDC II	0.01
CLN 1026 Breast-AC IDC II	2.77
CLN 1027 Breast-AC IDC II	1.29
CHT1782 Breast-Tumor IDC III	6.50
CHT1784 Breast-Tumor IDC III	27.30
CHT1786 Breast-Tumor IDC III	0.78
CLN 1023 Breast-AC IDC III	1.38
CLN 1024 Breast-AC IDC III	0.50
PIT 058 Lung-Breast Met	0.00
PIT 116 Lung-Breast Met	0.33
CHT841 LN-Breast Met	0.00
CLN 425 LN-Breast Met	0.04
PIT 059 Liver-Breast Met	0.87
PIT 236 Liver N	4.63

PIT 260 Liver N	0.06
PIT 207 Lung N	0.87
PIT 298 Lung N	0.07
Pooled LN normal	12.01
CHT 2248 Breast Normal	23.60

Table 3 shows 21617 mRNA expression in an Expanded Breast Panel.

Table 4: 21617 Expression in Oncology Phase II Panel

Tissue Type	Expression
PIT 400 Breast N	0.00
PIT 372 Breast N	0.00
CHT 1228 Breast N	0.00
MDA 304 Breast T: MD-IDC	0.00
CHT 2002 Breast T: IDC	0.00
MDA 236-Breast T:PD-IDC(ILC?)	0.00
CHT 562 Breast T: IDC	3.44
NDR 138 Breast T ILC (LG)	6.90
CHT 1841 Lymph node (Breast met)	0.00
PIT 58 Lung (Breast met)	0.00
CHT 620 Ovary N	0.00
CHT 619 Ovary N	0.00
CLN 012 Ovary T	0.00
CLN 07 Ovary T	0.00
CLN 17 Ovary T	0.00
MDA 25 Ovary T	0.00
CLN 08 Ovary T	0.00
PIT 298 Lung N	0.00
MDA 185 Lung N	0.00
CLN 930 Lung N	0.00
MPI 215 Lung T--SmC	0.43
MDA 259 Lung T-PDNSCCL	30.93
CHT 832 Lung T-PDNSCCL	1.26
MDA 262 Lung T-SCC	5.96
CHT 793 Lung T-ACA	0.20
CHT 331 Lung T-ACA	0.00
CHT 405 Colon N	0.00
CHT 1685 Colon N	0.00
CHT 371 Colon N	0.01
CHT 382 Colon T: MD	0.23
CHT 528 Colon T: MD	0.12
CLN 609 Colon T	0.18
NDR 210 Colon T: MD-PD	0.82
CHT 340 Colon-Liver Met	4.14
CHT 1637Colon-Liver Met	0.61
PIT 260 Liver N (female)	0.10

CHT 1653 Cervix Squamous CC	13.94
CHT 569 Cervix Squamous CC	0.00
A24 HMVEC-Arr	0.96
C48 HMVEC-Prol	0.10
Pooled Hemangiomas	0.00
HCT116N22 Normoxic	7.84
HCT116H22 Hypoxic	2.02

- Table 4 shows 21617 mRNA expression in an oncology phase II panel. The highest level of expression was found in lung tumor and cervical squamous carcinoma. In addition, elevated expression of 21617 mRNA was detected in a subset of breast (IDC and ILC) and lung tumor (PDNSCCL and SCC) samples as compared to normal breast and lung tissue. Expression of 21617 mRNA was also detected in human vascular endothelial cells (HMVECs).

Table 5: 21617 Expression in Xenograft Panel

Tissue Type	Expression
MCF-7 Breast T	16.63
ZR75 Breast T	33.84
T47D Breast T	24.43
MDA 231 Breast T	0.24
MDA 435 Breast T	1.58
SKBr3 Breast	75.10
DLD 1 ColonT (stageC)	138.22
SW480 Colon T (stage B)	6.99
SW620 ColonT (stageC)	92.46
HCT116	19.37
HT29	4.38
Colo 205	32.69
NCIH125	9.55
NCIH67	83.33
NCIH322	50.42
NCIH460	1.95
A549	11.92
NHBE	35.40
SKOV-3 ovary	6.87
OVCAR-3 ovary	8.37
293 Baby Kidney	27.97
293T Baby Kidney	113.05

10

Table 5 shows 21617 mRNA expression in a xenograft panel. Stage C colon tumor DLD cells showed the highest relative level of expression.

Example 3: Recombinant Expression of 21617 or 55562 in Bacterial Cells

In this example, 21617 or 55562 is expressed as a recombinant glutathione-S-transferase (GST) fusion polypeptide in *E. coli* and the fusion polypeptide is isolated and characterized. Specifically, 21617 or 55562 is fused to GST and this fusion polypeptide is expressed in *E. coli*, e.g., strain PEB199. Expression of the GST-21617 or 55562 fusion protein in PEB199 is induced with IPTG. The recombinant fusion polypeptide is purified from crude bacterial lysates of the induced PEB199 strain by affinity chromatography on glutathione beads. Using polyacrylamide gel electrophoretic analysis of the polypeptide purified from the bacterial lysates, the molecular weight of the resultant fusion polypeptide is determined.

Example 4: Expression of Recombinant 21617 or 55562 Protein in COS Cells

To express the 21617 or 55562 gene in COS cells, the pcDNA/Amp vector by Invitrogen Corporation (San Diego, CA) is used. This vector contains an SV40 origin of replication, an ampicillin resistance gene, an *E. coli* replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A DNA fragment encoding the entire 21617 or 55562 protein and an HA tag (Wilson *et al.* (1984) *Cell* 37:767) or a FLAG tag fused in-frame to its 3' end of the fragment is cloned into the polylinker region of the vector, thereby placing the expression of the recombinant protein under the control of the CMV promoter.

To construct the plasmid, the 21617 or 55562 DNA sequence is amplified by PCR using two primers. The 5' primer contains the restriction site of interest followed by approximately twenty nucleotides of the 21617 or 55562 coding sequence starting from the initiation codon; the 3' end sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag or FLAG tag and the last 20 nucleotides of the 21617 or 55562 coding sequence. The PCR amplified fragment and the pCDNA/Amp vector are digested with the appropriate restriction enzymes and the vector is dephosphorylated using the CIAP enzyme (New England Biolabs, Beverly, MA). Preferably the two restriction sites chosen are different so that the 21617 or 55562 gene is inserted in the correct orientation. The ligation mixture is transformed into *E. coli* cells (strains HB101, DH5 α , SURE, available from Stratagene Cloning Systems, La Jolla, CA, can be used), the transformed culture is plated on ampicillin media plates, and resistant

colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment.

COS cells are subsequently transfected with the 21617 or 55562-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-precipitation methods, 5 DEAE-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods for transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. The expression of the 21617 or 55562 polypeptide is detected by radiolabelling (³⁵S-methionine 10 or ³⁵S-cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D. (1988) *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) using an HA specific monoclonal antibody. Briefly, the cells are labeled for 8 hours with ³⁵S-methionine (or ³⁵S-cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 mM 15 NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated polypeptides are then analyzed by SDS-PAGE.

Alternatively, DNA containing the 21617 or 55562 coding sequence is cloned directly into the polylinker of the pCDNA/Amp vector using the appropriate restriction sites. 20 The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the 21617 or 55562 polypeptide is detected by radiolabelling and immunoprecipitation using a 21617 or 55562 specific monoclonal antibody.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than 25 routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.